Alere 10-Q 6 Sep 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	ALR
Entity Registrant Name	ALERE INC.
Entity Central Index Key	1,145,460
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		86,740,318

Consolidated Statements of Oper

Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Net product sales	$ 483,746	$ 491,049	$ 943,517	$ 975,387
Services revenue	124,809	126,628	240,518	250,484
Net product sales and services revenue	608,555	617,677	1,184,035	1,225,871
License and royalty revenue	2,533	5,694	5,262	10,392
Net revenue	611,088	623,371	1,189,297	1,236,263
Cost of net product sales	250,398	257,893	487,859	497,994
Cost of services revenue	78,294	76,800	151,394	152,426
Cost of net product sales and services revenue	328,692	334,693	639,253	650,420
Cost of license and royalty revenue	535	1,344	1,926	3,294
Cost of net revenue	329,227	336,037	641,179	653,714
Gross profit	281,861	287,334	548,118	582,549
Operating expenses:
Research and development	28,446	27,198	55,508	55,214
Sales and marketing	102,516	108,024	202,329	217,103
General and administrative	128,354	61,173	243,310	153,864
Impairment and (gain) loss on dispositions, net	0	5,542	(3,810)	40,334
Operating income (loss)	22,545	85,397	50,781	116,034
Interest expense, including amortization of original issue discounts and deferred financing costs	(42,329)	(59,494)	(84,435)	(105,925)
Other income (expense), net	(14,112)	3,195	(15,461)	828
Income (loss) from continuing operations before provision for income taxes	(33,896)	29,098	(49,115)	10,937
Provision (benefit) for income taxes	3,117	15,689	2,909	7,836
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(37,013)	13,409	(52,024)	3,101
Equity earnings of unconsolidated entities, net of tax	2,122	1,361	7,156	5,320
Income (loss) from continuing operations	(34,891)	14,770	(44,868)	8,421
Income from discontinued operations, net of tax	0	0	0	216,777
Net income (loss)	(34,891)	14,770	(44,868)	225,198
Less: Net income attributable to non-controlling interests	143	359	246	447
Net income (loss) attributable to Alere Inc. and Subsidiaries	(35,034)	14,411	(45,114)	224,751
Preferred stock dividends	(5,308)	(5,308)	(10,617)	(10,558)
Net income (loss) available to common stockholders	$ (40,342)	$ 9,103	$ (55,731)	$ 214,193
Basic net income (loss) per common share:
Income (loss) from continuing operations	$ (0.46)	$ 0.11	$ (0.64)	$ (0.03)
Income from discontinued operations	0	0	0	2.56
Net income (loss) per common share	(0.46)	0.11	(0.64)	2.53
Diluted net income (loss) per common share:
Income (loss) from continuing operations	(0.46)	0.11	(0.64)	(0.03)
Income from discontinued operations	0	0	0	2.56
Net income (loss) per common share	$ (0.46)	$ 0.11	$ (0.64)	$ 2.53
Weighted-average shares - basic	86,737	85,173	86,692	84,758
Weighted-average shares - diluted	86,737	86,635	86,692	84,758

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (34,891)	$ 14,770	$ (44,868)	$ 225,198
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(44,135)	46,726	(21,942)	(33,616)
Minimum pension liability adjustment	531	(374)	686	(1,756)
Other comprehensive income (loss), before tax	(43,604)	46,352	(21,256)	(35,372)
Other comprehensive income (loss)	(43,604)	46,352	(21,256)	(35,372)
Comprehensive income (loss)	(78,495)	61,122	(66,124)	189,826
Less: Comprehensive income attributable to non-controlling interests	143	359	246	447
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ (78,638)	$ 60,763	$ (66,370)	$ 189,379

Consolidated Balance Sheets (un

Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 506,164	$ 502,200
Restricted cash	5,662	5,694
Marketable securities	74	164
Accounts receivable, net of allowances of $92,983 and $89,701 at June 30, 2016 and December 31, 2015, respectively	427,222	445,833
Inventories, net	333,846	347,001
Prepaid expenses and other current assets	162,339	152,233
Assets held for sale - current	0	4,165
Total current assets	1,435,307	1,457,290
Property, plant and equipment, net	438,787	446,039
Goodwill	2,811,545	2,836,915
Other intangible assets with indefinite lives	28,279	28,110
Finite-lived intangible assets, net	909,208	997,281
Restricted cash	42,589	43,228
Other non-current assets	16,290	18,078
Investments in unconsolidated entities	74,511	65,333
Deferred tax assets	18,638	13,993
Non-current income tax receivable	3,517	3,517
Assets held for sale - non-current	12,223	13,337
Total assets	5,790,894	5,923,121
Current liabilities:
Short-term debt and current portion of long-term debt	43,681	199,992
Current portion of capital lease obligations	3,500	3,962
Accounts payable	194,235	195,752
Accrued expenses and other current liabilities	320,526	324,465
Liabilities related to assets held for sale - current	0	363
Total current liabilities	561,942	724,534
Long-term liabilities:
Long-term debt, net of current portion	2,920,789	2,831,166
Capital lease obligations, net of current portion	6,972	7,181
Deferred tax liabilities	140,864	147,618
Other long-term liabilities	148,165	154,193
Total long-term liabilities	3,216,790	3,140,158
Commitments and contingencies
Stockholders' equity:
Series B preferred stock, $0.001 par value (liquidation preference: $709,701 at June 30, 2016 and $709,763 at December 31, 2015); Authorized: 2,300 shares; Issued: 2,065 shares at June 30, 2016 and December 31, 2015; Outstanding: 1,774 shares at June 30, 2016 and December 31, 2015	606,406	606,468
Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,419 shares at June 30, 2016 and 94,043 shares at December 31, 2015; Outstanding: 86,740 shares at June 30, 2016 and 86,364 shares at December 31, 2015	94	94
Additional paid-in capital	3,458,639	3,438,732
Accumulated deficit	(1,511,481)	(1,466,381)
Treasury stock, at cost, 7,679 shares at June 30, 2016 and December 31, 2015	(184,971)	(184,971)
Accumulated other comprehensive loss	(361,033)	(339,777)
Total stockholders' equity	2,007,654	2,054,165
Non-controlling interests	4,508	4,264
Total equity	2,012,162	2,058,429
Total liabilities and equity	$ 5,790,894	$ 5,923,121

Consolidated Balance Sheets (u5

Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 92,983	$ 89,701
Series B preferred stock, par value	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,701	$ 709,763
Series B preferred stock, shares authorized	2,300,000	2,300,000
Series B preferred stock, shares issued	2,065,000	2,065,000
Series B preferred stock, shares outstanding	1,774,000	1,774,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	94,419,000	94,043,000
Common stock, shares outstanding	86,740,000	86,364,000
Treasury stock, shares	7,679,000	7,679,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash Flows from Operating Activities:
Net income (loss)	$ (44,868)	$ 225,198
Income from discontinued operations, net of tax	0	216,777
Income (loss) from continuing operations	(44,868)	8,421
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	5,261	7,784
Depreciation and amortization	142,405	147,103
Non-cash stock-based compensation expense	20,607	12,279
Impairment of inventory	870	68
Impairment of long-lived assets	633	387
Loss on disposition of fixed assets	4,235	3,318
Equity earnings of unconsolidated entities, net of tax	(7,156)	(5,320)
Gain on sales of marketable securities	0	(8)
Deferred income taxes	(13,210)	(42,171)
(Gain) loss related to impairment and net (gain) loss on dispositions	(3,810)	40,334
(Gain) loss on extinguishment of debt	0	3,480
Other non-cash items	9,720	(2,332)
Non-cash change in fair value of contingent purchase price consideration	(1,780)	(52,867)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	20,023	(18,016)
Inventories, net	(5,820)	(45,219)
Prepaid expenses and other current assets	(24,881)	(27,077)
Accounts payable	(1)	(23,251)
Accrued expenses and other current liabilities	(1,676)	23,052
Other non-current liabilities	(6,106)	8,536
Cash paid for contingent purchase price consideration	(324)	(3,781)
Net cash provided by (used in) continuing operations	94,122	34,720
Net cash provided by discontinued operations	0	318
Net cash provided by (used in) operating activities	94,122	35,038
Cash Flows from Investing Activities:
Increase in restricted cash	(449)	(424,025)
Purchases of property, plant and equipment	(32,318)	(47,284)
Proceeds from sale of property, plant and equipment	892	1,120
Cash received from dispositions, net of cash divested	21,470	586,625
Cash paid for business acquisitions, net of cash acquired	(5,958)	0
Cash received from equity method investments	2,383	14,297
Cash received from sales of marketable securities	90	93
Cash paid for investments	(184)	0
Decrease in other assets	495	1,750
Net cash provided by (used in) continuing operations	(13,579)	132,576
Net cash used in discontinued operations	0	(209)
Net cash provided by (used in) investing activities	(13,579)	132,367
Cash Flows from Financing Activities:
Cash paid for financing costs	(19,564)	(15,731)
Cash paid for contingent purchase price consideration	(485)	(6,373)
Proceeds from issuance of common stock, net of issuance costs	11,124	56,332
Proceeds from issuance of long-term debt	381	2,121,851
Payments on short-term debt	(791)	(584)
Payments on long-term debt	(177,637)	(2,118,264)
Net (payments) proceeds under revolving credit facilities	126,213	(126,320)
Cash paid for dividends	(10,646)	(10,646)
Principal payments on capital lease obligations	(2,210)	(2,910)
Net cash used in continuing operations	(73,615)	(102,645)
Net cash used in discontinued operations	0	(76)
Net cash used in financing activities	(73,615)	(102,721)
Foreign exchange effect on cash and cash equivalents	(2,964)	(1,574)
Net increase in cash and cash equivalents	3,964	63,110
Cash and cash equivalents, beginning of period - continuing operations	502,200	378,461
Cash and cash equivalents, beginning of period - discontinued operations	0	23,300
Cash and cash equivalents, end of period	506,164	464,871
Less: Cash and cash equivalents of discontinued operations, end of period	0	0
Cash and cash equivalents of continuing operations, end of period	$ 506,164	$ 464,871

Basis of Presentation of Financ

Basis of Presentation of Financial Information	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation of Financial Information	(1) Basis of Presentation of Financial Information The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2015 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on August 8, 2016. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2015. Certain amounts presented may not recalculate directly, due to rounding.

Revision of Previously Reported

Revision of Previously Reported Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2016
Accounting Changes and Error Corrections [Abstract]
Revision of Previously Reported Consolidated Financial Statements	(2) Revision of Previously Reported Consolidated Financial Statements In connection with the preparation of our consolidated financial statements for the fiscal year ended December 31, 2015, we determined that, in fiscal years 2013 and 2014, each of the interim periods of 2014 and the first three quarters of fiscal year 2015, we had incorrectly reported the timing of recognition of certain revenue transactions for such periods. As a result, we revised our consolidated financial statements as of December 31, 2014 and for the fiscal years ended December 31, 2014 and 2013, each of the interim periods in 2014 and the first three quarters of fiscal year 2015. Specifically, the errors in the application of U.S. GAAP rules regarding the timing of revenue recognition primarily related to: (i) transactions, principally in Africa, in which we recognized revenue when the product shipped to the distributor, but we contractually retained title in the products until the distributor paid for the products in full or the distributor was not obligated to pay us until the products were sold through to the end-user; (ii) “bill and hold” transactions, principally in China, which did not meet the criteria for revenue recognition under U.S. GAAP; and (iii) other transactions, in which we recognized revenue prior to full satisfaction of all contractual criteria for title and risk of loss passing to the customer. These errors required adjustments to the period in which certain revenues were recognized so that such revenues were recognized in the period in which: physical delivery occurred as defined by the contractual relationship; title and risk of loss had transferred to the buyer; or the buyer had the contractual obligation to pay the amounts invoiced, as required by U.S. GAAP revenue recognition rules and our accounting policy relating to revenue recognition. The impact of these adjustments was a decrease in revenue of $5.8 million and $1.0 million for the three and six months ended June 30, 2015, respectively. Additionally, we have reflected other out-of-period adjustments in the periods in which such adjustments originated. These adjustments were identified during the financial closing process in connection with the fiscal years ended December 31, 2014 and 2013 and the first three quarters of fiscal year 2015 but were not reflected in our prior filings because they were deemed immaterial. The financial statements included in this Quarterly Report on Form 10-Q have been adjusted to include the adjustments in the period in which these items originated. These out-of-period adjustments are treated as corrections to our prior period financial results. For the three months ended June 30, 2015 these adjustments include a $1.2 million increase in operating expenses related to a bonus accrual, a $1.1 million increase in other income and expense, net due to the measurement of a royalty obligation and the income tax impact of these adjustments. For the six months ended June 30, 2015 these adjustments include a $1.2 million increase in operating expenses related to a bonus accrual, a $2.2 million increase in other income and expense, net due to the measurement of a royalty obligation and the income tax impact of these adjustments. Although management has determined that the errors, as well as the revenue recognition issues noted in the preceding paragraphs, individually and in the aggregate, were not material to prior periods, the financial statements for the three and six months ended June 30, 2015, included herein, have been revised to correct for the impact of these items. Unless otherwise indicated, the consolidated financial information as of and for the three and six months ended June 30, 2015 presented in this Quarterly Report on Form 10-Q reflects these revisions. The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding revised amounts: Three Months Ended June 30, 2015 Revised Consolidated Statement of Operations (in thousands, except per share As Previously Reported Adjustment As Revised Net product sales $ 496,834 $ (5,785 ) $ 491,049 Net product sales and services revenue $ 623,462 $ (5,785 ) $ 617,677 Net revenue $ 629,156 $ (5,785 ) $ 623,371 Cost of net product sales $ 258,485 $ (592 ) $ 257,893 Cost of service revenue $ 76,753 $ 47 $ 76,800 Cost of net product sales and services revenue $ 335,238 $ (545 ) $ 334,693 Cost of net revenue $ 336,582 $ (545 ) $ 336,037 Gross profit $ 292,574 $ (5,240 ) $ 287,334 Sales and marketing $ 107,184 $ 840 $ 108,024 General and administrative $ 60,813 $ 360 $ 61,173 Operating income $ 91,837 $ (6,440 ) $ 85,397 Other income (loss), net $ 4,260 $ (1,065 ) $ 3,195 Income from continuing operations before provision for income taxes $ 36,603 $ (7,505 ) $ 29,098 Provision for income taxes $ 17,701 $ (2,012 ) $ 15,689 Income from continuing operations before equity earnings of unconsolidated entities, net of tax $ 18,902 $ (5,493 ) $ 13,409 Income from continuing operations $ 20,263 $ (5,493 ) $ 14,770 Net income $ 20,263 $ (5,493 ) $ 14,770 Net income attributable to Alere Inc. and Subsidiaries $ 19,904 $ (5,493 ) $ 14,411 Net income available to common stockholders $ 14,596 $ (5,493 ) $ 9,103 Basic and diluted income per common share: Income from continuing operations $ 0.17 $ (0.06 ) $ 0.11 Basic and diluted net income per common share: Net income per common share $ 0.17 $ (0.06 ) $ 0.11 Six Months Ended June 30, 2015 Revised Consolidated Statement of Operations (in thousands, except per share As Previously Reported Adjustment As Revised Net product sales $ 976,433 $ (1,046 ) $ 975,387 Net product sales and services revenue $ 1,226,917 $ (1,046 ) $ 1,225,871 Net revenue $ 1,237,309 $ (1,046 ) $ 1,236,263 Cost of net product sales $ 497,122 $ 872 $ 497,994 Cost of service revenue $ 152,334 $ 92 $ 152,426 Cost of net product sales and services revenue $ 649,456 $ 964 $ 650,420 Cost of net revenue $ 652,750 $ 964 $ 653,714 Gross profit $ 584,559 $ (2,010 ) $ 582,549 Sales and marketing $ 216,263 $ 840 $ 217,103 General and administrative $ 153,504 $ 360 $ 153,864 Operating income $ 119,244 $ (3,210 ) $ 116,034 Other income (loss), net $ 2,990 $ (2,162 ) $ 828 Income from continuing operations before benefit for income taxes $ 16,309 $ (5,372 ) $ 10,937 Provision for income taxes $ 8,915 $ (1,079 ) $ 7,836 Income from continuing operations before equity earnings of unconsolidated entities, net of tax $ 7,394 $ (4,293 ) $ 3,101 Income from continuing operations $ 12,714 $ (4,293 ) $ 8,421 Net income $ 229,491 $ (4,293 ) $ 225,198 Net income attributable to Alere Inc. and Subsidiaries $ 229,044 $ (4,293 ) $ 224,751 Net income available to common stockholders $ 218,486 $ (4,293 ) $ 214,193 Basic and diluted income (loss) per common share: Income (loss) from continuing operations $ 0.02 $ (0.05 ) $ (0.03 ) Basic and diluted net income per common share: Net income per common share $ 2.54 $ (0.01 ) $ 2.53 Three Months Ended June 30, 2015 Revised Consolidated Statement of Comprehensive Loss (in thousands) As Previously Reported Adjustment As Revised Net income $ 20,263 $ (5,493 ) $ 14,770 Comprehensive income $ 66,615 $ (5,493 ) $ 61,122 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 66,256 $ (5,493 ) $ 60,763 Six Months Ended June 30, 2015 Revised Consolidated Statement of Comprehensive Loss (in thousands) As Previously Reported Adjustment As Revised Net income $ 229,491 $ (4,293 ) $ 225,198 Comprehensive income $ 194,119 $ (4,293 ) $ 189,826 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 193,672 $ (4,293 ) $ 189,379 Six Months Ended June 30, 2015 Revised Consolidated Statement of Cash Flows (in thousands) As Previously Reported Adjustment As Revised Net income $ 229,491 $ (4,293 ) $ 225,198 Income from continuing operations $ 12,714 $ (4,293 ) $ 8,421 Depreciation and amortization $ 147,011 $ 92 $ 147,103 Deferred income taxes $ (40,655 ) $ (1,516 ) $ (42,171 ) Accounts receivable, net $ (27,464 ) $ 9,448 $ (18,016 ) Inventories, net $ (46,093 ) $ 874 $ (45,219 ) Accrued expenses and other current liabilities $ 27,657 $ (4,605 ) $ 23,052 Other non-current liabilities $ 6,025 $ 2,511 $ 8,536 Net cash provided by continuing operations $ 32,209 $ 2,511 $ 34,720 Net cash provided by operating activities $ 32,527 $ 2,511 $ 35,038 Excess tax benefits on exercised stock options $ 2,511 $ (2,511 ) $ — Net cash used in continuing operations $ (100,134 ) $ (2,511 ) $ (102,645 ) Net cash used in financing activities $ (100,210 ) $ (2,511 ) $ (102,721 ) We have also reflected these corrections as applicable in our consolidated financial statements and our consolidating financial statements presented in Note 22 Guarantor Financial Information

Merger Agreement

Merger Agreement	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Merger Agreement	(3) Merger Agreement Merger Agreement with Abbott Laboratories On January 30, 2016, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Abbott Laboratories, or Abbott. The Merger Agreement provides for the merger of a newly formed, wholly owned subsidiary of Abbott with and into Alere, or the merger, with Alere surviving the merger as a wholly owned subsidiary of Abbott, or the surviving corporation. Under the terms of the Merger Agreement, holders of shares of our common stock will receive $56.00 in cash, without interest, in exchange for each share of common stock. Each share of our Series B Convertible Perpetual Preferred Stock, par value $0.001 per share, or Series B Preferred Stock, issued and outstanding immediately prior to the effective time of the merger will remain issued and outstanding immediately following the consummation of the merger as one share of Series B Convertible Preferred Stock, par value $0.001 per share, of the surviving corporation. The Merger Agreement was approved by our board of directors. Completion of the merger is subject to customary closing conditions, including (1) the adoption of the Merger Agreement by the affirmative vote of the holders of at least a majority of all outstanding shares of our common stock, (2) there being no judgment or law enjoining or otherwise prohibiting the consummation of the merger and (3) the expiration of the waiting period applicable to the merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or the HSR Act, and receipt of other required antitrust approvals. The obligation of each of the parties to consummate the merger is also conditioned on the other party’s representations and warranties being true and correct (subject to certain materiality exceptions) and the other party having performed in all material respects its obligations under the Merger Agreement. The Merger Agreement contains certain termination rights and provides that, upon termination of the Merger Agreement under certain circumstances, Alere would be required to pay Abbott a termination fee equal to $177.0 million. On May 2, 2016, Abbott and Alere received a request for additional information, or a “second request,” from the United States Federal Trade Commission, or the FTC, relating to Abbott’s potential acquisition of Alere. The second request was issued under the HSR Act. In addition, Abbott has agreed voluntarily to provide the FTC at least 60 days advance notice before certifying substantial compliance with the second request and to extend the waiting period imposed by the HSR Act to not less than 60 days after Abbott and Alere have certified substantial compliance with the second request, unless the period is further extended voluntarily by the parties or terminated sooner by the FTC. On June 23, 2016, Abbott and Alere received a request for additional information, or a “supplemental information request,” from the Canadian Competition Bureau, or the Bureau, relating to Abbott’s potential acquisition of Alere. The supplemental information request was issued under the Competition Act of Canada, or the Competition Act. The effect of the supplemental information request is to extend the waiting period imposed by the Competition Act until 30 days after Abbott and Alere have each complied with the supplemental information request, unless the period is extended voluntarily by the parties or terminated sooner by the Bureau. Under the terms of the Merger Agreement, Abbott has agreed to make certain divestitures if necessary to obtain the consent of the antitrust authorities to the transaction contemplated by the Merger Agreement, subject to certain exceptions set forth in the Merger Agreement. On August 25, 2016, we filed a complaint against Abbott in Delaware Chancery Court, which seeks to compel Abbott to fulfill its obligations under the terms of the Merger Agreement to take all actions necessary to promptly obtain all required antitrust approvals for the merger. The complaint alleges, among other things, that Abbott is purposefully failing to comply with its obligations set forth in the Merger Agreement related to obtaining antitrust approvals. Specifically, the complaint alleges that Abbott: (i) purposefully failed to supply information requested by the FTC “as promptly as reasonably practicable” after such requests were made, as expressly required by the Merger Agreement; (ii) purposefully failed to supply information requested and make antitrust filings pursuant to antitrust laws in various foreign jurisdictions “as promptly as reasonably practicable” after such requests were made; (iii) purposefully failed to promptly take any and all steps necessary to avoid or eliminate impediments to obtaining antitrust clearance in the United States and in various foreign jurisdictions; (iv) purposefully failed to keep Alere informed in all material respects and on a reasonably timely basis of material communications with respect to the merger with antitrust authorities in the United States and in various foreign jurisdictions; and (v) purposefully failed to cooperate and consult with Alere, as well as give due consideration to Alere’s views with respect to antitrust matters. We have asked the Delaware Chancery Court to require Abbott to specifically perform its obligations with respect to these matters, as required by the Merger Agreement.

Discontinued Operations, Impair

Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net	6 Months Ended
	Jun. 30, 2016
Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net	(20) Impairment and (Gain) Loss on Dispositions, Net In January 2016, we completed the sale of our Alere E-Santé business, which was a component of our professional diagnostics reporting unit and business segment. We received cash consideration of approximately $8.1 million, net of a final working capital adjustment totaling approximately $0.2 million, and we are eligible to receive up to $1.5 million of contingent cash consideration. As a result of this transaction, we recorded a $3.8 million gain in the three months ended March 31, 2016 on the disposition of the Alere E-Santé business. In May 2015, we sold our Alere Analytics business, which was part of our professional diagnostics reporting unit and business segment. Under the terms of the sale we received nominal consideration and agreed to contribute working capital of $2.7 million to Alere Analytics, of which $2.4 million was contributed in cash immediately prior to the closing of the sale and the remaining $0.3 million of which was deposited in escrow pending the performance by the buyers under certain contracts. As a result of this transaction we recorded a loss of $4.7 million during the second quarter of 2015. During the three months ended March 31, 2015, before identifying a buyer for Alere Analytics, our management decided to close the business, and in connection with this decision we recorded an impairment charge of $26.7 million during the period, including the write-off of $26.2 million of acquisition-related intangible assets and $0.5 million of fixed assets. In March 2015, we sold certain assets of our AdnaGen GmbH business, which was part of our professional diagnostics reporting unit and business segment, for approximately $4.6 million in cash proceeds and, as a result of this transaction, we recorded a loss of $0.3 million during the three months ended March 31, 2015. In March 2015, we sold our Gesellschaft fur Patientenhilfe DGP GmbH subsidiary, which was part of our professional diagnostics reporting unit and business segment, for €7.6 million (approximately $8.2 million at March 31, 2015) and, as a result of this transaction, we recorded a loss on disposition of $7.5 million during the three months ended March 31, 2015. In December 2014, our management decided to close our Alere Connect, LLC subsidiary, which is part of our professional diagnostics reporting unit and business segment. During the six months ended June 30, 2015, in connection with this decision, we recorded impairment charges of $1.0 million, consisting primarily of severance costs, inventory write-offs and other closure-related expenses. The financial results for the above businesses are immaterial to our consolidated financial results.
Health Management Business [Member]
Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net	(4) Discontinued Operations On January 9, 2015, we completed the sale of our health management business to OptumHealth Care Solutions for a purchase price of $599.9 million. We used the net cash proceeds of the sale to repay $575.0 million in aggregate principal amount of outstanding indebtedness under our prior credit facility. The following summarized financial information related to the health management business has been segregated from continuing operations and reported as discontinued operations in our consolidated statements of operations for the three and six months ended June 30, 2015. The results are as follows (in thousands): Three and Six Months Ended June 30, 2015 Net revenue $ 7,373 Cost of net revenue (4,413 ) Sales and marketing (996 ) General and administrative (5,001 ) Interest expense (9 ) Other income (expense), net 160 Gain on disposal 366,191 Income from discontinued operations before provision for income taxes 363,305 Provision for income taxes 146,528 Income from discontinued operations, net of tax $ 216,777

Cash and Cash Equivalents

Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2016
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	(5) Cash and Cash Equivalents We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At June 30, 2016, our cash equivalents consisted of money market funds.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Inventories	(6) Inventories Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): June 30, 2016 December 31, 2015 Raw materials $ 121,904 $ 130,171 Work-in-process 74,206 69,178 Finished goods 137,736 147,652 $ 333,846 $ 347,001

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	(7) Stock-based Compensation We recorded stock-based compensation expense in our consolidated statements of operations for the three and six months ended June 30, 2016 and 2015, respectively, as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Cost of net revenue $ 601 $ 287 $ 1,080 $ 540 Research and development 481 282 879 606 Sales and marketing 2,636 1,251 4,561 2,345 General and administrative 7,286 5,310 14,086 8,788 $ 11,004 $ 7,130 $ 20,607 $ 12,279

Net Income (Loss) per Common Sh

Net Income (Loss) per Common Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Net Income (Loss) per Common Share	(8) Net Income (Loss) per Common Share The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods presented (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Basic and diluted net income (loss) per common share: Numerator Income (loss) from continuing operations $ (34,891 ) $ 14,770 $ (44,868 ) $ 8,421 Preferred stock dividends (5,308 ) (5,308 ) (10,617 ) (10,558 ) Income (loss) from continuing operations attributable to common shares (40,199 ) 9,462 (55,485 ) (2,137 ) Less: Net income attributable to non-controlling interest 143 359 246 447 Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries (40,342 ) 9,103 (55,731 ) (2,584 ) Income from discontinued operations — — — 216,777 Net income (loss) available to common stockholders $ (40,342 ) $ 9,103 $ (55,731 ) $ 214,193 Denominator Weighted-average common shares outstanding — basic 86,737 85,173 86,692 84,758 Weighted-average common shares outstanding — diluted 86,737 86,635 86,692 84,758 Basic net income (loss) per common share: Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries $ (0.46 ) $ 0.11 $ (0.64 ) $ (0.03 ) Income from discontinued operations — — — 2.56 Basic net income (loss) per common share $ (0.46 ) $ 0.11 $ (0.64 ) $ 2.53 Diluted net income (loss) per common share: Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries $ (0.46 ) $ 0.11 $ (0.64 ) $ (0.03 ) Income from discontinued operations — — — 2.56 Diluted net income (loss) per common share $ (0.46 ) $ 0.11 $ (0.64 ) $ 2.53 The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Denominator Options to purchase shares of common stock 7,329 7,627 7,329 7,627 Warrants — — — 4 Conversion shares related to 3% convertible senior subordinated notes 1,687 3,411 2,549 3,411 Conversion shares related to subordinated convertible promissory notes — 27 — 27 Conversion shares related to Series B convertible preferred stock 10,238 10,239 10,238 10,239 Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 19,254 21,304 20,116 21,308

Stockholders' Equity and Non-co

Stockholders' Equity and Non-controlling Interests	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stockholders' Equity and Non-controlling Interests	(9) Stockholders’ Equity and Non-controlling Interests (a) Preferred Stock For the three and six months ended June 30, 2016, Series B preferred stock dividends amounted to $5.3 million and $10.6 million, respectively, and for the three and six months ended June 30, 2015, Series B preferred stock dividends amounted to $5.3 million and $10.6 million, respectively, which reduced earnings available to common stockholders for purposes of calculating net income (loss) per common share for each of the respective periods. As of June 30, 2016, $5.3 million of Series B preferred stock dividends was accrued. As of July 15, 2016, payments have been made covering all dividend periods through June 30, 2016. The Series B preferred stock dividends for the three and six months ended June 30, 2016 and 2015 were paid in cash in the subsequent quarters. (b) Changes in Stockholders’ Equity and Non-controlling Interests A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the six months ended June 30, 2016 is provided below (in thousands): Six Months Ended June 30, 2016 Total Non- Total Equity, beginning of period $ 2,054,165 $ 4,264 $ 2,058,429 Issuance of common stock under employee compensation plans 11,308 — 11,308 Net issuance of common stock to settle taxes on restricted stock units (1,410 ) — (1,410 ) Preferred stock dividends (10,646 ) — (10,646 ) Stock-based compensation expense 20,607 — 20,607 Other adjustments — (2 ) (2 ) Net income (loss) (45,114 ) 246 (44,868 ) Total other comprehensive loss (21,256 ) — (21,256 ) Equity, end of period $ 2,007,654 $ 4,508 $ 2,012,162

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combinations	(10) Business Combinations Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner. Net assets acquired are recorded at their estimated fair value and are subject to adjustment upon finalization of the fair value analysis. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized. Acquisition in 2016 EDTS On February 11, 2016, we acquired the shares of European Drug Testing Services EDTS AB, or EDTS, located in Lidingo, Sweden, a provider of services related to on-site drug testing. The aggregate purchase price was approximately $6.5 million and was paid in cash. The operating results of EDTS are included in our professional diagnostics reporting unit and business segment. Our consolidated statements of operations for the three and six months ended June 30, 2016 included revenue totaling approximately $1.7 million and $2.6 million, respectively, related to this business. Goodwill has been recognized in the acquisition and amounted to approximately $2.1 million, which is deductible for tax purposes. A summary of the preliminary fair values of the net assets acquired from EDTS is as follows (in thousands): Fair Value Current assets $ 1,371 Property, plant and equipment 115 Goodwill 2,065 Intangible assets 4,220 Total assets acquired $ 7,771 Current liabilities $ 1,301 Total liabilities assumed $ 1,301 Net assets acquired $ 6,470 Cash paid $ 6,470 The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective preliminary fair values and weighted-average useful lives (dollars in thousands): Fair Value Weighted- Core technology and patents $ 540 10.0 years Trademarks and trade names 310 20.0 years Customer relationships 2,800 14.0 years Non-compete agreements 570 3.0 years Total intangible assets $ 4,220

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2016
Restructuring and Related Activities [Abstract]
Restructuring	(11) Restructuring The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three and six months ended June 30, 2016 and 2015 (in thousands): Three Months Ended June 30, Six Months Ended June 30, Statement of Operations Caption 2016 2015 2016 2015 Cost of net revenue $ 1,103 $ 896 $ 2,370 $ 2,399 Research and development 1,034 156 2,954 649 Sales and marketing 259 570 909 1,953 General and administrative 6,389 3,231 10,215 4,122 Total operating expenses 8,785 4,853 16,448 9,123 Interest expense, including amortization of original issue discounts and deferred financing costs 2 6 7 13 Total restructuring charges $ 8,787 $ 4,859 $ 16,455 $ 9,136 (a) Restructuring Plans During 2016, management developed world-wide cost reduction plans to reduce costs and improve operational efficiencies within our professional diagnostics and corporate and other business segments, primarily impacting our manufacturing and supply chain, and research and development groups, as well as closing certain business locations in Europe and the United States. The following table summarizes the restructuring activities related to the 2016 restructuring plans, in addition to our earlier restructuring plans as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, for the three and six months ended June 30, 2016 and 2015 and since inception of these restructuring plans (in thousands): Three Months Ended Six Months Ended Since Professional Diagnostics 2016 2015 2016 2015 Severance-related costs $ 3,183 $ 1,264 $ 6,274 $ 4,064 $ 44,261 Facility and transition costs 213 2,581 1,194 4,007 12,862 Other exit costs 2 6 7 13 829 Cash charges 3,398 3,851 7,475 8,084 57,952 Fixed asset and inventory impairments 21 445 419 454 16,372 Other non-cash charges (3 ) — 210 — 2,192 Total professional diagnostics charges $ 3,416 $ 4,296 $ 8,104 $ 8,538 $ 76,516 Corporate and Other Severance-related costs $ (19 ) $ 569 $ (4 ) $ 611 $ 4,273 Facility and transition costs 5,390 (6 ) 8,355 (13 ) 19,677 Total corporate and other charges $ 5,371 $ 563 $ 8,351 $ 598 $ 23,950 Total restructuring charges $ 8,787 $ 4,859 $ 16,455 $ 9,136 $ 100,466 We anticipate incurring approximately $4.4 million and $8.0 million in additional costs under our 2016 restructuring plans related to our professional diagnostics and corporate and other business segments, respectively, primarily related to integration and operational initiatives and site closures. We may develop additional restructuring plans over the remainder of 2016. In addition, we anticipate incurring approximately $3.7 million in additional costs under earlier restructuring plans as in effect at June 30, 2016, primarily related to the closure of our manufacturing facility in Israel. (b) Restructuring Reserves The following table summarizes our restructuring reserves related to the plans described above, of which $9.5 million is included in accrued expenses and other current liabilities and $0.6 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands): Severance- Facility and Other Exit Total Balance, December 31, 2015 $ 1,633 $ 1,966 $ 180 $ 3,779 Cash charges 6,270 9,549 7 15,826 Payments (3,814 ) (5,645 ) (73 ) (9,532 ) Currency adjustments (18 ) 11 — (7 ) Balance, June 30, 2016 $ 4,071 $ 5,881 $ 114 $ 10,066

Long-term Debt

Long-term Debt	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Long-term Debt	(12) Long-term Debt We had the following long-term debt balances outstanding (in thousands): June 30, 2016 December 31, 2015 A term loans (1)(2) $ 559,317 $ 575,746 B term loans (1)(2) 958,337 965,740 Revolving loans (1) 125,000 — 7.25% Senior notes (2) 442,533 446,320 6.5% Senior subordinated notes (2) 415,679 419,209 6.375% Senior subordinated notes (2) 414,033 418,133 3% Convertible senior subordinated notes (3) — 149,839 Other lines of credit 1,335 136 Other 48,236 56,035 2,964,470 3,031,158 Less: Short-term debt and current portion of long-term debt (43,681 ) (199,992 ) Long-term debt $ 2,920,789 $ 2,831,166 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) As discussed more fully below in this Note 12, (i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing our notes. On June 30, 2016, we were not in default under the Credit Agreement or the indentures governing our notes. As discussed more fully below in this Note 12, in August 2016 we entered into a further amendment to the Credit Agreement with respect to our failure to timely file this Quarterly Report on Form 10-Q. At September 1, 2016, we were in default under the indentures governing our outstanding notes with respect to our failure to timely file this Quarterly Report on Form 10-Q and, by filing this Quarterly Report on Form 10-Q prior to the expiration of the applicable cure periods under the notes, we have cured this default. (3) The principal amount of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheets as of December 31, 2015, as these notes matured (and were fully paid and discharged) in May 2016. In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three and six months ended June 30, 2016 and 2015 as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Secured credit facility (1) $ 17,834 $ 12,851 $ 34,877 $ 12,851 Prior credit facility (2) (3) — 19,726 — 39,188 7.25% Senior notes 8,904 8,525 17,428 17,049 6.5% Senior subordinated notes 7,405 7,234 14,636 14,467 6.375% Senior subordinated notes 7,112 542 14,115 542 8.625% Senior subordinated notes — 9,274 — 18,547 3% Convertible senior subordinated convertible notes 603 1,246 1,847 2,492 Other 471 96 1,532 789 $ 42,329 $ 59,494 $ 84,435 $ 105,925 (1) Includes “A” term loans, “B” term loans, and revolving line of credit loans. (2) Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans and later converted into and consolidated into the “B” term loans; and revolving line of credit loans. For the three and six months ended June 30, 2015, the amounts include $0.3 million and $0.7 million, respectively, related to the amortization of fees paid for certain debt modifications. (3) Includes a $3.5 million loss on extinguishment of debt associated with our prior credit facility. April and August 2016 Amendments to Secured Credit Facility On April 22, 2016, we and the requisite lenders under the Credit Agreement entered into an amendment to the Credit Agreement pursuant to which the requisite lenders agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, (x) our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and certain related deliverables for the year ended December 31, 2015 by the applicable deadline under the Credit Agreement, (y) any restatement of certain financial statements as a result of our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, or (z) any breach of any representation or affirmative covenant as a result of certain deliverables being incorrect when delivered, which breach is discovered as part of the audit of our financial statements for the year ended December 31, 2015, to the extent that such breach is due to our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, and (ii) extend the deadlines for delivery of the financial statements for the year ended December 31, 2015, the financial statements for the quarter ended March 31, 2016 and certain related deliverables. Under the terms of this amendment, we were required to deliver our unaudited financial statements for the three months ended March 31, 2016 and certain related deliverables on or before August 18, 2016. We made the required deliveries before that date. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.250% of the sum of (i) the aggregate principal amount of such lender’s Term Loans (as defined in the Credit Agreement) outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment (as defined in the Credit Agreement) outstanding on the effective date of the amendment, or approximately $4.5 million in the aggregate for all consenting lenders. The amendment was deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt. The amendment also increased the applicable interest rate margins for all loans outstanding under our secured credit facility by 0.25% per annum for the period from July 1, 2016 to the date of delivery of such financial reports and related deliverables under our secured credit facility. On August 18, 2016, we and the requisite lenders under the Credit Agreement entered into a further amendment to the Credit Agreement pursuant to which the requisite lenders agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) (x) the financial statements and certain related deliverables for the three months ended March 31, 2016, which we refer to as the Q1 Financial Reports, by the applicable deadline under the Credit Agreement or (y) the financial statements and certain related deliverables for the three months ended June 30, 2016, which we refer to as the Q2 Financial Reports, by the applicable deadline under the Credit Agreement, and (ii) extend the deadline for delivery of the Q1 Financial Reports to August 25, 2016 and the deadline for the delivery of the Q2 Financial Reports to September 13, 2016. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.125% of the sum of (i) the aggregate principal amount of such lender’s Term Loans outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment outstanding on the effective date of the amendment, or approximately $2.2 million in the aggregate for all consenting lenders. The amendment was deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt. May 2016 Waivers with respect to Senior Notes and Senior Subordinated Notes On April 29, 2016, we commenced consent solicitations relating to our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 7.25% senior notes, which we refer to collectively as the Notes. The consent solicitations were made to holders of record of the Notes as of April 28, 2016, and such solicitations were completed on May 9, 2016. Pursuant to the consent solicitations, the requisite holders of each series of Notes agreed to extend the deadline for delivery of certain financial information and to waive, through and until 5:00 p.m., New York City time, on August 31, 2016, any default or event of default that occurred, is continuing or may occur under the indentures under which the Notes were issued (and its consequences) in connection with any failure to timely file with the SEC or to timely furnish to the relevant trustees pursuant to the indentures, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and our subsequent Quarterly Reports on Form 10-Q, or the Failures to File. In connection with the Failures to File, we paid, in May and July 2016, to each holder of Notes who validly delivered a consent aggregate cash payments equal to $15.00 for each $1,000 aggregate principal amount of such holder’s Notes, or an aggregate of $19.2 million. The waivers were deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt. Maturity of our 3.0% convertible senior subordinated notes Our 3% convertible senior subordinated notes matured and were repaid in full on May 15, 2016. Based on the price of our common stock on the date of maturity, we paid all outstanding principal and accrued interest owing under such notes in cash. The aggregate amount paid to the noteholders at maturity was approximately $152.0 million, consisting of $125.0 million in cash drawn under our revolving credit facility plus $27.0 million of cash available on such date.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	(13) Fair Value Measurements We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Described below are the three levels of inputs that may be used to measure fair value: Level 1— Level 2— Level 3— The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description June 30, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 74 $ 74 $ — $ — Total assets $ 74 $ 74 $ — $ — Liabilities: Contingent consideration obligations (1) $ 55,100 $ — $ — $ 55,100 Total liabilities $ 55,100 $ — $ — $ 55,100 Description December 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 164 $ 164 $ — $ — Total assets $ 164 $ 164 $ — $ — Liabilities: Contingent consideration obligations (1) $ 57,744 $ — $ — $ 57,744 Total liabilities $ 57,744 $ — $ — $ 57,744 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. See Note 17(a) for additional information on the valuation of our contingent consideration obligations. Changes in the fair value of our Level 3 contingent consideration obligations during the six months ended June 30, 2016 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2015 $ 57,744 Payments (865 ) Fair value adjustments (1,780 ) Foreign currency adjustments 1 Fair value of contingent consideration obligations, June 30, 2016 $ 55,100 At June 30, 2016 and December 31, 2015, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values. The carrying amount and estimated fair value of our long-term debt (including the current portion) were both $3.0 billion at June 30, 2016. The carrying amount and estimated fair value of our long-term debt (including the current portion) were $3.1 billion and $3.0 billion, respectively, at December 31, 2015. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future.

Financial Information by Segmen

Financial Information by Segment	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Financial Information by Segment	(14) Financial Information by Segment Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. We currently have three reportable operating segments: (i) professional diagnostics, (ii) consumer diagnostics and (iii) corporate and other. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement. We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three and six months ended June 30, 2016 and 2015 is as follows (in thousands): Professional Consumer Corporate Total Three Months Ended June 30, 2016: Net revenue $ 591,294 $ 19,794 $ — $ 611,088 Operating income (loss) $ 85,535 $ 396 $ (63,386 ) $ 22,545 Depreciation and amortization $ 66,393 $ 1,374 $ 2,134 $ 69,901 Restructuring charge $ 3,414 $ — $ 5,371 $ 8,785 Stock-based compensation $ — $ — $ 11,004 $ 11,004 Professional Consumer Corporate Total Three Months Ended June 30, 2015: Net revenue $ 598,726 $ 24,645 $ — $ 623,371 Operating income (loss) $ 153,241 $ 1,079 $ (68,923 ) $ 85,397 Impairment and (gain) loss on dispositions, net $ (38,836 ) $ — $ 44,378 $ 5,542 Depreciation and amortization $ 70,189 $ 725 $ 1,775 $ 72,689 Restructuring charge $ 4,290 $ — $ 563 $ 4,853 Stock-based compensation $ — $ — $ 7,130 $ 7,130 Six Months Ended June 30, 2016: Net revenue $ 1,152,061 $ 37,236 $ — $ 1,189,297 Operating income (loss) $ 168,215 $ 563 $ (117,997 ) $ 50,781 Impairment and (gain) loss on dispositions, net $ (3,810 ) $ — $ — $ (3,810 ) Depreciation and amortization $ 135,225 $ 2,873 $ 4,307 $ 142,405 Restructuring charge $ 8,097 $ — $ 8,351 $ 16,448 Stock-based compensation $ — $ — $ 20,607 $ 20,607 Six Months Ended June 30, 2015: Net revenue $ 1,189,651 $ 46,612 $ — $ 1,236,263 Operating income (loss) $ 242,784 $ 3,283 $ (130,033 ) $ 116,034 Impairment and (gain) loss on dispositions, net $ (40,568 ) $ — $ 80,902 $ 40,334 Depreciation and amortization $ 142,658 $ 1,436 $ 3,009 $ 147,103 Restructuring charge $ 8,525 $ — $ 598 $ 9,123 Stock-based compensation $ — $ — $ 12,279 $ 12,279 Assets: As of June 30, 2016 $ 5,572,046 $ 179,445 $ 39,403 $ 5,790,894 As of December 31, 2015 $ 5,619,901 $ 172,551 $ 130,669 $ 5,923,121 The following tables summarize our net revenue from the professional diagnostics reporting segments by groups of similar products and services for the three and six months ended June 30, 2016 and 2015 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Cardiometabolic $ 203,982 $ 211,672 $ 398,559 $ 412,608 Infectious disease 190,168 172,834 373,402 358,236 Toxicology 158,199 157,495 304,982 306,251 Other 36,412 51,031 69,856 102,164 Total professional diagnostics net product sales and services revenue 588,761 593,032 1,146,799 1,179,259 License and royalty revenue 2,533 5,694 5,262 10,392 Total professional diagnostics net revenue $ 591,294 $ 598,726 $ 1,152,061 $ 1,189,651

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	(15) Related Party Transactions (a) SPD Joint Venture In May 2007, we completed the formation of SPD Swiss Precision Diagnostics GmbH, or SPD, our 50/50 joint venture with Procter & Gamble, or P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiometabolic, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting. We had a net payable to SPD of $3.7 million as of June 30, 2016 and $1.2 million as of December 31, 2015. The $3.7 million net payable balance as of June 30, 2016 is net of a receivable of approximately $1.3 million for costs incurred in connection with our 2008 SPD-related restructuring plans. The $1.2 million net payable balance as of December 31, 2015 is net of a receivable of approximately $1.5 million for costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately $6.7 million and $8.9 million as of June 30, 2016 and December 31, 2015, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the formation of the joint venture have been classified as other receivables within prepaid and other current assets on our consolidated balance sheets in the amounts of $8.8 million and $7.8 million as of June 30, 2016 and December 31, 2015, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled $21.8 million and $39.5 million during the three and six months ended June 30, 2016, respectively, and $21.7 million and $41.2 million during the three and six months ended June 30, 2015, respectively. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled $0.3 million and $0.5 million during the three and six months ended June 31, 2016, respectively, and $0.3 million and $0.6 million during the three and six months ended June 30, 2015, respectively. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying consolidated statements of operations. Under the terms of our product supply agreement, SPD purchases products from our manufacturing facilities in China. SPD in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, a portion of the tests are sold to P&G for distribution to third-party customers in North America. We defer our profit on products sold to SPD until the products are sold through to the customer. As a result of these related transactions, we have recorded $11.7 million and $9.9 million of trade receivables which are included in accounts receivable on our consolidated balance sheets as of June 30, 2016 and December 31, 2015, respectively, and $31.6 million and $24.9 million of trade accounts payable which are included in accounts payable on our consolidated balance sheets as of June 30, 2016 and December 31, 2015, respectively. The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption June 30, 2016 December 31, 2015 Accounts receivable, net of allowances $ 11,670 $ 9,873 Prepaid expenses and other current assets $ 8,768 $ 6,602 Other non-current assets $ 6,699 $ 8,895 Accounts payable $ 31,584 $ 24,887 As previously disclosed, SPD is currently involved in civil litigation brought by a competitor in the United States with respect to the advertising of one of SPD’s products in the United States. During 2015, SPD appealed the district court’s injunction with respect to sales and advertising of such product, which was based on a finding that SPD violated certain laws with respect to the advertising of such product. The appellate court has issued a stay of the injunction, pending the outcome of the appeal. In addition, a class action lawsuit has been initiated against SPD and P&G in the United States District Court for the Central District of California, alleging violations of certain laws in connection with the sales and advertising of one of SPD’s products which claims are based on similar grounds as those at issue in the litigation described above in this paragraph. On August 19, 2016, the class action lawsuit was dismissed with prejudice. The plaintiffs may appeal the decision prior to September 19, 2016. There may be additional lawsuits against SPD or us relating to this matter in the future. The ultimate resolution of these matters is not known at this time, nor is the potential impact they or future litigation may have on SPD or us, including whether any such resolution or any damages imposed by a court would have a material adverse impact on SPD and, ultimately, by virtue of our 50% interest in SPD, on our financial position or results of operations. (b) Entrustment Loan Arrangement with SPD Shanghai Our subsidiary Alere (Shanghai) Diagnostics Co., Ltd., or Alere Shanghai, and SPD’s subsidiary SPD Trading (Shanghai) Co., Ltd., or SPD Shanghai, entered into an entrustment loan arrangement for a maximum of CNY 23 million (approximately $3.5 million at June 30, 2016), in order to finance the latter’s short-term working capital needs, with the Royal Bank of Scotland (China) Co., Ltd. Shanghai Branch, or RBS. The agreement governs the setting up of an Entrustment Loan Account with RBS, into which Alere Shanghai deposits certain monies. This restricted cash account provides a guarantee to RBS of amounts borrowed from RBS by SPD Shanghai. The Alere Shanghai RBS account is recorded as restricted cash on our balance sheet and amounted to $3.5 million at June 30, 2016. (c) TechLab We have an equity method investment in TechLab, Inc., or TechLab, a company that provides diagnostic testing products used by physicians and other health care customers to diagnose, treat, and monitor intestinal diseases and other medical conditions. We own approximately 49% of Techlab. We have also entered into an exclusive distributor agreement with Techlab. This agreement grants us the global distribution rights to Techlab’s products with certain exceptions. We had trade payables owed to Techlab of $1.5 million and $3.2 million as of June 30, 2016 and December 31, 2015, respectively. We made product purchases from Techlab of $4.5 million and $4.1 million during the three months ended June 30, 2016 and 2015, respectively, and $9.2 million and $8.5 million during the six months ended June 30, 2016 and 2015.

Other Arrangements

Other Arrangements	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Arrangements	(16) Other Arrangements In September 2014, we entered into a contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, to develop diagnostic countermeasures for pandemic influenza. Under the terms of the 3.5 year contract, BARDA has agreed to provide up to $12.9 million to us to support the development of a rapid, molecular, low-cost influenza diagnostic device with PCR-like performance at the point of care. The project is designed to help support future preparedness and medical response to an influenza pandemic. Funding from BARDA is subject to successful completion of various interim feasibility and development milestones as defined in the agreement. For the three months ended June 30, 2016 and 2015, we had incurred $1.0 million and $0.9 million, respectively, of qualified expenditures under the contract, for which we had received cash reimbursement from BARDA in the amount of $0.0 million and $0.5 million, respectively, and $1.0 million and $0.4 million was recorded as a receivable as of June 30, 2016 and 2015, respectively. Reimbursements of qualified expenditures under this contract are recorded as a reduction of our related qualified research and development expenditures. In February 2013, we entered into an agreement with the Bill & Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of validated, low-cost, nucleic-acid assays and cartridges for clinical tuberculosis detection and drug-resistance testing, and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provided for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to $20.6 million. In April 2016, we and the Gates Foundation agreed to mutually terminate this grant and loan agreement and, therefore, there will be no additional grants and no advances will be available under the loan agreement. Prior to its termination, we did not borrow any amounts under the Gates Loan Agreement. As of June 30, 2016, we had received approximately $19.7 million in grant-related funding from the Gates Foundation. Grant funds were recorded upon receipt as restricted cash and deferred grant funding, with the deferred grant funding classified within accrued expenses and other current liabilities on our accompanying consolidated balance sheet. As qualified expenditures were incurred under the terms of the grant, we used the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three months ended June 30, 2015, we incurred approximately $1.8 million of qualified expenditures, for which we reduced our deferred grant funding balance and recorded an offset to our research and development expenses. There were no amounts remaining as restricted cash or deferred grant funding under the February 2013 grant agreement as of June 30, 2016. In addition to the February 2013 grant discussed above, we have also been awarded several smaller grants by the Gates Foundation in the aggregate amount of approximately $2.9 million to support the elimination of malaria. We incurred qualifying expenses totaling approximately $0.3 million and $0.1 million for the three months ended June 30, 2016 and 2015, respectively. We incurred qualifying expenses totaling approximately $0.5 million and $0.3 million for the six months ended June 30, 2016 and 2015, respectively. As of June 30, 2016, $1.4 million under these grants was recorded as restricted cash and $1.3 million as deferred grant funding on our accompanying consolidated balance sheet.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(17) Commitments and Contingencies (a) Acquisition-related Contingent Consideration Obligations We have contractual contingent purchase price consideration obligations related to certain of our acquisitions. We determine the acquisition date fair value of the contingent consideration obligations based on a probability-weighted approach derived from the overall likelihood of achieving certain performance targets, including product development milestones or financial metrics. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement, as defined in fair value measurement accounting. The resultant probability-weighted earn-out payments are discounted using a discount rate based upon the weighted-average cost of capital. At each reporting date, we revalue the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in our consolidated statements of operations. Increases or decreases in the fair values of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria. The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions, as follows (in thousands): Acquisition Acquisition Date Acquisition Maximum Remaining Estimated Estimated Payments TwistDx, Inc. (1) March 11, 2010 $ 35,600 $ 102,870 2016 – 2025 (3) $ 46,600 $ 47,800 $ 377 Epocal (2) February 1, 2013 $ 75,000 $ 45,500 2016 – 2018 3,900 4,700 — Other Various $ 30,373 $ — (4) 2016 4,600 5,244 488 $ 55,100 $ 57,744 $ 865 (1) The terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and product development targets through 2025. (2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (3) The maximum earn-out period ends on the fifteenth anniversary of the acquisition date. (4) The maximum remaining earn-out potential for the other acquisitions is not determinable due to the nature of one of the earn-outs, which is tied to an unlimited revenue metric. (b) Legal Proceedings Abbott Laboratories On August 25, 2016, Alere Inc. filed suit against Abbott Laboratories in the Delaware Chancery Court, and filed an accompanying motion to expedite the proceedings. The complaint alleges, among other things, that Abbott is purposefully failing to comply with its obligations set forth in the Merger Agreement related to obtaining antitrust approvals. Specifically, the complaint alleges that Abbott: (i) purposefully failed to supply information requested by the FTC “as promptly as reasonably practicable” after such requests were made, as expressly required by the Merger Agreement; (ii) purposefully failed to supply information requested and make antitrust filings pursuant to antitrust laws in various foreign jurisdictions “as promptly as reasonably practicable” after such requests were made; (iii) purposefully failed to promptly take any and all steps necessary to avoid or eliminate impediments to obtaining antitrust clearance in the United States and in various foreign jurisdictions; (iv) purposefully failed to keep Alere informed in all material respects and on a reasonably timely basis of material communications with respect to the merger with antitrust authorities in the United States and in various foreign jurisdictions; and (v) purposefully failed to cooperate and consult with Alere, as well as give due consideration to Alere’s views with respect to antitrust matters. We have asked the Delaware Chancery Court to require Abbott to specifically perform its obligations with respect to these matters, as required by the Merger Agreement. On August 30, 2016, Abbott filed its response in opposition to the motion to expedite the proceedings in this matter. On September 2, 2016, the Delaware Chancery Court granted our motion to expedite the proceedings. U.S. Securities and Exchange Commission Subpoenas On August 28, 2015, we received a subpoena from the SEC which indicated that it is conducting a formal investigation of Alere. The SEC’s subpoena relates to, among other things, (i) our previously filed restatement and revision to our financial statements, including the accounting for deferred taxes for discontinued operations, as well as our tax strategies and policies and (ii) our sales practices and dealings with third parties (including distributors and foreign government officials) in Africa relating to sales to government entities. On January 14, 2016, we received a second subpoena from the SEC in connection with this formal investigation seeking, among other things, additional information related to sales of products and services to end-users in Africa, as well as revenue recognition relating to sales of products and services to end-users in Africa. We have also received, from time to time, requests in connection with the investigation to voluntarily produce additional information to the SEC, including information pertaining to certain other countries in Asia and Latin America. We are cooperating with the SEC and have provided documents in response to the subpoenas and voluntary requests. We are unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it. Department of Justice Grand Jury Subpoena On March 11, 2016, we received a grand jury subpoena from the United States Department of Justice requiring the production of documents relating to, among other things, sales, sales practices and dealings with third parties (including distributors and foreign governmental officials) in Africa, Asia and Latin America and other matters related to the U.S. Foreign Corrupt Practices Act. We are cooperating with the Department of Justice and have provided information in response to the subpoena. We are unable to predict when this matter will be resolved or what further action, if any, the Department of Justice may take in connection with it. Securities Class Actions On April 21, 2016, a class action lawsuit captioned Godinez Alere Inc. Breton Alere Inc. We are unable at this time to determine the outcome of this class action lawsuit or our potential liability, if any. Matters Relating to our San Diego Facility On October 9, 2012, we received a warning letter from the FDA referencing inspectional observations set forth in a Form FDA 483 received in June 2012. The observations were the result of an inspection of our San Diego facility conducted earlier during 2012 relating to our Alere Triage products, which resulted in two recalls of certain Alere Triage products and revised release specifications for our Alere Triage meter-based products. In September 2014, as follow up to a further inspection of our San Diego facility, the FDA notified us that this inspection was classified “voluntary action indicated,” meaning that the objectionable conditions or practices found in the inspection did not meet the threshold of significance requiring regulatory action, but that formal close-out of the October 2012 warning letter could not occur until after a future inspection. In May 2012, we also received a subpoena from the Office of Inspector General of the Department of Health and Human Services, or the OIG, seeking documents relating primarily to the quality control testing and performance characteristics of Alere Triage products. We are cooperating with the government and are responding to the investigation, which is ongoing. We have been engaged in discussions with the government about this matter, including a resolution of potential related False Claims Act and common law liability exposure for the products under review. As a result of these discussions, management has accrued $10.2 million for this matter in the three months ended June 30, 2016. We would need to obtain certain approvals before we could agree to any proposed resolution. There can be no assurance that future discussions with the government to resolve these matters will be successful, that the approvals we need will be obtained or that any potential settlement will be agreed to or finalized. We may be required to engage in litigation of this matter, which may be time consuming and costly. Based on the ongoing uncertainties and potentially wide range of outcomes associated with any potential resolution, the ultimate amount of potential loss may materially exceed the accrual we have established. We are unable to predict when these matters will be resolved or what further action, if any, the government will take in connection with them. INRatio Class Actions On May 26, 2016, a class action lawsuit captioned Dina Andren and Sidney Bludman v. Alere Inc et al. J.E, J.D., and all others similarly situated v. Alere Inc., Alere San Diego, Inc. and Alere Home Monitoring, Inc., Dina Andren and Sidney Bludman J.E, J.D., and all others similarly situated Andren We are unable, at this time, to predict the outcome of these class action lawsuits. Claims in the Ordinary Course and Other Matters We are also party to certain other legal proceedings and other governmental investigations, or are requested to provide information in connection with such proceedings or investigations. For example, in December 2014, we and our subsidiary, Avee Laboratories Inc., or Avee, received subpoenas from the United States Attorney for the District of New Jersey seeking marketing materials and other documents relating primarily to billing and marketing practices related to toxicology testing. In addition, we received a U.S. Department of Justice criminal subpoena addressed to Alere Toxicology Services, Inc. on July 1, 2016 which seeks records related to Medicare, Medicaid and Tricare billings dating back to 2010 for specific patient samples tested at our Austin, Texas pain management laboratory and payments made to physicians. We are cooperating with these investigations and are providing documents in response to both subpoenas. We and our subsidiary, Arriva Medical, LLC, are also in the process of responding to Civil Investigative Demands, or CIDs, the most recent of which was received in July 2016, from the United States Attorney for the Middle District of Tennessee in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The CIDs request patient and insurance billing and medical records, records related to interactions with third parties, and correspondence related to the same, dating back to January 2010. We are cooperating with the investigation and are providing documents responsive to the CIDs. We cannot predict what effect, if any, these investigations, or any resulting claims, could have on Alere or its subsidiaries. We have received, from time to time, additional subpoenas and requests for information from the United States Department of Justice, other federal government agencies and state attorneys general, and we have, in each of these cases, cooperated with the applicable governmental entity in responding to the applicable subpoena or request for information. For example, in May 2016, we received a subpoena from the U.S. Attorney for the District of New Jersey, which seeks various documents related to the accuracy, reliability and performance of the INRatio System, including documents relating to prior interactions with the FDA and others regarding the system. Our diabetes, toxicology and patient self-testing businesses are subject to audit and claims for reimbursement brought in the ordinary course by private third-party payers, including health insurers, Zone Program Integrity Contractors, or ZPICs, and Medicare Administrative Contractors, or MACs, to monitor compliance with coverage and reimbursement rules and guidelines. These types of audits and claims can include, but are not limited to, claims relating to proper documentation and support or claims relating to the medical necessity of certain testing and can lead to assertions or determinations that certain claims should not have been, or will no longer be, paid by the private third-party payer or by Medicare or Medicaid. In such cases, the payer or program may seek to recoup or offset amounts they assert have been paid in error. Our businesses may also be subject at any time to other commercial disputes, product liability claims, personal injury claims, including claims arising from or relating to product recalls, negligence claims, third-party subpoenas or various other lawsuits arising in the ordinary course of business, including infringement, employment or investor matters, and we expect that this will continue to be the case in the future. For example, several individuals have filed suits against us alleging personal injury claims in connection with the use of our INRatio products (which are in addition to the class action suits described above). Such lawsuits or claims generally seek damages or reimbursement, sometimes in substantial amounts. There are possible unfavorable outcomes related to litigation or governmental investigations that could adversely impact our business, results of operations, financial condition, and cash flows.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2016
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	(18) Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt on or before the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption. Please also see Note 3, Summary of Significant Accounting Policies Recently Issued Standards In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting, In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), We believe that there were no other accounting standards recently issued that had or are expected to have a material impact on our consolidated financial statements. Recently Adopted Standards In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs Interest —Imputation of Interest (Subtopic 835-30) — Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting), In June 2014, the FASB issued ASU No. 2014-12, Compensation — Stock Compensation (Topic 718) — Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period

Equity Investments

Equity Investments	6 Months Ended
	Jun. 30, 2016
Equity Method Investments and Joint Ventures [Abstract]
Equity Investments	(19) Equity Investments We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323, Investments — Equity Method and Joint Ventures, (a) SPD We recorded earnings of $1.6 million and $6.2 million during the three and six months ended June 30, 2016, respectively, and earnings of $0.6 million and $4.2 million during the three and six months ended June 30, 2015, respectively, in equity earnings of unconsolidated entities, net of tax, in our consolidated statements of operations, which represented our 50% share of SPD’s net income for the respective periods and elimination of intercompany profit in inventory related to sales from Alere to SPD which is reflected in SPD’s net income. During the three and six months ended June 30, 2015, we received $12.1 million in cash from SPD as a return of capital. (b) TechLab We recorded earnings of $0.6 million and $1.0 million during the three and six months ended June 30, 2016, respectively, and earnings of $0.4 million and $0.8 million during the three and six months ended June 30, 2015, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our minority share of TechLab’s net income for the respective periods. During the three and six months ended June 30, 2015, we received $2.2 million in cash from TechLab as a return of capital. As of June 30, 2016, we continued to meet the held for sale criteria with respect to our 49% investment in TechLab. We intend to use all or a portion of the proceeds from any sale of this investment to fund our working capital, operations, research and development or repay a portion of our outstanding indebtedness. Accordingly, we have classified our investment in TechLab in assets held for sale – non-current in our consolidated balance sheet as of June 30, 2016. Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, Combined Condensed Results of Operations: 2016 2015 2016 2015 Net revenue $ 55,077 $ 53,159 $ 108,511 $ 101,016 Gross profit $ 36,634 $ 34,559 $ 72,853 $ 67,830 Net income after taxes $ 4,328 $ 3,039 $ 14,469 $ 11,096 Combined Condensed Balance Sheet: June 30, 2016 December 31, 2015 Current assets $ 91,942 $ 71,542 Non-current assets 31,826 30,802 Total assets $ 123,768 $ 102,344 Current liabilities $ 47,764 $ 37,609 Non-current liabilities 5,845 5,157 Total liabilities $ 53,609 $ 42,766

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	(21) Income Taxes We determine our estimated annual effective tax rate at the end of each interim period based on forecasted full-year pre-tax income (loss) by jurisdiction and permanent items. Our effective tax rate by quarter may vary based on actual quarter to date income and the forecasted mix of jurisdictional income (loss), as well as discrete items. A reconciliation between the U.S. federal statutory rate and our effective tax rate is summarized as follows: For the Three Months Ended For the Six Months Ended 2016 2015 2016 2015 Statutory rate 35 % 35 % 35 % 35 % State income taxes, net of federal benefit (5) % (4) % (4) % (5) % Rate differential on foreign earnings (61) % (19) % (58) % (27) % Change in valuation allowance (4) % (3) % (6) % 10 % Stock-based compensation 11 % 5 % 11 % (9) % Uncertain tax positions 12 % 7 % 9 % 15 % Disposition of BBI 0 % 27 % 0 % 65 % Other 3 % 6 % 7 % (12) % Effective tax rate (9 )% 54 % (6 )% 72 % For the three months and six months ended June 30, 2016, compared to the same periods in 2015, our effective tax rate decrease is primarily attributed to a more favorable jurisdictional mix of income and losses in the current year and non-recurring discrete tax impacts in 2015.

Guarantor Financial Information

Guarantor Financial Information	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Guarantor Financial Information	(22) Guarantor Financial Information Our 7.25% senior notes due 2018, our 6.5% senior subordinated notes due 2020 and our 6.375% senior subordinated notes due 2023 are guaranteed, and before their redemption on October 1, 2015, our 8.625% senior subordinated notes due 2018 were guaranteed, by certain of our consolidated 100% owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of June 30, 2016 and December 31, 2015, the related statements of operations and statements of comprehensive income (loss) for the three and six months ended June 30, 2016 and 2015, and statements of cash flows for the six months ended June 30, 2016 and 2015, respectively, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting. We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties. Effective December 31, 2015, we adopted ASU 2015-03 and ASU 2015-15, and accordingly we have reclassified $49.6 million and $34.1 million of debt issuance costs from other non-current assets to long-term debt, net of current portion on our balance sheet as of June 30, 2016 and December 31, 2015, respectively, as described in Note 18 Recent Accounting Pronouncements As discussed in Note 2 Revision to Previously Reported Financial Statements The following schedules reconcile the amounts as previously reported in our consolidating financial statements to the corresponding revised amounts: Three Months Ended June 30, 2015 Revised Consolidating Statement of Operations- Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 330,820 $ (1,011 ) $ 329,809 Cost of net revenue $ 199,233 $ 14 $ 199,247 Income from continuing operations before benefit for income taxes $ 55,133 $ (2,090 ) $ 53,043 Provision for income taxes $ 11,277 $ (447 ) $ 10,830 Income from continuing operations $ 43,856 $ (1,643 ) $ 42,213 Three Months Ended June 30, 2015 Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 367,418 $ (4,774 ) $ 362,644 Cost of net revenue $ 205,840 $ (559 ) $ 205,281 Income from continuing operations before benefit for income taxes $ 111,130 $ (5,415 ) $ 105,715 Provision for income taxes $ 22,768 $ (1,565 ) $ 21,203 Income from continuing operations $ 88,786 $ (3,850 ) $ 84,936 Six Months Ended June 30, 2015 Revised Consolidating Statement of Operations- Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 659,282 $ (3,181 ) $ 656,101 Cost of net revenue $ 387,269 $ (882 ) $ 386,387 Income from continuing operations before benefit for income taxes $ 60,049 $ (4,461 ) $ 55,588 Provision for income taxes $ 13,097 $ (1,516 ) $ 11,581 Income from continuing operations $ 46,952 $ (2,945 ) $ 44,007 Six Months Ended June 30, 2015 Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 710,777 $ 2,135 $ 712,912 Cost of net revenue $ 398,325 $ 1,846 $ 400,171 Income from continuing operations before benefit for income taxes $ 188,294 $ (911 ) $ 187,383 Provision for income taxes $ 32,483 $ 437 $ 32,920 Income from continuing operations $ 159,803 $ (1,348 ) $ 158,455 CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended June 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 222,954 $ 335,540 $ (74,748 ) $ 483,746 Services revenue — 112,698 12,111 — 124,809 Net product sales and services revenue — 335,652 347,651 (74,748 ) 608,555 License and royalty revenue — 3,448 2,008 (2,923 ) 2,533 Net revenue — 339,100 349,659 (77,671 ) 611,088 Cost of net product sales 220 126,795 188,478 (65,095 ) 250,398 Cost of services revenue 104 79,203 7,760 (8,773 ) 78,294 Cost of net product sales and services revenue 324 205,998 196,238 (73,868 ) 328,692 Cost of license and royalty revenue — (7 ) 3,466 (2,924 ) 535 Cost of net revenue 324 205,991 199,704 (76,792 ) 329,227 Gross profit (loss) (324 ) 133,109 149,955 (879 ) 281,861 Operating expenses: Research and development 2,997 16,194 9,255 — 28,446 Sales and marketing 1,568 53,155 47,793 — 102,516 General and administrative 57,740 30,460 40,154 — 128,354 Impairment and (gain) loss on dispositions, net — — — — — Operating income (loss) (62,629 ) 33,300 52,753 (879 ) 22,545 Interest expense, including amortization of original issue discounts and deferred financing costs (41,857 ) (2,223 ) (2,775 ) 4,526 (42,329 ) Other income (expense), net (8,144 ) 4,103 (5,544 ) (4,527 ) (14,112 ) Income (loss) before provision (benefit) for income taxes (112,630 ) 35,180 44,434 (880 ) (33,896 ) Provision (benefit) for income taxes 19,765 (6,759 ) (9,889 ) — 3,117 Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (132,395 ) 41,939 54,323 (880 ) (37,013 ) Equity in earnings of subsidiaries, net of tax 96,916 — — (96,916 ) — Equity earnings of unconsolidated entities, net of tax 588 — 1,557 (23 ) 2,122 Net income (loss) (34,891 ) 41,939 55,880 (97,819 ) (34,891 ) Less: Net income attributable to non-controlling interests — — 143 — 143 Net income (loss) attributable to Alere Inc. and Subsidiaries (34,891 ) 41,939 55,737 (97,819 ) (35,034 ) Preferred stock dividends (5,308 ) — — — (5,308 ) Net income (loss) available to common stockholders $ (40,199 ) $ 41,939 $ 55,737 $ (97,819 ) $ (40,342 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended June 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 211,593 $ 345,289 $ (65,833 ) $ 491,049 Services revenue — 114,983 11,645 — 126,628 Net product sales and services revenue — 326,576 356,934 (65,833 ) 617,677 License and royalty revenue — 3,233 5,710 (3,249 ) 5,694 Net revenue — 329,809 362,644 (69,082 ) 623,371 Cost of net product sales 417 120,953 193,593 (57,070 ) 257,893 Cost of services revenue 80 77,884 7,524 (8,688 ) 76,800 Cost of net product sales and services revenue 497 198,837 201,117 (65,758 ) 334,693 Cost of license and royalty revenue 19 410 4,164 (3,249 ) 1,344 Cost of net revenue 516 199,247 205,281 (69,007 ) 336,037 Gross profit (loss) (516 ) 130,562 157,363 (75 ) 287,334 Operating expenses: Research and development 3,241 13,993 9,964 — 27,198 Sales and marketing 1,570 52,101 54,353 — 108,024 General and administrative 24,390 51,288 (14,505 ) — 61,173 Impairment and (gain) loss on dispositions, net 44,378 (39,412 ) 576 — 5,542 Operating income (loss) (74,095 ) 52,592 106,975 (75 ) 85,397 Interest expense, including amortization of original issue discounts and deferred financing costs (59,086 ) (3,060 ) (4,702 ) 7,354 (59,494 ) Other income (expense), net 3,596 3,511 3,442 (7,354 ) 3,195 Income (loss) from continuing operations before provision (benefit) for income taxes (129,585 ) 53,043 105,715 (75 ) 29,098 Provision (benefit) for income taxes (16,306 ) 10,830 21,203 (38 ) 15,689 Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (113,279 ) 42,213 84,512 (37 ) 13,409 Equity in earnings of subsidiaries, net of tax 127,127 — — (127,127 ) — Equity earnings of unconsolidated entities, net of tax 922 — 424 15 1,361 Net income 14,770 42,213 84,936 (127,149 ) 14,770 Less: Net income attributable to non-controlling interests — — 359 — 359 Net income attributable to Alere Inc. and Subsidiaries 14,770 42,213 84,577 (127,149 ) 14,411 Preferred stock dividends (5,308 ) — — — (5,308 ) Net income available to common stockholders $ 9,462 $ 42,213 $ 84,577 $ (127,149 ) $ 9,103 CONSOLIDATING STATEMENT OF OPERATIONS For the Six Months Ended June 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 447,334 $ 632,377 $ (136,194 ) $ 943,517 Services revenue — 217,182 23,336 — 240,518 Net product sales and services revenue — 664,516 655,713 (136,194 ) 1,184,035 License and royalty revenue — 6,368 4,566 (5,672 ) 5,262 Net revenue — 670,884 660,279 (141,866 ) 1,189,297 Cost of net product sales 334 251,553 354,460 (118,488 ) 487,859 Cost of services revenue 104 151,698 15,800 (16,208 ) 151,394 Cost of net product sales and services revenue 438 403,251 370,260 (134,696 ) 639,253 Cost of license and royalty revenue — 10 7,589 (5,673 ) 1,926 Cost of net revenue 438 403,261 377,849 (140,369 ) 641,179 Gross profit (loss) (438 ) 267,623 282,430 (1,497 ) 548,118 Operating expenses: Research and development 7,131 30,653 17,724 — 55,508 Sales and marketing 2,904 107,620 91,805 — 202,329 General and administrative 102,355 63,646 77,309 — 243,310 Impairment and (gain) loss on dispositions, net — — (3,810 ) — (3,810 ) Operating income (loss) (112,828 ) 65,704 99,402 (1,497 ) 50,781 Interest expense, including amortization of original issue discounts and deferred financing costs (82,944 ) (4,875 ) (5,842 ) 9,226 (84,435 ) Other income (expense), net (6,156 ) 6,605 (6,683 ) (9,227 ) (15,461 ) Income (loss) before provision (benefit) for income taxes (201,928 ) 67,434 86,877 (1,498 ) (49,115 ) Provision (benefit) for income taxes 19,711 (6,509 ) (10,293 ) — 2,909 Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (221,639 ) 73,943 97,170 (1,498 ) (52,024 ) Equity in earnings of subsidiaries, net of tax 175,502 — — (175,502 ) — Equity earnings of unconsolidated entities, net of tax 1,269 — 6,138 (251 ) 7,156 Net income (loss) (44,868 ) 73,943 103,308 (177,251 ) (44,868 ) Less: Net income attributable to non-controlling interests — — 246 — 246 Net income (loss) attributable to Alere Inc. and Subsidiaries (44,868 ) 73,943 103,062 (177,251 ) (45,114 ) Preferred stock dividends (10,617 ) — — — (10,617 ) Net income (loss) available to common stockholders $ (55,485 ) $ 73,943 $ 103,062 $ (177,251 ) $ (55,731 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Six Months Ended June 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 426,631 $ 675,395 $ (126,639 ) $ 975,387 Services revenue — 223,040 27,444 — 250,484 Net product sales and services revenue — 649,671 702,839 (126,639 ) 1,225,871 License and royalty revenue — 6,430 10,073 (6,111 ) 10,392 Net revenue — 656,101 712,912 (132,750 ) 1,236,263 Cost of net product sales 833 233,248 375,999 (112,086 ) 497,994 Cost of services revenue 130 151,921 15,964 (15,589 ) 152,426 Cost of net product sales and services revenue 963 385,169 391,963 (127,675 ) 650,420 Cost of license and royalty revenue (21 ) 1,218 8,208 (6,111 ) 3,294 Cost of net revenue 942 386,387 400,171 (133,786 ) 653,714 Gross profit (loss) (942 ) 269,714 312,741 1,036 582,549 Operating expenses: Research and development 5,543 28,912 20,759 — 55,214 Sales and marketing 2,830 105,328 108,945 — 217,103 General and administrative 44,913 89,058 19,893 — 153,864 Impairment and (gain) loss on dispositions, net 80,901 (8,804 ) (31,763 ) — 40,334 Operating income (loss) (135,129 ) 55,220 194,907 1,036 116,034 Interest expense, including amortization of original issue discounts and deferred financing costs (105,184 ) (6,345 ) (8,745 ) 14,349 (105,925 ) Other income (expense), net 7,243 6,713 1,221 (14,349 ) 828 Income (loss) from continuing operations before provision (benefit) for income taxes (233,070 ) 55,588 187,383 1,036 10,937 Provision (benefit) for income taxes (36,973 ) 11,581 32,920 308 7,836 Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (196,097 ) 44,007 154,463 728 3,101 Equity in earnings of subsidiaries, net of tax 201,260 — — (201,260 ) — Equity earnings of unconsolidated entities, net of tax 1,346 — 3,992 (18 ) 5,320 Income from continuing operations 6,509 44,007 158,455 (200,550 ) 8,421 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Net income 225,198 42,095 158,455 (200,550 ) 225,198 Less: Net income attributable to non-controlling interests — — 447 — 447 Net income attributable to Alere Inc. and Subsidiaries 225,198 42,095 158,008 (200,550 ) 224,751 Preferred stock dividends (10,558 ) — — — (10,558 ) Net income available to common stockholders $ 214,640 $ 42,095 $ 158,008 $ (200,550 ) $ 214,193 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended June 30, 2016 (in thousands) Issuer Guarantor Subsidiaries Non- Guarantor Subsidiaries Eliminations Consolidated Net income (loss) $ (34,891 ) $ 41,939 $ 55,880 $ (97,819 ) $ (34,891 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 276 (699 ) (43,720 ) 8 (44,135 ) Minimum pension liability adjustment — — 531 — 531 Other comprehensive income (loss), before tax 276 (699 ) (43,189 ) 8 (43,604 ) Other comprehensive income (loss) 276 (699 ) (43,189 ) 8 (43,604 ) Comprehensive income (loss) (34,615 ) 41,240 12,691 (97,811 ) (78,495 ) Less: Comprehensive income attributable to non-controlling interests — — 143 — 143 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (34,615 ) $ 41,240 $ 12,548 $ (97,811 ) $ (78,638 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended June 30, 2015 (in thousands) Issuer Guarantor Subsidiaries Non- Guarantor Subsidiaries Eliminations Consolidated Net income $ 14,770 $ 42,213 $ 84,936 $ (127,149 ) $ 14,770 Other comprehensive income, before tax: Changes in cumulative translation adjustment 197 689 45,840 — 46,726 Minimum pension liability adjustment — — (374 ) — (374 ) Other comprehensive income, before tax 197 689 45,466 — 46,352 Other comprehensive income 197 689 45,466 — 46,352 Comprehensive income 14,967 42,902 130,402 (127,149 ) 61,122 Less: Comprehensive income attributable to non-controlling interests — — 359 — 359 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 14,967 $ 42,902 $ 130,043 $ (127,149 ) $ 60,763 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Six Months Ended June 30, 2016 (in thousands) Issuer Guarantor Subsidiaries Non- Guarantor Subsidiaries Eliminations Consolidated Net income (loss) $ (44,868 ) $ 73,943 $ 103,308 $ (177,251 ) $ (44,868 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 391 (828 ) (21,513 ) 8 (21,942 ) Minimum pension liability adjustment — — 686 — 686 Other comprehensive income (loss), before tax 391 (828 ) (20,827 ) 8 (21,256 ) Other comprehensive income (loss) 391 (828 ) (20,827 ) 8 (21,256 ) Comprehensive income (loss) (44,477 ) 73,115 82,481 (177,243 ) (66,124 ) Less: Comprehensive income attributable to non-controlling interests — — 246 — 246 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (44,477 ) $ 73,115 $ 82,235 $ (177,243 ) $ (66,370 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Six Months Ended June 30, 2015 (in thousands) Issuer Guarantor Subsidiaries Non- Guarantor Subsidiaries Eliminations Consolidated Net income $ 225,198 $ 42,095 $ 158,455 $ (200,550 ) $ 225,198 Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment (460 ) 117 (33,273 ) — (33,616 ) Minimum pension liability adjustment — — (1,756 ) — (1,756 ) Other comprehensive income (loss), before tax (460 ) 117 (35,029 ) — (35,372 ) Other comprehensive income (loss) (460 ) 117 (35,029 ) — (35,372 ) Comprehensive income 224,738 42,212 123,426 (200,550 ) 189,826 Less: Comprehensive income attributable to non-controlling interests — — 447 — 447 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 224,738 $ 42,212 $ 122,979 $ (200,550 ) $ 189,379 CONSOLIDATING BALANCE SHEET June 30, 2016 (in thousands) Issuer Guarantor Subsidiaries Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 49,465 $ 6,881 $ 449,818 $ — $ 506,164 Restricted cash 1,415 — 4,247 — 5,662 Marketable securities — 74 — — 74 Accounts receivable, net of allowances — 190,438 236,784 — 427,222 Inventories, net — 168,413 188,448 (23,015 ) 333,846 Deferred tax assets (455 ) 6,513 (6,058 ) — — Prepaid expenses and other current assets 12,194 33,489 110,122 6,534 162,339 Intercompany receivables 360,548 827,927 158,858 (1,347,333 ) — Total current assets 423,167 1,233,735 1,142,219 (1,363,814 ) 1,435,307 Property, plant and equipment, net 29,742 224,796 187,337 (3,088 ) 438,787 Goodwill — 1,823,018 988,527 — 2,811,545 Other intangible assets with indefinite lives — 7,538 20,800 (59 ) 28,279 Finite-lived intangible assets, net 2,745 566,973 342,690 (3,200 ) 909,208 Restricted cash — — 42,589 — 42,589 Other non-current assets 570 2,052 14,317 (649 ) 16,290 Investments in subsidiaries 3,455,642 158,195 57,650 (3,671,487 ) — Investments in unconsolidated entities 687 14,765 44,654 14,405 74,511 Deferred tax assets (66,034 ) 24,785 62,006 (2,119 ) 18,638 Non-current income tax receivable 3,517 — — — 3,517 Assets held for sale — non-current 12,223 — — — 12,223 Intercompany notes receivables 1,887,589 708,708 2,901 (2,599,198 ) — Total assets $ 5,749,848 $ 4,764,565 $ 2,905,690 $ (7,629,209 ) $ 5,790,894 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 40,073 $ — $ 3,608 $ — $ 43,681 Current portion of capital lease obligations — 1,654 1,846 — 3,500 Accounts payable 23,789 77,283 93,163 — 194,235 Accrued expenses and other current liabilities (514,898 ) 635,590 197,663 2,171 320,526 Intercompany payables 965,315 178,406 203,621 (1,347,342 ) — Total current liabilities 514,279 892,933 499,901 (1,345,171 ) 561,942 Long-term liabilities: Long-term debt, net of current portion 2,874,825 — 45,964 — 2,920,789 Capital lease obligations, net of current portion — 1,466 5,506 — 6,972 Deferred tax liabilities (158,407 ) 250,292 48,897 82 140,864 Other long-term liabilities 14,741 56,618 77,455 (649 ) 148,165 Intercompany notes payables 496,756 1,162,748 939,694 (2,599,198 ) — Total long-term liabilities 3,227,915 1,471,124 1,117,516 (2,599,765 ) 3,216,790 Total stockholders’ equity 2,007,654 2,400,508 1,283,765 (3,684,273 ) 2,007,654 Non-controlling interests — — 4,508 — 4,508 Total equity 2,007,654 2,400,508 1,288,273 (3,684,273 ) 2,012,162 Total liabilities and equity $ 5,749,848 $ 4,764,565 $ 2,905,690 $ (7,629,209 ) $ 5,790,894 CONSOLIDATING BALANCE SHEET December 31, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 139,153 $ 21,150 $ 341,897 $ — $ 502,200 Restricted cash 1,250 — 4,444 — 5,694 Marketable securities — 164 — — 164 Accounts receivable, net of allowances — 192,591 253,242 — 445,833 Inventories, net — 173,383 194,192 (20,574 ) 347,001 Deferred tax assets (52,410 ) 31,285 23,244 (2,119 ) — Prepaid expenses and other current assets 7,575 27,095 110,961 6,602 152,233 Assets held for sale — current — — 4,165 — 4,165 Intercompany receivables 620,838 812,957 50,691 (1,484,486 ) — Total current assets 716,406 1,258,625 982,836 (1,500,577 ) 1,457,290 Property, plant and equipment, net 31,384 228,065 188,084 (1,494 ) 446,039 Goodwill — 1,823,919 1,012,996 — 2,836,915 Other intangible assets with indefinite lives — 7,638 20,531 (59 ) 28,110 Finite-lived intangible assets, net 2,951 627,269 370,261 (3,200 ) 997,281 Restricted cash — — 43,228 — 43,228 Other non-current assets 804 2,340 15,380 (446 ) 18,078 Investments in subsidiaries 3,294,857 158,195 57,650 (3,510,702 ) — Investments in unconsolidated entities 502 14,764 37,947 12,120 65,333 Deferred tax assets (14,078 ) (14 ) 28,085 — 13,993 Non-current income tax receivable 3,517 — — — 3,517 Assets held for sale — non-current 13,337 — — — 13,337 Intercompany notes receivables 1,905,188 672,032 6,900 (2,584,120 ) — Total assets $ 5,954,868 $ 4,792,833 $ 2,763,898 $ (7,588,478 ) $ 5,923,121 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 197,084 $ — $ 2,908 $ — $ 199,992 Current portion of capital lease obligations — 2,018 1,944 — 3,962 Accounts payable 15,981 76,890 102,881 — 195,752 Accrued expenses and other current liabilities (554,350 ) 650,632 225,944 2,239 324,465 Liabilities related to assets held for sale — current — — 363 — 363 Intercompany payables 1,122,042 249,553 112,891 (1,484,486 ) — Total current liabilities 780,757 979,093 446,931 (1,482,247 ) 724,534 Long-term liabilities: Long-term debt, net of current portion 2,784,913 — 46,253 — 2,831,166 Capital lease obligations, net of current portion — 840 6,341 — 7,181 Deferred tax liabilities (157,708 ) 250,495 54,749 82 147,618 Other long-term liabilities 14,962 59,309 80,369 (447 ) 154,193 Intercompany notes payables 477,779 1,181,168 925,173 (2,584,120 ) — Total long-term liabilities 3,119,946 1,491,812 1,112,885 (2,584,485 ) 3,140,158 Total stockholders’ equity 2,054,165 2,321,928 1,199,818 (3,521,746 ) 2,054,165 Non-controlling interests — — 4,264 — 4,264 Total equity 2,054,165 2,321,928 1,204,082 (3,521,746 ) 2,058,429 Total liabilities and equity $ 5,954,868 $ 4,792,833 $ 2,763,898 $ (7,588,478 ) $ 5,923,121 CONSOLIDATING STATEMENT OF CASH FLOWS For the Six Months Ended June 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (44,868 ) $ 73,943 $ 103,308 $ (177,251 ) $ (44,868 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (175,502 ) — — 175,502 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 5,175 7 79 — 5,261 Depreciation and amortization 4,484 88,973 48,109 839 142,405 Non-cash stock-based compensation expense 10,541 5,462 4,604 — 20,607 Impairment of inventory — — 870 — 870 Impairment of long-lived assets — 548 85 — 633 Loss on disposition of fixed assets 1 3,522 712 — 4,235 Equity earnings of unconsolidated entities, net of tax (1,269 ) — (6,138 ) 251 (7,156 ) Deferred income taxes — (200 ) (13,010 ) — (13,210 ) (Gain) loss related to impairment and net (gain) loss on dispositions — — (3,810 ) — (3,810 ) Other non-cash items (66 ) 459 9,323 4 9,720 Non-cash change in fair value of contingent purchase price consideration (800 ) (823 ) (157 ) — (1,780 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — 2,141 17,882 — 20,023 Inventories, net — (11,723 ) 5,243 660 (5,820 ) Prepaid expenses and other current assets (4,283 ) (7,408 ) (13,258 ) 68 (24,881 ) Accounts payable 7,807 396 (8,204 ) — (1 ) Accrued expenses and other current liabilities 40,481 (13,721 ) (28,367 ) (69 ) (1,676 ) Other non-current liabilities (1,054 ) (1,561 ) (3,491 ) — (6,106 ) Cash paid for contingent consideration (321 ) — (3 ) — (324 ) Intercompany payable (receivable) 145,358 (141,518 ) (3,836 ) (4 ) — Net cash provided by (used in) operating activities (14,316 ) (1,503 ) 109,941 — 94,122 Cash Flows from Investing Activities: Increase in restricted cash (165 ) — (284 ) — (449 ) Purchases of property, plant and equipment (2,680 ) (11,750 ) (18,972 ) 1,084 (32,318 ) Proceeds from sale of property, plant and equipment 92 45 1,839 (1,084 ) 892 Cash received from (used in) dispositions, net of cash divested (1,337 ) — 22,807 — 21,470 Cash paid for business acquisitions, net of cash acquired — — (5,958 ) — (5,958 ) Cash received from equity method investments 2,383 — — — 2,383 Cash received from sales of marketable securities. — 90 — — 90 Cash paid for investments (184 ) — — — (184 ) (Increase) decrease in other assets (50 ) 13 532 — 495 Net cash used in investing activities (1,941 ) (11,602 ) (36 ) — (13,579 ) Cash Flows from Financing Activities: Cash paid for financing costs (19,564 ) — — — (19,564 ) Cash paid for contingent purchase price consideration — — (485 ) — (485 ) Proceeds from issuance of common stock, net of issuance costs 11,124 — — — 11,124 Proceeds from issuance of long-term debt — — 381 — 381 Payments on short-term debt — — (791 ) — (791 ) Payments on long-term debt (176,861 ) — (776 ) — (177,637 ) Net proceeds under revolving credit facilities 125,000 — 1,213 — 126,213 Cash paid for dividends (10,646 ) — — — (10,646 ) Principal payments on capital lease obligations — (1,324 ) (886 ) — (2,210 ) Net cash used in financing activities (70,947 ) (1,324 ) (1,344 ) — (73,615 ) Foreign exchange effect on cash and cash equivalents (2,484 ) 160 (640 ) — (2,964 ) Net increase (decrease) in cash and cash equivalents (89,688 ) (14,269 ) 107,921 — 3,964 Cash and cash equivalents, beginning of period 139,153 21,150 341,897 — 502,200 Cash and cash equivalents, end of period $ 49,465 $ 6,881 $ 449,818 $ — $ 506,164 CONSOLIDATING STATEMENT OF CASH FLOWS For the Six Months Ended June 30, 2015 (in thousands) Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash Flows from Operating Activities: Net income $ 225,198 $ 42,095 $ 158,455 $ (200,550 ) $ 225,198 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Income from continuing operations 6,509 44,007 158,455 (200,550 ) 8,421 Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (201,260 ) — — 201,260 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 7,728 13 43 — 7,784 Depreciation and amortization 3,840 82,576 60,652 35 147,103 Non-cash stock-based compensation expense 6,458 2,633 3,188 — 12,279 Impairment of inventory — 133 (65 ) — 68 Impairment of long-lived assets — 64 323 — 387 Loss on disposition of fixed assets — 2,764 554 — 3,318 Equity earnings of unconsolidated entities, net of tax (1,346 ) — (3,992 ) 18 (5,320 ) Gain on sales of marketable securities — (8 ) — — (8 ) Deferred income taxes (8,686 ) (32,097 ) (1,826 ) 438 (42,171 ) (Gain) loss related to impairment and net (gain) loss on dispositions 80,901 (8,804 ) (31,763 ) — 40,334 Loss on extinguishment of debt 3,480 — — — 3,480 Other non-cash items (159 ) (1,497 ) (676 ) — (2,332 ) Non-cash change in fair value of contingent purchase price consideration (30,895 ) 15,748 (37,720 ) — (52,867 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (2,599 ) (15,417 ) — (18,016 ) Inventories, net — (27,824 ) (15,984 ) (1,411 ) (45,219 ) Prepaid expenses and other current assets (3,052 ) (19,127 ) 810 (5,708 ) (27,077 ) Accounts payable (7,499 ) (11,331 ) (4,421 ) — (23,251 ) Accrued expenses and other current liabilities (8,944 ) 61,472 (33,374 ) 3,898 23,052 Other non-current liabilities 2,226 6,171 (1,476 ) 1,615 8,536 Cash paid for contingent purchase price consideration (3,768 ) — (13 ) — (3,781 ) Intercompany payable (receivable) 127,569 (101,515 ) (26,054 ) — — Net cash provided by (used in) continuing operations (26,898 ) 10,779 51,244 (405 ) 34,720 Net cash provided by discontinued operations — 318 — — 318 Net cash provided by (used in) operating activities (26,898 ) 11,097 51,244 (405 ) 35,038 Cash Flows from Investing Activities: Increase in restricted cash (422,169 ) — (1,856 ) — (424,025 ) Purchases of property, plant and equipment (5,147 ) (19,386 ) (23,907 ) 1,156 (47,284 ) Proceeds from sale of property, plant and equipment — 738 1,199 (817 ) 1,120 Cash received from (used in) disposition, net of cash divested 593,217 (8,723 ) 2,131 — 586,625 Cash received from equity method investments 2,205 — 12,092 — 14,297 Cash received from sales of marketable securities — 93 — — 93 Decrease in other assets 348 409 927 66 1,750 Net cash provided by (used in) continuing operations 168,454 (26,869 ) (9,414 ) 405 132,576 Net cash used in discontinued operations — (209 ) — — (209 ) Net cash provided by (used in) investing activities 168,454 (27,078 ) (9,414 ) 405 132,367 Cash Flows from Financing Activities: Cash paid for financing costs (15,731 ) — — — (15,731 ) Cash paid for contingent purchase price consideration (5,503 ) — (870 ) — (6,373 ) Proceeds from issuance of common stock, net of issuance costs 56,332 — — — 56,332 Proceeds from issuance of long-term debt 2,119,125 — 2,726 — 2,121,851 Payments on short-term debt — — (584 ) — (584 ) Payments on long-term debt (2,117,875 ) — (389 ) — (2,118,264 ) Net payments under revolving credit facilities (127,000 ) — 680 — (126,320 ) Cash paid for dividends (10,646 ) — — — (10,646 ) Principal payments on capital lease obligations — (1,263 ) (1,647 ) — (2,910 ) Net cash used in continuing operations (101,298 ) (1,263 ) (84 ) — (102,645 ) Net cash used in discontinued operations — (76 ) — — (76 ) Net cash used in financing activities (101,298 ) (1,339 ) (84 ) — (102,721 ) Foreign exchange effect on cash and cash equivalents — (129 ) (1,445 ) — (1,574 ) Net increase (decrease) in cash and cash equivalents 40,258 (17,449 ) 40,301 — 63,110 Cash and cash equivalents, beginning of period — continuing operations 2,149 69,154 307,158 — 378,461 Cash and cash equivalents, beginning of period — discontinued operations — 23,300 — — 23,300 Cash and cash equivalents of continuing operations, end of period $ 42,407 $ 75,005 $ 347,459 $ — $ 464,871

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	(23) Subsequent Events Amendment to Credit Facility As further described in Note 12 above, in August 2016 we entered into an amendment to our Credit Agreement. INRatio and INRatio ® In July 2016 we announced that we will be initiating a voluntary withdrawal of the Alere INRatio and INRatio2 PT/INR Monitoring System. We are currently working with the FDA on implementing the product withdrawal and eventual product discontinuation. In December 2014, we initiated a voluntary correction to inform users of the Alere INRatio and INRatio2 PT/INR Monitoring Systems that patients with certain medical conditions should not be tested with the systems. We proactively reported these device concerns to the FDA and began conducting a thorough investigation into these events. Over the course of the past two years, Alere invested in the research and development of software enhancements intended to address the potential, in certain cases, of the system to deliver a result that differs from that of another measurement method. We submitted the software enhancements to the FDA at the end of 2015. The FDA notified us that it believes that our studies do not adequately demonstrate the effectiveness of the software modification and advised us to submit a proposed plan to voluntarily remove the INRatio ® In light of this input from the FDA and our business considerations, in July 2016 we determined to voluntarily remove the INRatio systems from the market. Due to the fact that the circumstances giving rise to the voluntary withdrawal in the United States and related action outside the U.S. existed as of December 31, 2015, certain charges incurred in connection with the withdrawal were recorded in the fourth quarter of 2015. Specifically, we recorded a charge of approximately $38 million in the year ended December 31, 2015, related to impairment of inventory and production equipment and estimated costs of removing our INRatio and INRatio2 from the market. As of June 30, 2016, $16.0 million of the estimated costs of removing INRatio and INRatio 2 from the market were included in accrued expenses. Additionally, our decision to withdraw the INRatio and INRatio2 PT/INR Monitoring Systems impacted the useful life assumptions of certain tangible and intangible assets. As a result of this change in estimate, we recorded approximately $4.1 million and $8.2 million of accelerated amortization of intangible assets and approximately $0.8 million and $1.5 million of accelerated depreciation of tangible assets in the three and six months ended June 30, 2016, respectively. Finally, during the remainder of fiscal year 2016 we expect to incur approximately $8.2 million of accelerated amortization, approximately $1.6 million of accelerated depreciation, and $2.0 million of other one-time cash expenditures.

Basis of Presentation of Fina29

Basis of Presentation of Financial Information (Policies)	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation of Financial Information	Basis of Presentation of Financial Information The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2015 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on August 8, 2016. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2015. Certain amounts presented may not recalculate directly, due to rounding.
Cash and Cash Equivalents	We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At June 30, 2016, our cash equivalents consisted of money market funds.

Revision of Previously Report30

Revision of Previously Reported Consolidated Financial Statements (Tables)	6 Months Ended
	Jun. 30, 2016
Accounting Changes and Error Corrections [Abstract]
Restated and Revised Consolidated Statement of Operations	The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding revised amounts: Three Months Ended June 30, 2015 Revised Consolidated Statement of Operations (in thousands, except per share As Previously Reported Adjustment As Revised Net product sales $ 496,834 $ (5,785 ) $ 491,049 Net product sales and services revenue $ 623,462 $ (5,785 ) $ 617,677 Net revenue $ 629,156 $ (5,785 ) $ 623,371 Cost of net product sales $ 258,485 $ (592 ) $ 257,893 Cost of service revenue $ 76,753 $ 47 $ 76,800 Cost of net product sales and services revenue $ 335,238 $ (545 ) $ 334,693 Cost of net revenue $ 336,582 $ (545 ) $ 336,037 Gross profit $ 292,574 $ (5,240 ) $ 287,334 Sales and marketing $ 107,184 $ 840 $ 108,024 General and administrative $ 60,813 $ 360 $ 61,173 Operating income $ 91,837 $ (6,440 ) $ 85,397 Other income (loss), net $ 4,260 $ (1,065 ) $ 3,195 Income from continuing operations before provision for income taxes $ 36,603 $ (7,505 ) $ 29,098 Provision for income taxes $ 17,701 $ (2,012 ) $ 15,689 Income from continuing operations before equity earnings of unconsolidated entities, net of tax $ 18,902 $ (5,493 ) $ 13,409 Income from continuing operations $ 20,263 $ (5,493 ) $ 14,770 Net income $ 20,263 $ (5,493 ) $ 14,770 Net income attributable to Alere Inc. and Subsidiaries $ 19,904 $ (5,493 ) $ 14,411 Net income available to common stockholders $ 14,596 $ (5,493 ) $ 9,103 Basic and diluted income per common share: Income from continuing operations $ 0.17 $ (0.06 ) $ 0.11 Basic and diluted net income per common share: Net income per common share $ 0.17 $ (0.06 ) $ 0.11 Six Months Ended June 30, 2015 Revised Consolidated Statement of Operations (in thousands, except per share As Previously Reported Adjustment As Revised Net product sales $ 976,433 $ (1,046 ) $ 975,387 Net product sales and services revenue $ 1,226,917 $ (1,046 ) $ 1,225,871 Net revenue $ 1,237,309 $ (1,046 ) $ 1,236,263 Cost of net product sales $ 497,122 $ 872 $ 497,994 Cost of service revenue $ 152,334 $ 92 $ 152,426 Cost of net product sales and services revenue $ 649,456 $ 964 $ 650,420 Cost of net revenue $ 652,750 $ 964 $ 653,714 Gross profit $ 584,559 $ (2,010 ) $ 582,549 Sales and marketing $ 216,263 $ 840 $ 217,103 General and administrative $ 153,504 $ 360 $ 153,864 Operating income $ 119,244 $ (3,210 ) $ 116,034 Other income (loss), net $ 2,990 $ (2,162 ) $ 828 Income from continuing operations before benefit for income taxes $ 16,309 $ (5,372 ) $ 10,937 Provision for income taxes $ 8,915 $ (1,079 ) $ 7,836 Income from continuing operations before equity earnings of unconsolidated entities, net of tax $ 7,394 $ (4,293 ) $ 3,101 Income from continuing operations $ 12,714 $ (4,293 ) $ 8,421 Net income $ 229,491 $ (4,293 ) $ 225,198 Net income attributable to Alere Inc. and Subsidiaries $ 229,044 $ (4,293 ) $ 224,751 Net income available to common stockholders $ 218,486 $ (4,293 ) $ 214,193 Basic and diluted income (loss) per common share: Income (loss) from continuing operations $ 0.02 $ (0.05 ) $ (0.03 ) Basic and diluted net income per common share: Net income per common share $ 2.54 $ (0.01 ) $ 2.53
Restated and Revised Consolidated Statement of Comprehensive Loss	Three Months Ended June 30, 2015 Revised Consolidated Statement of Comprehensive Loss (in thousands) As Previously Reported Adjustment As Revised Net income $ 20,263 $ (5,493 ) $ 14,770 Comprehensive income $ 66,615 $ (5,493 ) $ 61,122 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 66,256 $ (5,493 ) $ 60,763 Six Months Ended June 30, 2015 Revised Consolidated Statement of Comprehensive Loss (in thousands) As Previously Reported Adjustment As Revised Net income $ 229,491 $ (4,293 ) $ 225,198 Comprehensive income $ 194,119 $ (4,293 ) $ 189,826 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 193,672 $ (4,293 ) $ 189,379
Restated and Revised Consolidated Statement of Cash Flows	Six Months Ended June 30, 2015 Revised Consolidated Statement of Cash Flows (in thousands) As Previously Reported Adjustment As Revised Net income $ 229,491 $ (4,293 ) $ 225,198 Income from continuing operations $ 12,714 $ (4,293 ) $ 8,421 Depreciation and amortization $ 147,011 $ 92 $ 147,103 Deferred income taxes $ (40,655 ) $ (1,516 ) $ (42,171 ) Accounts receivable, net $ (27,464 ) $ 9,448 $ (18,016 ) Inventories, net $ (46,093 ) $ 874 $ (45,219 ) Accrued expenses and other current liabilities $ 27,657 $ (4,605 ) $ 23,052 Other non-current liabilities $ 6,025 $ 2,511 $ 8,536 Net cash provided by continuing operations $ 32,209 $ 2,511 $ 34,720 Net cash provided by operating activities $ 32,527 $ 2,511 $ 35,038 Excess tax benefits on exercised stock options $ 2,511 $ (2,511 ) $ — Net cash used in continuing operations $ (100,134 ) $ (2,511 ) $ (102,645 ) Net cash used in financing activities $ (100,210 ) $ (2,511 ) $ (102,721 )

Discontinued Operations, Impa31

Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net (Tables)	6 Months Ended
	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Summarized Financial Information Related to Health Management Business	The following summarized financial information related to the health management business has been segregated from continuing operations and reported as discontinued operations in our consolidated statements of operations for the three and six months ended June 30, 2015. The results are as follows (in thousands): Three and Six Months Ended June 30, 2015 Net revenue $ 7,373 Cost of net revenue (4,413 ) Sales and marketing (996 ) General and administrative (5,001 ) Interest expense (9 ) Other income (expense), net 160 Gain on disposal 366,191 Income from discontinued operations before provision for income taxes 363,305 Provision for income taxes 146,528 Income from discontinued operations, net of tax $ 216,777

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Inventories are Stated at Lower of Cost (First In, First Out) or Market	Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): June 30, 2016 December 31, 2015 Raw materials $ 121,904 $ 130,171 Work-in-process 74,206 69,178 Finished goods 137,736 147,652 $ 333,846 $ 347,001

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation Expense	We recorded stock-based compensation expense in our consolidated statements of operations for the three and six months ended June 30, 2016 and 2015, respectively, as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Cost of net revenue $ 601 $ 287 $ 1,080 $ 540 Research and development 481 282 879 606 Sales and marketing 2,636 1,251 4,561 2,345 General and administrative 7,286 5,310 14,086 8,788 $ 11,004 $ 7,130 $ 20,607 $ 12,279

Net Income (Loss) per Common 34

Net Income (Loss) per Common Share (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Income (Loss) Per Common Share	The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods presented (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Basic and diluted net income (loss) per common share: Numerator Income (loss) from continuing operations $ (34,891 ) $ 14,770 $ (44,868 ) $ 8,421 Preferred stock dividends (5,308 ) (5,308 ) (10,617 ) (10,558 ) Income (loss) from continuing operations attributable to common shares (40,199 ) 9,462 (55,485 ) (2,137 ) Less: Net income attributable to non-controlling interest 143 359 246 447 Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries (40,342 ) 9,103 (55,731 ) (2,584 ) Income from discontinued operations — — — 216,777 Net income (loss) available to common stockholders $ (40,342 ) $ 9,103 $ (55,731 ) $ 214,193 Denominator Weighted-average common shares outstanding — basic 86,737 85,173 86,692 84,758 Weighted-average common shares outstanding — diluted 86,737 86,635 86,692 84,758 Basic net income (loss) per common share: Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries $ (0.46 ) $ 0.11 $ (0.64 ) $ (0.03 ) Income from discontinued operations — — — 2.56 Basic net income (loss) per common share $ (0.46 ) $ 0.11 $ (0.64 ) $ 2.53 Diluted net income (loss) per common share: Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries $ (0.46 ) $ 0.11 $ (0.64 ) $ (0.03 ) Income from discontinued operations — — — 2.56 Diluted net income (loss) per common share $ (0.46 ) $ 0.11 $ (0.64 ) $ 2.53
Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share	The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Denominator Options to purchase shares of common stock 7,329 7,627 7,329 7,627 Warrants — — — 4 Conversion shares related to 3% convertible senior subordinated notes 1,687 3,411 2,549 3,411 Conversion shares related to subordinated convertible promissory notes — 27 — 27 Conversion shares related to Series B convertible preferred stock 10,238 10,239 10,238 10,239 Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 19,254 21,304 20,116 21,308

Stockholders' Equity and Non-35

Stockholders' Equity and Non-controlling Interests (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Summary of Changes in Stockholders' Equity and Non-Controlling Interests Comprising Total Equity	A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the six months ended June 30, 2016 is provided below (in thousands): Six Months Ended June 30, 2016 Total Non- Total Equity, beginning of period $ 2,054,165 $ 4,264 $ 2,058,429 Issuance of common stock under employee compensation plans 11,308 — 11,308 Net issuance of common stock to settle taxes on restricted stock units (1,410 ) — (1,410 ) Preferred stock dividends (10,646 ) — (10,646 ) Stock-based compensation expense 20,607 — 20,607 Other adjustments — (2 ) (2 ) Net income (loss) (45,114 ) 246 (44,868 ) Total other comprehensive loss (21,256 ) — (21,256 ) Equity, end of period $ 2,007,654 $ 4,508 $ 2,012,162

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Summary of Aggregate Purchase Price Allocation	A summary of the preliminary fair values of the net assets acquired from EDTS is as follows (in thousands): Fair Value Current assets $ 1,371 Property, plant and equipment 115 Goodwill 2,065 Intangible assets 4,220 Total assets acquired $ 7,771 Current liabilities $ 1,301 Total liabilities assumed $ 1,301 Net assets acquired $ 6,470 Cash paid $ 6,470
Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives	The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective preliminary fair values and weighted-average useful lives (dollars in thousands): Fair Value Weighted- Core technology and patents $ 540 10.0 years Trademarks and trade names 310 20.0 years Customer relationships 2,800 14.0 years Non-compete agreements 570 3.0 years Total intangible assets $ 4,220

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2016
Restructuring and Related Activities [Abstract]
Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income	The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three and six months ended June 30, 2016 and 2015 (in thousands): Three Months Ended June 30, Six Months Ended June 30, Statement of Operations Caption 2016 2015 2016 2015 Cost of net revenue $ 1,103 $ 896 $ 2,370 $ 2,399 Research and development 1,034 156 2,954 649 Sales and marketing 259 570 909 1,953 General and administrative 6,389 3,231 10,215 4,122 Total operating expenses 8,785 4,853 16,448 9,123 Interest expense, including amortization of original issue discounts and deferred financing costs 2 6 7 13 Total restructuring charges $ 8,787 $ 4,859 $ 16,455 $ 9,136
Restructuring Activities Related to Restructuring Plans	The following table summarizes the restructuring activities related to the 2016 restructuring plans, in addition to our earlier restructuring plans as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, for the three and six months ended June 30, 2016 and 2015 and since inception of these restructuring plans (in thousands): Three Months Ended Six Months Ended Since Professional Diagnostics 2016 2015 2016 2015 Severance-related costs $ 3,183 $ 1,264 $ 6,274 $ 4,064 $ 44,261 Facility and transition costs 213 2,581 1,194 4,007 12,862 Other exit costs 2 6 7 13 829 Cash charges 3,398 3,851 7,475 8,084 57,952 Fixed asset and inventory impairments 21 445 419 454 16,372 Other non-cash charges (3 ) — 210 — 2,192 Total professional diagnostics charges $ 3,416 $ 4,296 $ 8,104 $ 8,538 $ 76,516 Corporate and Other Severance-related costs $ (19 ) $ 569 $ (4 ) $ 611 $ 4,273 Facility and transition costs 5,390 (6 ) 8,355 (13 ) 19,677 Total corporate and other charges $ 5,371 $ 563 $ 8,351 $ 598 $ 23,950 Total restructuring charges $ 8,787 $ 4,859 $ 16,455 $ 9,136 $ 100,466
Cash Activity for Restructuring Reserves	The following table summarizes our restructuring reserves related to the plans described above, of which $9.5 million is included in accrued expenses and other current liabilities and $0.6 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands): Severance- Facility and Other Exit Total Balance, December 31, 2015 $ 1,633 $ 1,966 $ 180 $ 3,779 Cash charges 6,270 9,549 7 15,826 Payments (3,814 ) (5,645 ) (73 ) (9,532 ) Currency adjustments (18 ) 11 — (7 ) Balance, June 30, 2016 $ 4,071 $ 5,881 $ 114 $ 10,066

Long-term Debt (Tables)

Long-term Debt (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Long-Term Debt Balances Outstanding	We had the following long-term debt balances outstanding (in thousands): June 30, 2016 December 31, 2015 A term loans (1)(2) $ 559,317 $ 575,746 B term loans (1)(2) 958,337 965,740 Revolving loans (1) 125,000 — 7.25% Senior notes (2) 442,533 446,320 6.5% Senior subordinated notes (2) 415,679 419,209 6.375% Senior subordinated notes (2) 414,033 418,133 3% Convertible senior subordinated notes (3) — 149,839 Other lines of credit 1,335 136 Other 48,236 56,035 2,964,470 3,031,158 Less: Short-term debt and current portion of long-term debt (43,681 ) (199,992 ) Long-term debt $ 2,920,789 $ 2,831,166 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) As discussed more fully below in this Note 12, (i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing our notes. On June 30, 2016, we were not in default under the Credit Agreement or the indentures governing our notes. As discussed more fully below in this Note 12, in August 2016 we entered into a further amendment to the Credit Agreement with respect to our failure to timely file this Quarterly Report on Form 10-Q. At September 1, 2016, we were in default under the indentures governing our outstanding notes with respect to our failure to timely file this Quarterly Report on Form 10-Q and, by filing this Quarterly Report on Form 10-Q prior to the expiration of the applicable cure periods under the notes, we have cured this default. (3) The principal amount of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheets as of December 31, 2015, as these notes matured (and were fully paid and discharged) in May 2016.
Long-Term Debt Interest Expense	In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three and six months ended June 30, 2016 and 2015 as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Secured credit facility (1) $ 17,834 $ 12,851 $ 34,877 $ 12,851 Prior credit facility (2) (3) — 19,726 — 39,188 7.25% Senior notes 8,904 8,525 17,428 17,049 6.5% Senior subordinated notes 7,405 7,234 14,636 14,467 6.375% Senior subordinated notes 7,112 542 14,115 542 8.625% Senior subordinated notes — 9,274 — 18,547 3% Convertible senior subordinated convertible notes 603 1,246 1,847 2,492 Other 471 96 1,532 789 $ 42,329 $ 59,494 $ 84,435 $ 105,925 (1) Includes “A” term loans, “B” term loans, and revolving line of credit loans. (2) Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans and later converted into and consolidated into the “B” term loans; and revolving line of credit loans. For the three and six months ended June 30, 2015, the amounts include $0.3 million and $0.7 million, respectively, related to the amortization of fees paid for certain debt modifications. (3) Includes a $3.5 million loss on extinguishment of debt associated with our prior credit facility.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques	The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description June 30, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 74 $ 74 $ — $ — Total assets $ 74 $ 74 $ — $ — Liabilities: Contingent consideration obligations (1) $ 55,100 $ — $ — $ 55,100 Total liabilities $ 55,100 $ — $ — $ 55,100 Description December 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 164 $ 164 $ — $ — Total assets $ 164 $ 164 $ — $ — Liabilities: Contingent consideration obligations (1) $ 57,744 $ — $ — $ 57,744 Total liabilities $ 57,744 $ — $ — $ 57,744 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. See Note 17(a) for additional information on the valuation of our contingent consideration obligations.
Changes in Fair Value of Contingent Consideration Obligations	Changes in the fair value of our Level 3 contingent consideration obligations during the six months ended June 30, 2016 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2015 $ 57,744 Payments (865 ) Fair value adjustments (1,780 ) Foreign currency adjustments 1 Fair value of contingent consideration obligations, June 30, 2016 $ 55,100

Financial Information by Segm40

Financial Information by Segment (Tables)	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Performance of Our Operating Segments Based on Revenue and Operating Income (Loss)	Segment information for the three and six months ended June 30, 2016 and 2015 is as follows (in thousands): Professional Consumer Corporate Total Three Months Ended June 30, 2016: Net revenue $ 591,294 $ 19,794 $ — $ 611,088 Operating income (loss) $ 85,535 $ 396 $ (63,386 ) $ 22,545 Depreciation and amortization $ 66,393 $ 1,374 $ 2,134 $ 69,901 Restructuring charge $ 3,414 $ — $ 5,371 $ 8,785 Stock-based compensation $ — $ — $ 11,004 $ 11,004 Professional Consumer Corporate Total Three Months Ended June 30, 2015: Net revenue $ 598,726 $ 24,645 $ — $ 623,371 Operating income (loss) $ 153,241 $ 1,079 $ (68,923 ) $ 85,397 Impairment and (gain) loss on dispositions, net $ (38,836 ) $ — $ 44,378 $ 5,542 Depreciation and amortization $ 70,189 $ 725 $ 1,775 $ 72,689 Restructuring charge $ 4,290 $ — $ 563 $ 4,853 Stock-based compensation $ — $ — $ 7,130 $ 7,130 Six Months Ended June 30, 2016: Net revenue $ 1,152,061 $ 37,236 $ — $ 1,189,297 Operating income (loss) $ 168,215 $ 563 $ (117,997 ) $ 50,781 Impairment and (gain) loss on dispositions, net $ (3,810 ) $ — $ — $ (3,810 ) Depreciation and amortization $ 135,225 $ 2,873 $ 4,307 $ 142,405 Restructuring charge $ 8,097 $ — $ 8,351 $ 16,448 Stock-based compensation $ — $ — $ 20,607 $ 20,607 Six Months Ended June 30, 2015: Net revenue $ 1,189,651 $ 46,612 $ — $ 1,236,263 Operating income (loss) $ 242,784 $ 3,283 $ (130,033 ) $ 116,034 Impairment and (gain) loss on dispositions, net $ (40,568 ) $ — $ 80,902 $ 40,334 Depreciation and amortization $ 142,658 $ 1,436 $ 3,009 $ 147,103 Restructuring charge $ 8,525 $ — $ 598 $ 9,123 Stock-based compensation $ — $ — $ 12,279 $ 12,279 Assets: As of June 30, 2016 $ 5,572,046 $ 179,445 $ 39,403 $ 5,790,894 As of December 31, 2015 $ 5,619,901 $ 172,551 $ 130,669 $ 5,923,121
Summary of Company's Net Revenue from Professional Diagnostics Reporting Segments by Groups of Similar Products and Services	The following tables summarize our net revenue from the professional diagnostics reporting segments by groups of similar products and services for the three and six months ended June 30, 2016 and 2015 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Cardiometabolic $ 203,982 $ 211,672 $ 398,559 $ 412,608 Infectious disease 190,168 172,834 373,402 358,236 Toxicology 158,199 157,495 304,982 306,251 Other 36,412 51,031 69,856 102,164 Total professional diagnostics net product sales and services revenue 588,761 593,032 1,146,799 1,179,259 License and royalty revenue 2,533 5,694 5,262 10,392 Total professional diagnostics net revenue $ 591,294 $ 598,726 $ 1,152,061 $ 1,189,651

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Balances with SPD within Consolidated Balance Sheets	The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption June 30, 2016 December 31, 2015 Accounts receivable, net of allowances $ 11,670 $ 9,873 Prepaid expenses and other current assets $ 8,768 $ 6,602 Other non-current assets $ 6,699 $ 8,895 Accounts payable $ 31,584 $ 24,887

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions	The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions, as follows (in thousands): Acquisition Acquisition Date Acquisition Maximum Remaining Estimated Estimated Payments TwistDx, Inc. (1) March 11, 2010 $ 35,600 $ 102,870 2016 – 2025 (3) $ 46,600 $ 47,800 $ 377 Epocal (2) February 1, 2013 $ 75,000 $ 45,500 2016 – 2018 3,900 4,700 — Other Various $ 30,373 $ — (4) 2016 4,600 5,244 488 $ 55,100 $ 57,744 $ 865 (1) The terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and product development targets through 2025. (2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (3) The maximum earn-out period ends on the fifteenth anniversary of the acquisition date. (4) The maximum remaining earn-out potential for the other acquisitions is not determinable due to the nature of one of the earn-outs, which is tied to an unlimited revenue metric.

Equity Investments (Tables)

Equity Investments (Tables)	6 Months Ended
	Jun. 30, 2016
Financial Information Combined Condensed Results of Operations	CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended June 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 222,954 $ 335,540 $ (74,748 ) $ 483,746 Services revenue — 112,698 12,111 — 124,809 Net product sales and services revenue — 335,652 347,651 (74,748 ) 608,555 License and royalty revenue — 3,448 2,008 (2,923 ) 2,533 Net revenue — 339,100 349,659 (77,671 ) 611,088 Cost of net product sales 220 126,795 188,478 (65,095 ) 250,398 Cost of services revenue 104 79,203 7,760 (8,773 ) 78,294 Cost of net product sales and services revenue 324 205,998 196,238 (73,868 ) 328,692 Cost of license and royalty revenue — (7 ) 3,466 (2,924 ) 535 Cost of net revenue 324 205,991 199,704 (76,792 ) 329,227 Gross profit (loss) (324 ) 133,109 149,955 (879 ) 281,861 Operating expenses: Research and development 2,997 16,194 9,255 — 28,446 Sales and marketing 1,568 53,155 47,793 — 102,516 General and administrative 57,740 30,460 40,154 — 128,354 Impairment and (gain) loss on dispositions, net — — — — — Operating income (loss) (62,629 ) 33,300 52,753 (879 ) 22,545 Interest expense, including amortization of original issue discounts and deferred financing costs (41,857 ) (2,223 ) (2,775 ) 4,526 (42,329 ) Other income (expense), net (8,144 ) 4,103 (5,544 ) (4,527 ) (14,112 ) Income (loss) before provision (benefit) for income taxes (112,630 ) 35,180 44,434 (880 ) (33,896 ) Provision (benefit) for income taxes 19,765 (6,759 ) (9,889 ) — 3,117 Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (132,395 ) 41,939 54,323 (880 ) (37,013 ) Equity in earnings of subsidiaries, net of tax 96,916 — — (96,916 ) — Equity earnings of unconsolidated entities, net of tax 588 — 1,557 (23 ) 2,122 Net income (loss) (34,891 ) 41,939 55,880 (97,819 ) (34,891 ) Less: Net income attributable to non-controlling interests — — 143 — 143 Net income (loss) attributable to Alere Inc. and Subsidiaries (34,891 ) 41,939 55,737 (97,819 ) (35,034 ) Preferred stock dividends (5,308 ) — — — (5,308 ) Net income (loss) available to common stockholders $ (40,199 ) $ 41,939 $ 55,737 $ (97,819 ) $ (40,342 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended June 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 211,593 $ 345,289 $ (65,833 ) $ 491,049 Services revenue — 114,983 11,645 — 126,628 Net product sales and services revenue — 326,576 356,934 (65,833 ) 617,677 License and royalty revenue — 3,233 5,710 (3,249 ) 5,694 Net revenue — 329,809 362,644 (69,082 ) 623,371 Cost of net product sales 417 120,953 193,593 (57,070 ) 257,893 Cost of services revenue 80 77,884 7,524 (8,688 ) 76,800 Cost of net product sales and services revenue 497 198,837 201,117 (65,758 ) 334,693 Cost of license and royalty revenue 19 410 4,164 (3,249 ) 1,344 Cost of net revenue 516 199,247 205,281 (69,007 ) 336,037 Gross profit (loss) (516 ) 130,562 157,363 (75 ) 287,334 Operating expenses: Research and development 3,241 13,993 9,964 — 27,198 Sales and marketing 1,570 52,101 54,353 — 108,024 General and administrative 24,390 51,288 (14,505 ) — 61,173 Impairment and (gain) loss on dispositions, net 44,378 (39,412 ) 576 — 5,542 Operating income (loss) (74,095 ) 52,592 106,975 (75 ) 85,397 Interest expense, including amortization of original issue discounts and deferred financing costs (59,086 ) (3,060 ) (4,702 ) 7,354 (59,494 ) Other income (expense), net 3,596 3,511 3,442 (7,354 ) 3,195 Income (loss) from continuing operations before provision (benefit) for income taxes (129,585 ) 53,043 105,715 (75 ) 29,098 Provision (benefit) for income taxes (16,306 ) 10,830 21,203 (38 ) 15,689 Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (113,279 ) 42,213 84,512 (37 ) 13,409 Equity in earnings of subsidiaries, net of tax 127,127 — — (127,127 ) — Equity earnings of unconsolidated entities, net of tax 922 — 424 15 1,361 Net income 14,770 42,213 84,936 (127,149 ) 14,770 Less: Net income attributable to non-controlling interests — — 359 — 359 Net income attributable to Alere Inc. and Subsidiaries 14,770 42,213 84,577 (127,149 ) 14,411 Preferred stock dividends (5,308 ) — — — (5,308 ) Net income available to common stockholders $ 9,462 $ 42,213 $ 84,577 $ (127,149 ) $ 9,103 CONSOLIDATING STATEMENT OF OPERATIONS For the Six Months Ended June 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 447,334 $ 632,377 $ (136,194 ) $ 943,517 Services revenue — 217,182 23,336 — 240,518 Net product sales and services revenue — 664,516 655,713 (136,194 ) 1,184,035 License and royalty revenue — 6,368 4,566 (5,672 ) 5,262 Net revenue — 670,884 660,279 (141,866 ) 1,189,297 Cost of net product sales 334 251,553 354,460 (118,488 ) 487,859 Cost of services revenue 104 151,698 15,800 (16,208 ) 151,394 Cost of net product sales and services revenue 438 403,251 370,260 (134,696 ) 639,253 Cost of license and royalty revenue — 10 7,589 (5,673 ) 1,926 Cost of net revenue 438 403,261 377,849 (140,369 ) 641,179 Gross profit (loss) (438 ) 267,623 282,430 (1,497 ) 548,118 Operating expenses: Research and development 7,131 30,653 17,724 — 55,508 Sales and marketing 2,904 107,620 91,805 — 202,329 General and administrative 102,355 63,646 77,309 — 243,310 Impairment and (gain) loss on dispositions, net — — (3,810 ) — (3,810 ) Operating income (loss) (112,828 ) 65,704 99,402 (1,497 ) 50,781 Interest expense, including amortization of original issue discounts and deferred financing costs (82,944 ) (4,875 ) (5,842 ) 9,226 (84,435 ) Other income (expense), net (6,156 ) 6,605 (6,683 ) (9,227 ) (15,461 ) Income (loss) before provision (benefit) for income taxes (201,928 ) 67,434 86,877 (1,498 ) (49,115 ) Provision (benefit) for income taxes 19,711 (6,509 ) (10,293 ) — 2,909 Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (221,639 ) 73,943 97,170 (1,498 ) (52,024 ) Equity in earnings of subsidiaries, net of tax 175,502 — — (175,502 ) — Equity earnings of unconsolidated entities, net of tax 1,269 — 6,138 (251 ) 7,156 Net income (loss) (44,868 ) 73,943 103,308 (177,251 ) (44,868 ) Less: Net income attributable to non-controlling interests — — 246 — 246 Net income (loss) attributable to Alere Inc. and Subsidiaries (44,868 ) 73,943 103,062 (177,251 ) (45,114 ) Preferred stock dividends (10,617 ) — — — (10,617 ) Net income (loss) available to common stockholders $ (55,485 ) $ 73,943 $ 103,062 $ (177,251 ) $ (55,731 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Six Months Ended June 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 426,631 $ 675,395 $ (126,639 ) $ 975,387 Services revenue — 223,040 27,444 — 250,484 Net product sales and services revenue — 649,671 702,839 (126,639 ) 1,225,871 License and royalty revenue — 6,430 10,073 (6,111 ) 10,392 Net revenue — 656,101 712,912 (132,750 ) 1,236,263 Cost of net product sales 833 233,248 375,999 (112,086 ) 497,994 Cost of services revenue 130 151,921 15,964 (15,589 ) 152,426 Cost of net product sales and services revenue 963 385,169 391,963 (127,675 ) 650,420 Cost of license and royalty revenue (21 ) 1,218 8,208 (6,111 ) 3,294 Cost of net revenue 942 386,387 400,171 (133,786 ) 653,714 Gross profit (loss) (942 ) 269,714 312,741 1,036 582,549 Operating expenses: Research and development 5,543 28,912 20,759 — 55,214 Sales and marketing 2,830 105,328 108,945 — 217,103 General and administrative 44,913 89,058 19,893 — 153,864 Impairment and (gain) loss on dispositions, net 80,901 (8,804 ) (31,763 ) — 40,334 Operating income (loss) (135,129 ) 55,220 194,907 1,036 116,034 Interest expense, including amortization of original issue discounts and deferred financing costs (105,184 ) (6,345 ) (8,745 ) 14,349 (105,925 ) Other income (expense), net 7,243 6,713 1,221 (14,349 ) 828 Income (loss) from continuing operations before provision (benefit) for income taxes (233,070 ) 55,588 187,383 1,036 10,937 Provision (benefit) for income taxes (36,973 ) 11,581 32,920 308 7,836 Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (196,097 ) 44,007 154,463 728 3,101 Equity in earnings of subsidiaries, net of tax 201,260 — — (201,260 ) — Equity earnings of unconsolidated entities, net of tax 1,346 — 3,992 (18 ) 5,320 Income from continuing operations 6,509 44,007 158,455 (200,550 ) 8,421 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Net income 225,198 42,095 158,455 (200,550 ) 225,198 Less: Net income attributable to non-controlling interests — — 447 — 447 Net income attributable to Alere Inc. and Subsidiaries 225,198 42,095 158,008 (200,550 ) 224,751 Preferred stock dividends (10,558 ) — — — (10,558 ) Net income available to common stockholders $ 214,640 $ 42,095 $ 158,008 $ (200,550 ) $ 214,193
Financial Information Combined Condensed Balance Sheet	CONSOLIDATING BALANCE SHEET June 30, 2016 (in thousands) Issuer Guarantor Subsidiaries Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 49,465 $ 6,881 $ 449,818 $ — $ 506,164 Restricted cash 1,415 — 4,247 — 5,662 Marketable securities — 74 — — 74 Accounts receivable, net of allowances — 190,438 236,784 — 427,222 Inventories, net — 168,413 188,448 (23,015 ) 333,846 Deferred tax assets (455 ) 6,513 (6,058 ) — — Prepaid expenses and other current assets 12,194 33,489 110,122 6,534 162,339 Intercompany receivables 360,548 827,927 158,858 (1,347,333 ) — Total current assets 423,167 1,233,735 1,142,219 (1,363,814 ) 1,435,307 Property, plant and equipment, net 29,742 224,796 187,337 (3,088 ) 438,787 Goodwill — 1,823,018 988,527 — 2,811,545 Other intangible assets with indefinite lives — 7,538 20,800 (59 ) 28,279 Finite-lived intangible assets, net 2,745 566,973 342,690 (3,200 ) 909,208 Restricted cash — — 42,589 — 42,589 Other non-current assets 570 2,052 14,317 (649 ) 16,290 Investments in subsidiaries 3,455,642 158,195 57,650 (3,671,487 ) — Investments in unconsolidated entities 687 14,765 44,654 14,405 74,511 Deferred tax assets (66,034 ) 24,785 62,006 (2,119 ) 18,638 Non-current income tax receivable 3,517 — — — 3,517 Assets held for sale — non-current 12,223 — — — 12,223 Intercompany notes receivables 1,887,589 708,708 2,901 (2,599,198 ) — Total assets $ 5,749,848 $ 4,764,565 $ 2,905,690 $ (7,629,209 ) $ 5,790,894 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 40,073 $ — $ 3,608 $ — $ 43,681 Current portion of capital lease obligations — 1,654 1,846 — 3,500 Accounts payable 23,789 77,283 93,163 — 194,235 Accrued expenses and other current liabilities (514,898 ) 635,590 197,663 2,171 320,526 Intercompany payables 965,315 178,406 203,621 (1,347,342 ) — Total current liabilities 514,279 892,933 499,901 (1,345,171 ) 561,942 Long-term liabilities: Long-term debt, net of current portion 2,874,825 — 45,964 — 2,920,789 Capital lease obligations, net of current portion — 1,466 5,506 — 6,972 Deferred tax liabilities (158,407 ) 250,292 48,897 82 140,864 Other long-term liabilities 14,741 56,618 77,455 (649 ) 148,165 Intercompany notes payables 496,756 1,162,748 939,694 (2,599,198 ) — Total long-term liabilities 3,227,915 1,471,124 1,117,516 (2,599,765 ) 3,216,790 Total stockholders’ equity 2,007,654 2,400,508 1,283,765 (3,684,273 ) 2,007,654 Non-controlling interests — — 4,508 — 4,508 Total equity 2,007,654 2,400,508 1,288,273 (3,684,273 ) 2,012,162 Total liabilities and equity $ 5,749,848 $ 4,764,565 $ 2,905,690 $ (7,629,209 ) $ 5,790,894 CONSOLIDATING BALANCE SHEET December 31, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 139,153 $ 21,150 $ 341,897 $ — $ 502,200 Restricted cash 1,250 — 4,444 — 5,694 Marketable securities — 164 — — 164 Accounts receivable, net of allowances — 192,591 253,242 — 445,833 Inventories, net — 173,383 194,192 (20,574 ) 347,001 Deferred tax assets (52,410 ) 31,285 23,244 (2,119 ) — Prepaid expenses and other current assets 7,575 27,095 110,961 6,602 152,233 Assets held for sale — current — — 4,165 — 4,165 Intercompany receivables 620,838 812,957 50,691 (1,484,486 ) — Total current assets 716,406 1,258,625 982,836 (1,500,577 ) 1,457,290 Property, plant and equipment, net 31,384 228,065 188,084 (1,494 ) 446,039 Goodwill — 1,823,919 1,012,996 — 2,836,915 Other intangible assets with indefinite lives — 7,638 20,531 (59 ) 28,110 Finite-lived intangible assets, net 2,951 627,269 370,261 (3,200 ) 997,281 Restricted cash — — 43,228 — 43,228 Other non-current assets 804 2,340 15,380 (446 ) 18,078 Investments in subsidiaries 3,294,857 158,195 57,650 (3,510,702 ) — Investments in unconsolidated entities 502 14,764 37,947 12,120 65,333 Deferred tax assets (14,078 ) (14 ) 28,085 — 13,993 Non-current income tax receivable 3,517 — — — 3,517 Assets held for sale — non-current 13,337 — — — 13,337 Intercompany notes receivables 1,905,188 672,032 6,900 (2,584,120 ) — Total assets $ 5,954,868 $ 4,792,833 $ 2,763,898 $ (7,588,478 ) $ 5,923,121 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 197,084 $ — $ 2,908 $ — $ 199,992 Current portion of capital lease obligations — 2,018 1,944 — 3,962 Accounts payable 15,981 76,890 102,881 — 195,752 Accrued expenses and other current liabilities (554,350 ) 650,632 225,944 2,239 324,465 Liabilities related to assets held for sale — current — — 363 — 363 Intercompany payables 1,122,042 249,553 112,891 (1,484,486 ) — Total current liabilities 780,757 979,093 446,931 (1,482,247 ) 724,534 Long-term liabilities: Long-term debt, net of current portion 2,784,913 — 46,253 — 2,831,166 Capital lease obligations, net of current portion — 840 6,341 — 7,181 Deferred tax liabilities (157,708 ) 250,495 54,749 82 147,618 Other long-term liabilities 14,962 59,309 80,369 (447 ) 154,193 Intercompany notes payables 477,779 1,181,168 925,173 (2,584,120 ) — Total long-term liabilities 3,119,946 1,491,812 1,112,885 (2,584,485 ) 3,140,158 Total stockholders’ equity 2,054,165 2,321,928 1,199,818 (3,521,746 ) 2,054,165 Non-controlling interests — — 4,264 — 4,264 Total equity 2,054,165 2,321,928 1,204,082 (3,521,746 ) 2,058,429 Total liabilities and equity $ 5,954,868 $ 4,792,833 $ 2,763,898 $ (7,588,478 ) $ 5,923,121
Swiss Precision Diagnostics And Techlab [Member]
Financial Information Combined Condensed Results of Operations	Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, Combined Condensed Results of Operations: 2016 2015 2016 2015 Net revenue $ 55,077 $ 53,159 $ 108,511 $ 101,016 Gross profit $ 36,634 $ 34,559 $ 72,853 $ 67,830 Net income after taxes $ 4,328 $ 3,039 $ 14,469 $ 11,096
Financial Information Combined Condensed Balance Sheet	Combined Condensed Balance Sheet: June 30, 2016 December 31, 2015 Current assets $ 91,942 $ 71,542 Non-current assets 31,826 30,802 Total assets $ 123,768 $ 102,344 Current liabilities $ 47,764 $ 37,609 Non-current liabilities 5,845 5,157 Total liabilities $ 53,609 $ 42,766

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Reconciliation between U.S. Federal Statutory Rate and Effective Tax Rate	A reconciliation between the U.S. federal statutory rate and our effective tax rate is summarized as follows: For the Three Months Ended For the Six Months Ended 2016 2015 2016 2015 Statutory rate 35 % 35 % 35 % 35 % State income taxes, net of federal benefit (5) % (4) % (4) % (5) % Rate differential on foreign earnings (61) % (19) % (58) % (27) % Change in valuation allowance (4) % (3) % (6) % 10 % Stock-based compensation 11 % 5 % 11 % (9) % Uncertain tax positions 12 % 7 % 9 % 15 % Disposition of BBI 0 % 27 % 0 % 65 % Other 3 % 6 % 7 % (12) % Effective tax rate (9 )% 54 % (6 )% 72 %

Guarantor Financial Informati45

Guarantor Financial Information (Tables)	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Reconciliation of Previously Reported and Revised Consolidating Financial Statements	The following schedules reconcile the amounts as previously reported in our consolidating financial statements to the corresponding revised amounts: Three Months Ended June 30, 2015 Revised Consolidating Statement of Operations- Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 330,820 $ (1,011 ) $ 329,809 Cost of net revenue $ 199,233 $ 14 $ 199,247 Income from continuing operations before benefit for income taxes $ 55,133 $ (2,090 ) $ 53,043 Provision for income taxes $ 11,277 $ (447 ) $ 10,830 Income from continuing operations $ 43,856 $ (1,643 ) $ 42,213 Three Months Ended June 30, 2015 Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 367,418 $ (4,774 ) $ 362,644 Cost of net revenue $ 205,840 $ (559 ) $ 205,281 Income from continuing operations before benefit for income taxes $ 111,130 $ (5,415 ) $ 105,715 Provision for income taxes $ 22,768 $ (1,565 ) $ 21,203 Income from continuing operations $ 88,786 $ (3,850 ) $ 84,936 Six Months Ended June 30, 2015 Revised Consolidating Statement of Operations- Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 659,282 $ (3,181 ) $ 656,101 Cost of net revenue $ 387,269 $ (882 ) $ 386,387 Income from continuing operations before benefit for income taxes $ 60,049 $ (4,461 ) $ 55,588 Provision for income taxes $ 13,097 $ (1,516 ) $ 11,581 Income from continuing operations $ 46,952 $ (2,945 ) $ 44,007 Six Months Ended June 30, 2015 Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 710,777 $ 2,135 $ 712,912 Cost of net revenue $ 398,325 $ 1,846 $ 400,171 Income from continuing operations before benefit for income taxes $ 188,294 $ (911 ) $ 187,383 Provision for income taxes $ 32,483 $ 437 $ 32,920 Income from continuing operations $ 159,803 $ (1,348 ) $ 158,455
Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss)	CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended June 30, 2016 (in thousands) Issuer Guarantor Subsidiaries Non- Guarantor Subsidiaries Eliminations Consolidated Net income (loss) $ (34,891 ) $ 41,939 $ 55,880 $ (97,819 ) $ (34,891 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 276 (699 ) (43,720 ) 8 (44,135 ) Minimum pension liability adjustment — — 531 — 531 Other comprehensive income (loss), before tax 276 (699 ) (43,189 ) 8 (43,604 ) Other comprehensive income (loss) 276 (699 ) (43,189 ) 8 (43,604 ) Comprehensive income (loss) (34,615 ) 41,240 12,691 (97,811 ) (78,495 ) Less: Comprehensive income attributable to non-controlling interests — — 143 — 143 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (34,615 ) $ 41,240 $ 12,548 $ (97,811 ) $ (78,638 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended June 30, 2015 (in thousands) Issuer Guarantor Subsidiaries Non- Guarantor Subsidiaries Eliminations Consolidated Net income $ 14,770 $ 42,213 $ 84,936 $ (127,149 ) $ 14,770 Other comprehensive income, before tax: Changes in cumulative translation adjustment 197 689 45,840 — 46,726 Minimum pension liability adjustment — — (374 ) — (374 ) Other comprehensive income, before tax 197 689 45,466 — 46,352 Other comprehensive income 197 689 45,466 — 46,352 Comprehensive income 14,967 42,902 130,402 (127,149 ) 61,122 Less: Comprehensive income attributable to non-controlling interests — — 359 — 359 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 14,967 $ 42,902 $ 130,043 $ (127,149 ) $ 60,763 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Six Months Ended June 30, 2016 (in thousands) Issuer Guarantor Subsidiaries Non- Guarantor Subsidiaries Eliminations Consolidated Net income (loss) $ (44,868 ) $ 73,943 $ 103,308 $ (177,251 ) $ (44,868 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 391 (828 ) (21,513 ) 8 (21,942 ) Minimum pension liability adjustment — — 686 — 686 Other comprehensive income (loss), before tax 391 (828 ) (20,827 ) 8 (21,256 ) Other comprehensive income (loss) 391 (828 ) (20,827 ) 8 (21,256 ) Comprehensive income (loss) (44,477 ) 73,115 82,481 (177,243 ) (66,124 ) Less: Comprehensive income attributable to non-controlling interests — — 246 — 246 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (44,477 ) $ 73,115 $ 82,235 $ (177,243 ) $ (66,370 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Six Months Ended June 30, 2015 (in thousands) Issuer Guarantor Subsidiaries Non- Guarantor Subsidiaries Eliminations Consolidated Net income $ 225,198 $ 42,095 $ 158,455 $ (200,550 ) $ 225,198 Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment (460 ) 117 (33,273 ) — (33,616 ) Minimum pension liability adjustment — — (1,756 ) — (1,756 ) Other comprehensive income (loss), before tax (460 ) 117 (35,029 ) — (35,372 ) Other comprehensive income (loss) (460 ) 117 (35,029 ) — (35,372 ) Comprehensive income 224,738 42,212 123,426 (200,550 ) 189,826 Less: Comprehensive income attributable to non-controlling interests — — 447 — 447 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 224,738 $ 42,212 $ 122,979 $ (200,550 ) $ 189,379
Guarantor Financial Information Consolidating Statement of Cash Flows	CONSOLIDATING STATEMENT OF CASH FLOWS For the Six Months Ended June 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (44,868 ) $ 73,943 $ 103,308 $ (177,251 ) $ (44,868 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (175,502 ) — — 175,502 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 5,175 7 79 — 5,261 Depreciation and amortization 4,484 88,973 48,109 839 142,405 Non-cash stock-based compensation expense 10,541 5,462 4,604 — 20,607 Impairment of inventory — — 870 — 870 Impairment of long-lived assets — 548 85 — 633 Loss on disposition of fixed assets 1 3,522 712 — 4,235 Equity earnings of unconsolidated entities, net of tax (1,269 ) — (6,138 ) 251 (7,156 ) Deferred income taxes — (200 ) (13,010 ) — (13,210 ) (Gain) loss related to impairment and net (gain) loss on dispositions — — (3,810 ) — (3,810 ) Other non-cash items (66 ) 459 9,323 4 9,720 Non-cash change in fair value of contingent purchase price consideration (800 ) (823 ) (157 ) — (1,780 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — 2,141 17,882 — 20,023 Inventories, net — (11,723 ) 5,243 660 (5,820 ) Prepaid expenses and other current assets (4,283 ) (7,408 ) (13,258 ) 68 (24,881 ) Accounts payable 7,807 396 (8,204 ) — (1 ) Accrued expenses and other current liabilities 40,481 (13,721 ) (28,367 ) (69 ) (1,676 ) Other non-current liabilities (1,054 ) (1,561 ) (3,491 ) — (6,106 ) Cash paid for contingent consideration (321 ) — (3 ) — (324 ) Intercompany payable (receivable) 145,358 (141,518 ) (3,836 ) (4 ) — Net cash provided by (used in) operating activities (14,316 ) (1,503 ) 109,941 — 94,122 Cash Flows from Investing Activities: Increase in restricted cash (165 ) — (284 ) — (449 ) Purchases of property, plant and equipment (2,680 ) (11,750 ) (18,972 ) 1,084 (32,318 ) Proceeds from sale of property, plant and equipment 92 45 1,839 (1,084 ) 892 Cash received from (used in) dispositions, net of cash divested (1,337 ) — 22,807 — 21,470 Cash paid for business acquisitions, net of cash acquired — — (5,958 ) — (5,958 ) Cash received from equity method investments 2,383 — — — 2,383 Cash received from sales of marketable securities. — 90 — — 90 Cash paid for investments (184 ) — — — (184 ) (Increase) decrease in other assets (50 ) 13 532 — 495 Net cash used in investing activities (1,941 ) (11,602 ) (36 ) — (13,579 ) Cash Flows from Financing Activities: Cash paid for financing costs (19,564 ) — — — (19,564 ) Cash paid for contingent purchase price consideration — — (485 ) — (485 ) Proceeds from issuance of common stock, net of issuance costs 11,124 — — — 11,124 Proceeds from issuance of long-term debt — — 381 — 381 Payments on short-term debt — — (791 ) — (791 ) Payments on long-term debt (176,861 ) — (776 ) — (177,637 ) Net proceeds under revolving credit facilities 125,000 — 1,213 — 126,213 Cash paid for dividends (10,646 ) — — — (10,646 ) Principal payments on capital lease obligations — (1,324 ) (886 ) — (2,210 ) Net cash used in financing activities (70,947 ) (1,324 ) (1,344 ) — (73,615 ) Foreign exchange effect on cash and cash equivalents (2,484 ) 160 (640 ) — (2,964 ) Net increase (decrease) in cash and cash equivalents (89,688 ) (14,269 ) 107,921 — 3,964 Cash and cash equivalents, beginning of period 139,153 21,150 341,897 — 502,200 Cash and cash equivalents, end of period $ 49,465 $ 6,881 $ 449,818 $ — $ 506,164 CONSOLIDATING STATEMENT OF CASH FLOWS For the Six Months Ended June 30, 2015 (in thousands) Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Cash Flows from Operating Activities: Net income $ 225,198 $ 42,095 $ 158,455 $ (200,550 ) $ 225,198 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Income from continuing operations 6,509 44,007 158,455 (200,550 ) 8,421 Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (201,260 ) — — 201,260 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 7,728 13 43 — 7,784 Depreciation and amortization 3,840 82,576 60,652 35 147,103 Non-cash stock-based compensation expense 6,458 2,633 3,188 — 12,279 Impairment of inventory — 133 (65 ) — 68 Impairment of long-lived assets — 64 323 — 387 Loss on disposition of fixed assets — 2,764 554 — 3,318 Equity earnings of unconsolidated entities, net of tax (1,346 ) — (3,992 ) 18 (5,320 ) Gain on sales of marketable securities — (8 ) — — (8 ) Deferred income taxes (8,686 ) (32,097 ) (1,826 ) 438 (42,171 ) (Gain) loss related to impairment and net (gain) loss on dispositions 80,901 (8,804 ) (31,763 ) — 40,334 Loss on extinguishment of debt 3,480 — — — 3,480 Other non-cash items (159 ) (1,497 ) (676 ) — (2,332 ) Non-cash change in fair value of contingent purchase price consideration (30,895 ) 15,748 (37,720 ) — (52,867 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (2,599 ) (15,417 ) — (18,016 ) Inventories, net — (27,824 ) (15,984 ) (1,411 ) (45,219 ) Prepaid expenses and other current assets (3,052 ) (19,127 ) 810 (5,708 ) (27,077 ) Accounts payable (7,499 ) (11,331 ) (4,421 ) — (23,251 ) Accrued expenses and other current liabilities (8,944 ) 61,472 (33,374 ) 3,898 23,052 Other non-current liabilities 2,226 6,171 (1,476 ) 1,615 8,536 Cash paid for contingent purchase price consideration (3,768 ) — (13 ) — (3,781 ) Intercompany payable (receivable) 127,569 (101,515 ) (26,054 ) — — Net cash provided by (used in) continuing operations (26,898 ) 10,779 51,244 (405 ) 34,720 Net cash provided by discontinued operations — 318 — — 318 Net cash provided by (used in) operating activities (26,898 ) 11,097 51,244 (405 ) 35,038 Cash Flows from Investing Activities: Increase in restricted cash (422,169 ) — (1,856 ) — (424,025 ) Purchases of property, plant and equipment (5,147 ) (19,386 ) (23,907 ) 1,156 (47,284 ) Proceeds from sale of property, plant and equipment — 738 1,199 (817 ) 1,120 Cash received from (used in) disposition, net of cash divested 593,217 (8,723 ) 2,131 — 586,625 Cash received from equity method investments 2,205 — 12,092 — 14,297 Cash received from sales of marketable securities — 93 — — 93 Decrease in other assets 348 409 927 66 1,750 Net cash provided by (used in) continuing operations 168,454 (26,869 ) (9,414 ) 405 132,576 Net cash used in discontinued operations — (209 ) — — (209 ) Net cash provided by (used in) investing activities 168,454 (27,078 ) (9,414 ) 405 132,367 Cash Flows from Financing Activities: Cash paid for financing costs (15,731 ) — — — (15,731 ) Cash paid for contingent purchase price consideration (5,503 ) — (870 ) — (6,373 ) Proceeds from issuance of common stock, net of issuance costs 56,332 — — — 56,332 Proceeds from issuance of long-term debt 2,119,125 — 2,726 — 2,121,851 Payments on short-term debt — — (584 ) — (584 ) Payments on long-term debt (2,117,875 ) — (389 ) — (2,118,264 ) Net payments under revolving credit facilities (127,000 ) — 680 — (126,320 ) Cash paid for dividends (10,646 ) — — — (10,646 ) Principal payments on capital lease obligations — (1,263 ) (1,647 ) — (2,910 ) Net cash used in continuing operations (101,298 ) (1,263 ) (84 ) — (102,645 ) Net cash used in discontinued operations — (76 ) — — (76 ) Net cash used in financing activities (101,298 ) (1,339 ) (84 ) — (102,721 ) Foreign exchange effect on cash and cash equivalents — (129 ) (1,445 ) — (1,574 ) Net increase (decrease) in cash and cash equivalents 40,258 (17,449 ) 40,301 — 63,110 Cash and cash equivalents, beginning of period — continuing operations 2,149 69,154 307,158 — 378,461 Cash and cash equivalents, beginning of period — discontinued operations — 23,300 — — 23,300 Cash and cash equivalents of continuing operations, end of period $ 42,407 $ 75,005 $ 347,459 $ — $ 464,871

Revision of Previously Report46

Revision of Previously Reported Consolidated Financial Statements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 611,088	$ 623,371	$ 1,189,297	$ 1,236,263
Other income (expense), net	$ (14,112)	3,195	$ (15,461)	828
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		(5,785)		(1,046)
Other income (expense), net		(1,065)		(2,162)
Operating expenses		$ 1,200		$ 1,200

Revision of Previously Report47

Revision of Previously Reported Consolidated Financial Statements - Restated and Revised Consolidated Statement of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales	$ 483,746	$ 491,049	$ 943,517	$ 975,387
Net product sales and services revenue	608,555	617,677	1,184,035	1,225,871
Net revenue	611,088	623,371	1,189,297	1,236,263
Cost of net product sales	250,398	257,893	487,859	497,994
Cost of service revenue	78,294	76,800	151,394	152,426
Cost of net product sales and services revenue	328,692	334,693	639,253	650,420
Cost of net revenue	329,227	336,037	641,179	653,714
Gross profit	281,861	287,334	548,118	582,549
Sales and marketing	102,516	108,024	202,329	217,103
General and administrative	128,354	61,173	243,310	153,864
Operating income (loss)	22,545	85,397	50,781	116,034
Other income (loss), net	(14,112)	3,195	(15,461)	828
Income (loss) before provision (benefit) for income taxes	(33,896)	29,098	(49,115)	10,937
Provision for income taxes	3,117	15,689	2,909	7,836
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(37,013)	13,409	(52,024)	3,101
Income (loss) from continuing operations	(34,891)	14,770	(44,868)	8,421
Net income (loss)	(34,891)	14,770	(44,868)	225,198
Net income attributable to Alere Inc. and Subsidiaries	(35,034)	14,411	(45,114)	224,751
Net income available to common stockholders	$ (40,342)	$ 9,103	$ (55,731)	$ 214,193
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:
Basic and diluted income (loss) per common share: Income (loss) from continuing operations		$ 0.11		$ (0.03)
Basic and diluted net income per common share: Net income per common share		$ 0.11		$ 2.53
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales		$ 496,834		$ 976,433
Net product sales and services revenue		623,462		1,226,917
Net revenue		629,156		1,237,309
Cost of net product sales		258,485		497,122
Cost of service revenue		76,753		152,334
Cost of net product sales and services revenue		335,238		649,456
Cost of net revenue		336,582		652,750
Gross profit		292,574		584,559
Sales and marketing		107,184		216,263
General and administrative		60,813		153,504
Operating income (loss)		91,837		119,244
Other income (loss), net		4,260		2,990
Income (loss) before provision (benefit) for income taxes		36,603		16,309
Provision for income taxes		17,701		8,915
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax		18,902		7,394
Income (loss) from continuing operations		20,263		12,714
Net income (loss)		20,263		229,491
Net income attributable to Alere Inc. and Subsidiaries		19,904		229,044
Net income available to common stockholders		$ 14,596		$ 218,486
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:
Basic and diluted income (loss) per common share: Income (loss) from continuing operations		$ 0.17		$ 0.02
Basic and diluted net income per common share: Net income per common share		$ 0.17		$ 2.54
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales		$ (5,785)		$ (1,046)
Net product sales and services revenue		(5,785)		(1,046)
Net revenue		(5,785)		(1,046)
Cost of net product sales		(592)		872
Cost of service revenue		47		92
Cost of net product sales and services revenue		(545)		964
Cost of net revenue		(545)		964
Gross profit		(5,240)		(2,010)
Sales and marketing		840		840
General and administrative		360		360
Operating income (loss)		(6,440)		(3,210)
Other income (loss), net		(1,065)		(2,162)
Income (loss) before provision (benefit) for income taxes		(7,505)		(5,372)
Provision for income taxes		(2,012)		(1,079)
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax		(5,493)		(4,293)
Income (loss) from continuing operations		(5,493)		(4,293)
Net income (loss)		(5,493)		(4,293)
Net income attributable to Alere Inc. and Subsidiaries		(5,493)		(4,293)
Net income available to common stockholders		$ (5,493)		$ (4,293)
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:
Basic and diluted income (loss) per common share: Income (loss) from continuing operations		$ (0.06)		$ (0.05)
Basic and diluted net income per common share: Net income per common share		$ (0.06)		$ (0.01)

Revision of Previously Report48

Revision of Previously Reported Consolidated Financial Statements - Restated and Revised Consolidated Statement of Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)	$ (34,891)	$ 14,770	$ (44,868)	$ 225,198
Comprehensive income	(78,495)	61,122	(66,124)	189,826
Comprehensive income attributable to Alere Inc. and Subsidiaries	$ (78,638)	60,763	$ (66,370)	189,379
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		20,263		229,491
Comprehensive income		66,615		194,119
Comprehensive income attributable to Alere Inc. and Subsidiaries		66,256		193,672
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		(5,493)		(4,293)
Comprehensive income		(5,493)		(4,293)
Comprehensive income attributable to Alere Inc. and Subsidiaries		$ (5,493)		$ (4,293)

Revision of Previously Report49

Revision of Previously Reported Consolidated Financial Statements - Restated and Revised Consolidated Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)	$ (34,891)	$ 14,770	$ (44,868)	$ 225,198
Income (loss) from continuing operations	(34,891)	14,770	(44,868)	8,421
Depreciation and amortization	$ 69,901	72,689	142,405	147,103
Deferred income taxes			(13,210)	(42,171)
Accounts receivable, net			20,023	(18,016)
Inventories, net			(5,820)	(45,219)
Accrued expenses and other current liabilities			(1,676)	23,052
Other non-current liabilities			(6,106)	8,536
Net cash provided by continuing operations			94,122	34,720
Net cash provided by operating activities			94,122	35,038
Excess tax benefits on exercised stock options				0
Net cash used in continuing operations			(73,615)	(102,645)
Net cash used in financing activities			$ (73,615)	(102,721)
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		20,263		229,491
Income (loss) from continuing operations		20,263		12,714
Depreciation and amortization				147,011
Deferred income taxes				(40,655)
Accounts receivable, net				(27,464)
Inventories, net				(46,093)
Accrued expenses and other current liabilities				27,657
Other non-current liabilities				6,025
Net cash provided by continuing operations				32,209
Net cash provided by operating activities				32,527
Excess tax benefits on exercised stock options				2,511
Net cash used in continuing operations				(100,134)
Net cash used in financing activities				(100,210)
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		(5,493)		(4,293)
Income (loss) from continuing operations		$ (5,493)		(4,293)
Depreciation and amortization				92
Deferred income taxes				(1,516)
Accounts receivable, net				9,448
Inventories, net				874
Accrued expenses and other current liabilities				(4,605)
Other non-current liabilities				2,511
Net cash provided by continuing operations				2,511
Net cash provided by operating activities				2,511
Excess tax benefits on exercised stock options				(2,511)
Net cash used in continuing operations				(2,511)
Net cash used in financing activities				$ (2,511)

Merger Agreement - Additional I

Merger Agreement - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Jan. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Preferred Stock, par value		$ 0.001	$ 0.001
Merger Agreement [Member]
Business Acquisition [Line Items]
Right to receive cash by each common stockholder	$ 56
Termination fee of agreement	$ 177
Merger Agreement [Member] | Series B Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred Stock, par value	$ 0.001
Merger Agreement [Member] | Series B Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred Stock, par value	$ 0.001

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) - Health Management Business [Member] $ in Millions	Jan. 09, 2015USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of subsidiary	$ 599.9
Prior Credit Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayment of senior secured credit facility	$ 575

Discontinued Operations - Summa

Discontinued Operations - Summarized Financial Information Related to Health Management Business (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax	$ 0	$ 0	$ 0	$ 216,777
Health Management Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue				7,373
Cost of net revenue				(4,413)
Sales and marketing				(996)
General and administrative				(5,001)
Interest expense				(9)
Other income (expense), net				160
Gain on disposal				366,191
Income from discontinued operations before provision for income taxes				363,305
Provision for income taxes				146,528
Income from discontinued operations, net of tax				$ 216,777

Cash and Cash Equivalents - Add

Cash and Cash Equivalents - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2016
Cash and Cash Equivalents [Abstract]
Cash investments maturity period	Three months or less

Inventories - Inventories are S

Inventories - Inventories are Stated at Lower of Cost (First In, First Out) or Market (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 121,904	$ 130,171
Work-in-process	74,206	69,178
Finished goods	137,736	147,652
Inventories, net	$ 333,846	$ 347,001

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 11,004	$ 7,130	$ 20,607	$ 12,279
Cost of Net Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	601	287	1,080	540
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	481	282	879	606
Sales and Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	2,636	1,251	4,561	2,345
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 7,286	$ 5,310	$ 14,086	$ 8,788

Net Income (Loss) Per Common 56

Net Income (Loss) Per Common Share - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Numerator:
Income (loss) from continuing operations	$ (34,891)	$ 14,770	$ (44,868)	$ 8,421
Preferred stock dividends	(5,308)	(5,308)	(10,617)	(10,558)
Income (loss) from continuing operations attributable to common shares	(40,199)	9,462	(55,485)	(2,137)
Less: Net income attributable to non-controlling interest	143	359	246	447
Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries	(40,342)	9,103	(55,731)	(2,584)
Income from discontinued operations	0	0	0	216,777
Net income (loss) available to common stockholders	$ (40,342)	$ 9,103	$ (55,731)	$ 214,193
Denominator:
Weighted-average common shares outstanding - basic	86,737	85,173	86,692	84,758
Weighted-average common shares outstanding - diluted	86,737	86,635	86,692	84,758
Basic net income (loss) per common share:
Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries	$ (0.46)	$ 0.11	$ (0.64)	$ (0.03)
Income from discontinued operations	0	0	0	2.56
Basic net income (loss) per common share	(0.46)	0.11	(0.64)	2.53
Diluted net income (loss) per common share:
Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries	(0.46)	0.11	(0.64)	(0.03)
Income from discontinued operations	0	0	0	2.56
Diluted net income (loss) per common share	$ (0.46)	$ 0.11	$ (0.64)	$ 2.53

Net Income (Loss) Per Common 57

Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	19,254	21,304	20,116	21,308
Options to Purchase Shares of Common Stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	7,329	7,627	7,329	7,627
Warrants [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	0	0	4
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	1,687	3,411	2,549	3,411
Conversion Shares Related to Subordinated Convertible Promissory Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	27	0	27
Conversion Shares Related to Series B Convertible Preferred Stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	10,238	10,239	10,238	10,239

Net Income (Loss) Per Common 58

Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Parenthetical) (Detail)	Jun. 30, 2016	Jun. 30, 2015
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest rate of debt instrument	3.00%	3.00%

Stockholders' Equity and Non-59

Stockholders' Equity and Non-controlling Interests - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Class of Stock [Line Items]
Preferred stock dividends	$ 5,308	$ 5,308	$ 10,617	$ 10,558
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock dividends	5,300	5,300	10,600	10,600
Preferred stock dividends accrued	5,300		5,300
Preferred stock dividends cash paid	$ 5,300	$ 5,300	$ 10,600	$ 10,600

Stockholders' Equity and Non-60

Stockholders' Equity and Non-controlling Interests - Summary of Changes in Stockholders' Equity and Non-controlling Interests Comprising Total Equity (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period			$ 2,058,429
Issuance of common stock under employee compensation plans			11,308
Net issuance of common stock to settle taxes on restricted stock units			(1,410)
Preferred stock dividends			(10,646)
Stock-based compensation expense			20,607
Other adjustments			(2)
Net income (loss)	$ (34,891)	$ 14,770	(44,868)	$ 225,198
Total other comprehensive loss	(43,604)	$ 46,352	(21,256)	$ (35,372)
Equity, end of period	2,012,162		2,012,162
Total Stockholders' Equity [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period			2,054,165
Issuance of common stock under employee compensation plans			11,308
Net issuance of common stock to settle taxes on restricted stock units			(1,410)
Preferred stock dividends			(10,646)
Stock-based compensation expense			20,607
Other adjustments			0
Net income (loss)			(45,114)
Total other comprehensive loss			(21,256)
Equity, end of period	2,007,654		2,007,654
Non-controlling Interests [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period			4,264
Issuance of common stock under employee compensation plans			0
Net issuance of common stock to settle taxes on restricted stock units			0
Preferred stock dividends			0
Stock-based compensation expense			0
Other adjustments			(2)
Net income (loss)			246
Total other comprehensive loss			0
Equity, end of period	$ 4,508		$ 4,508

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Feb. 11, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 2,811,545	$ 2,811,545		$ 2,836,915
EDTS [Member]
Business Acquisition [Line Items]
Preliminary aggregate purchase price			$ 6,500
Total revenue related to acquisition	1,700	2,600
Goodwill	$ 2,100	$ 2,100

Business Combinations - Summary

Business Combinations - Summary of Aggregate Purchase Price Allocation (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Business Combinations [Abstract]
Current assets	$ 1,371
Property, plant and equipment	115
Goodwill	2,065
Intangible assets	4,220
Total assets acquired	7,771
Current liabilities	1,301
Total liabilities assumed	1,301
Net assets acquired	6,470
Cash paid	$ 6,470

Business Combinations - Intangi

Business Combinations - Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Finite And Infinite Lived Intangible Assets [Line Items]
Total intangible assets	$ 4,220
Core Technology and Patents [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 540
Weighted-average Useful Life	10 years
Trademarks and Trade Names [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 310
Weighted-average Useful Life	20 years
Customer Relationships [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 2,800
Weighted-average Useful Life	14 years
Non-Competition Agreements [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 570
Weighted-average Useful Life	3 years

Restructuring - Aggregate Charg

Restructuring - Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 8,785	$ 4,853	$ 16,448	$ 9,123
Restructuring charges	8,787	4,859	16,455	9,136
Interest Expense, Including Amortization of Original Issue Discounts and Deferred Financing Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2	6	7	13
Cost of Net Revenue [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,103	896	2,370	2,399
Research and Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,034	156	2,954	649
Sales and Marketing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	259	570	909	1,953
General and Administrative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	6,389	3,231	10,215	4,122
Total Operating Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 8,785	$ 4,853	$ 16,448	$ 9,123

Restructuring - Restructuring A

Restructuring - Restructuring Activities Related to Restructuring Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		102 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 8,785	$ 4,853	$ 16,448	$ 9,123
Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,414	4,290	8,097	8,525
Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	5,371	563	8,351	598
2016 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	8,787	4,859	16,455	9,136	$ 100,466
2016 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,416	4,296	8,104	8,538	76,516
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,183	1,264	6,274	4,064	44,261
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	213	2,581	1,194	4,007	12,862
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Cash Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3,398	3,851	7,475	8,084	57,952
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	21	445	419	454	16,372
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Other Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2	6	7	13	829
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Other Non-Cash Recoveries [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(3)	0	210	0	2,192
2016 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	5,371	563	8,351	598	23,950
2016 Restructuring Plans [Member] | Corporate and Other [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(19)	569	(4)	611	4,273
2016 Restructuring Plans [Member] | Corporate and Other [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 5,390	$ (6)	$ 8,355	$ (13)	$ 19,677

Restructuring - Additional Info

Restructuring - Additional Information (Detail) $ in Millions	Jun. 30, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring reserves included in accrued expenses and other current liabilities	$ 9.5
Restructuring reserves included in other long-term liabilities	0.6
2016 Restructuring Plans [Member] | Manufacturing Facility [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	3.7
2016 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	4.4
2016 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	$ 8

Restructuring - Cash Activity f

Restructuring - Cash Activity for Restructuring Reserves (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Restructuring Cost and Reserve [Line Items]
Cash charges	$ 8,785	$ 4,853	$ 16,448	$ 9,123
Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			3,779
Cash charges			15,826
Payments			(9,532)
Currency adjustments			(7)
Restructuring Reserve, Ending Balance	10,066		10,066
Severance-Related Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			1,633
Cash charges			6,270
Payments			(3,814)
Currency adjustments			(18)
Restructuring Reserve, Ending Balance	4,071		4,071
Facility and Transition Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			1,966
Cash charges			9,549
Payments			(5,645)
Currency adjustments			11
Restructuring Reserve, Ending Balance	5,881		5,881
Other Exit Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			180
Cash charges			7
Payments			(73)
Currency adjustments			0
Restructuring Reserve, Ending Balance	$ 114		$ 114

Long-Term Debt - Long-Term Debt

Long-Term Debt - Long-Term Debt Balances Outstanding (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt, Total	$ 2,964,470	$ 3,031,158
Less: Short-term debt and current portion of long-term debt	(43,681)	(199,992)
Long-term debt	2,920,789	2,831,166
Revolver Facility [Member]
Debt Instrument [Line Items]
Long-term debt, Total	125,000	0
A Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	559,317	575,746
B Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	958,337	965,740
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	442,533	446,320
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	415,679	419,209
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	414,033	418,133
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	0	149,839
Other Lines of Credit [Member]
Debt Instrument [Line Items]
Long-term debt, Total	1,335	136
Other [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 48,236	$ 56,035

Long-Term Debt - Long-Term De69

Long-Term Debt - Long-Term Debt Balances Outstanding (Parenthetical) (Detail)	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Description of default under credit agreement		(i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing our notes. On June 30, 2016, we were not in default under the Credit Agreement or the indentures governing our notes. As discussed more fully below in this Note 12, in August 2016 we entered into a further amendment to the Credit Agreement with respect to our failure to timely file this Quarterly Report on Form 10-Q.
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	7.25%	7.25%	7.25%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.50%	6.50%	6.50%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%	6.375%
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	3.00%	3.00%	3.00%
Maturity date	May 31, 2016

Long-Term Debt - Long-Term De70

Long-Term Debt - Long-Term Debt Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 42,329	$ 59,494	$ 84,435	$ 105,925
Secured Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	17,834	12,851	34,877	12,851
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	0	19,726	0	39,188
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	8,904	8,525	17,428	17,049
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	7,405	7,234	14,636	14,467
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	7,112	542	14,115	542
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	0	9,274	0	18,547
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	603	1,246	1,847	2,492
Other [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 471	$ 96	$ 1,532	$ 789

Long-Term Debt - Long-Term De71

Long-Term Debt - Long-Term Debt Interest Expense (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Debt Instrument [Line Items]
Amortization fee	$ 300		$ 700
Loss on extinguishment of debt		$ 0	$ 3,480
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 3,500
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	7.25%	7.25%	7.25%	7.25%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.50%	6.50%	6.50%	6.50%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%	6.375%	6.375%
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	8.625%	8.625%	8.625%
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	3.00%	3.00%	3.00%	3.00%

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($)	Aug. 18, 2016	Jul. 01, 2016	May 15, 2016	Apr. 22, 2016	Jul. 31, 2016	May 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Rate of aggregate consent fee				0.25%
Amount of aggregate consent fee				$ 4,500,000
Consent aggregate payments per 1,000 aggregate principal amount						$ 15
Aggregate payments to note holders						$ 19,200,000
Repayment of long term debt							$ 177,637,000	$ 2,118,264,000
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Repayment of long term debt			$ 152,000,000
3% Convertible Senior Subordinated Notes [Member] | Cash [Member]
Debt Instrument [Line Items]
Repayment of long term debt			27,000,000
3% Convertible Senior Subordinated Notes [Member] | Revolver Facility [Member]
Debt Instrument [Line Items]
Repayment of long term debt			$ 125,000,000
Subsequent Event [Member]
Debt Instrument [Line Items]
Rate of aggregate consent fee	0.125%
Amount of aggregate consent fee	$ 2,200,000
Increase in applicable interest rate margin for all loans outstanding		0.25%
Consent aggregate payments per 1,000 aggregate principal amount					$ 15
Aggregate payments to note holders					$ 19,200,000

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	$ 74	$ 164
Total assets	74	164
Liabilities:
Contingent consideration obligations	55,100	57,744
Total liabilities	55,100	57,744
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	74	164
Total assets	74	164
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Unobservable Inputs (Level 3) [Member]
Liabilities:
Contingent consideration obligations	55,100	57,744
Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	55,100	57,744
Total liabilities	$ 55,100	$ 57,744

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Contingent Consideration Obligations (Detail) - Unobservable Inputs (Level 3) [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent consideration obligations, Beginning balance	$ 57,744
Payments	(865)
Fair value adjustments	(1,780)
Foreign currency adjustments	1
Fair value of contingent consideration obligations, Ending balance	$ 55,100

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Billions	Jun. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Estimated fair value of long-term debt	$ 3	$ 3
Long-term debt, Total	$ 3	$ 3.1

Financial Information by Segm76

Financial Information by Segment - Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net revenue	$ 611,088	$ 623,371	$ 1,189,297	$ 1,236,263
Operating income (loss)	22,545	85,397	50,781	116,034
Impairment and (gain) loss on dispositions, net	0	5,542	(3,810)	40,334
Depreciation and amortization	69,901	72,689	142,405	147,103
Restructuring charge	8,785	4,853	16,448	9,123
Stock-based compensation	11,004	7,130	20,607	12,279
Assets	5,790,894		5,790,894		$ 5,923,121
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	591,294	598,726	1,152,061	1,189,651
Operating income (loss)	85,535	153,241	168,215	242,784
Impairment and (gain) loss on dispositions, net		(38,836)	(3,810)	(40,568)
Depreciation and amortization	66,393	70,189	135,225	142,658
Restructuring charge	3,414	4,290	8,097	8,525
Stock-based compensation	0	0	0	0
Assets	5,572,046		5,572,046		5,619,901
Consumer Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	19,794	24,645	37,236	46,612
Operating income (loss)	396	1,079	563	3,283
Impairment and (gain) loss on dispositions, net		0	0	0
Depreciation and amortization	1,374	725	2,873	1,436
Restructuring charge	0	0	0	0
Stock-based compensation	0	0	0	0
Assets	179,445		179,445		172,551
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Operating income (loss)	(63,386)	(68,923)	(117,997)	(130,033)
Impairment and (gain) loss on dispositions, net		44,378	0	80,902
Depreciation and amortization	2,134	1,775	4,307	3,009
Restructuring charge	5,371	563	8,351	598
Stock-based compensation	11,004	$ 7,130	20,607	$ 12,279
Assets	$ 39,403		$ 39,403		$ 130,669

Financial Information by Segm77

Financial Information by Segment - Summary of Company's Net Revenue from Professional Diagnostics Reporting Segments by Groups of Similar Products and Services (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting Information [Line Items]
Sales revenue net	$ 608,555	$ 617,677	$ 1,184,035	$ 1,225,871
Total professional diagnostics net product sales and services revenue	124,809	126,628	240,518	250,484
License and royalty revenue	2,533	5,694	5,262	10,392
Net revenue	611,088	623,371	1,189,297	1,236,263
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	591,294	598,726	1,152,061	1,189,651
Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Total professional diagnostics net product sales and services revenue	588,761	593,032	1,146,799	1,179,259
License and royalty revenue	2,533	5,694	5,262	10,392
Net revenue	591,294	598,726	1,152,061	1,189,651
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Cardiometabolic [Member]
Segment Reporting Information [Line Items]
Sales revenue net	203,982	211,672	398,559	412,608
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Infectious Disease [Member]
Segment Reporting Information [Line Items]
Sales revenue net	190,168	172,834	373,402	358,236
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Toxicology [Member]
Segment Reporting Information [Line Items]
Sales revenue net	158,199	157,495	304,982	306,251
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Sales revenue net	$ 36,412	$ 51,031	$ 69,856	$ 102,164

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Jun. 30, 2016CNY (¥)	May 31, 2007
Related Party Transaction [Line Items]
Restructuring charges	$ 8,785	$ 4,853	$ 16,448	$ 9,123
SPD [Member]
Related Party Transaction [Line Items]
Equity method investment ownership percentage	50.00%		50.00%			50.00%	50.00%
SPD Shanghai [Member]
Related Party Transaction [Line Items]
Restricted cash	$ 3,500		$ 3,500
SPD Shanghai [Member] | Maximum [Member] | Alere Shanghai [Member]
Related Party Transaction [Line Items]
Loan arrangement from related party	$ 3,500		$ 3,500			¥ 23,000,000
TechLab [Member]
Related Party Transaction [Line Items]
Equity method investment ownership percentage	49.00%		49.00%			49.00%
Net payable to SPD	$ 1,500		$ 1,500		$ 3,200
Purchases from related party	4,500	4,100	9,200	8,500
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Net payable to SPD	3,700		3,700		1,200
Restructuring charges			1,300		1,500
Long-term receivable cost related to restructuring plan	6,700		6,700		8,900
Customer receivables associated with revenue earned after SPD was completed have been classified as other receivables	8,800		8,800		7,800
Trade receivables from SPD	11,700		11,700		9,900
Trade payable to SPD	31,600		31,600		$ 24,900
SPD Joint Venture [Member] | Sales Revenue Goods [Member]
Related Party Transaction [Line Items]
Revenue from joint venture	21,800	21,700	39,500	41,200
SPD Joint Venture [Member] | Sales Revenue Services [Member]
Related Party Transaction [Line Items]
Revenue from joint venture	$ 300	$ 300	$ 500	$ 600

Related Party Transactions - Re

Related Party Transactions - Related Party Balances with SPD within Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	$ 427,222	$ 445,833
Prepaid expenses and other current assets	162,339	152,233
Other non-current assets	16,290	18,078
Accounts payable	194,235	195,752
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	11,670	9,873
Prepaid expenses and other current assets	8,768	6,602
Other non-current assets	6,699	8,895
Accounts payable	$ 31,584	$ 24,887

Other Arrangements - Additional

Other Arrangements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Sep. 30, 2014	Feb. 28, 2013	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Period of contract	3 years 6 months
The amount provided for development of diagnostic device by BARDA as defined in the agreement	$ 12,900,000
Net expenditure incurred under the contract			$ 1,000,000	$ 900,000
The amount of cash reimbursement received from BARDA			0	500,000
Amount of accounts receivables			1,000,000	400,000	$ 1,000,000	$ 400,000
Restricted cash			5,662,000		5,662,000		$ 5,694,000
Gates Foundation [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue from grant awarded		$ 21,600,000
Cash received from grant-related funding					19,700,000
Qualified expenditures				1,800,000
Deferred grant funding			0		0
Restricted cash			0		0
Gates Foundation [Member] | Malaria Program [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue from grant awarded					2,900,000
Qualified expenditures			300,000	$ 100,000	500,000	$ 300,000
Deferred grant funding			1,300,000		1,300,000
Restricted cash			$ 1,400,000		$ 1,400,000
Gates Loan Agreement [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Aggregate principal amount of subordinated term loan		$ 20,600,000

Commitments and Contingencies -

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Business Acquisition, Contingent Consideration [Line Items]
Estimated Fair Value	$ 55,100,000	$ 57,744,000
Payments Made During 2016	865,000
Loss Contingency Accrual	$ 10,200,000
TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Mar. 11, 2010
Acquisition Date Fair Value	$ 35,600,000
Maximum Remaining Earn-out Potential	102,870,000
Estimated Fair Value	46,600,000	47,800,000
Payments Made During 2016	$ 377,000
Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Feb. 1, 2013
Acquisition Date Fair Value	$ 75,000,000
Maximum Remaining Earn-out Potential	45,500,000
Estimated Fair Value	3,900,000	4,700,000
Payments Made During 2016	$ 0
Other [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Various
Acquisition Date Fair Value	$ 30,373,000
Maximum Remaining Earn-out Potential	$ 0
Remaining Earn-out Period	2,016
Estimated Fair Value	$ 4,600,000	$ 5,244,000
Payments Made During 2016	$ 488,000
Minimum [Member] | TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,016
Minimum [Member] | Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,016
Maximum [Member] | TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,025
Maximum [Member] | Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,018

Commitments and Contingencies82

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Earn-out period	15 years

Recent Accounting Pronounceme83

Recent Accounting Pronouncements - Additional Information (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Accounting Standards Update 2015-15 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs	$ 49.6	$ 34.1

Equity Investments - Additional

Equity Investments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	May 31, 2007
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax	$ 2,122	$ 1,361	$ 7,156	$ 5,320
SPD [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax	$ 1,600	600	$ 6,200	4,200
Equity method investment ownership percentage	50.00%		50.00%		50.00%
Return of capital		12,100		12,100
TechLab [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax	$ 600	400	$ 1,000	800
Equity method investment ownership percentage	49.00%		49.00%
Return of capital		$ 2,200		$ 2,200

Equity Investments - Financial

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Results of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]
Net revenue	$ 55,077	$ 53,159	$ 108,511	$ 101,016
Gross profit	36,634	34,559	72,853	67,830
Net income after taxes	$ 4,328	$ 3,039	$ 14,469	$ 11,096

Equity Investments - Financia86

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Balance Sheet (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Equity Method Investments and Joint Ventures [Abstract]
Current assets	$ 91,942	$ 71,542
Non-current assets	31,826	30,802
Total assets	123,768	102,344
Current liabilities	47,764	37,609
Non-current liabilities	5,845	5,157
Total liabilities	$ 53,609	$ 42,766

Impairment and (Gain) Loss on D

Impairment and (Gain) Loss on Dispositions, Net - Additional Information (Detail) € in Millions, $ in Millions	1 Months Ended			3 Months Ended			6 Months Ended
	Jan. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Mar. 31, 2015EUR (€)	Mar. 31, 2016USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Jun. 30, 2015USD ($)	May 31, 2015USD ($)
Alere E-Sante [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale of business, cash received	$ 8.1
Sale of business, working capital adjustment	0.2
Sale of business, contingent consideration	$ 1.5
Gain (Loss) on sale of disposal group				$ 3.8
AdnaGen GmbH [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) from sale of assets						$ (0.3)
Proceeds from sale of assets		$ 4.6
Gesellschaft Fur Patientenhilfe DGP GmbH [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on sale of disposal group						(7.5)
Cash proceeds from sale of business		$ 8.2	€ 7.6
Alere Analytics [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charges						26.7
Write-off of intangible assets						26.2
Write-off of fixed assets						$ 0.5
Contribution to working capital								$ 2.7
Gain (loss) from sale of assets					$ 4.7
Alere Analytics [Member] | Cash [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to working capital								2.4
Alere Analytics [Member] | Escrow [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to working capital								$ 0.3
Alere Connect LLC [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charges							$ 1

Income Taxes - Reconciliation b

Income Taxes - Reconciliation between U.S. Federal Statutory Rate and Effective Tax Rate (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Statutory rate	35.00%	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	(5.00%)	(4.00%)	(4.00%)	(5.00%)
Rate differential on foreign earnings	(61.00%)	(19.00%)	(58.00%)	(27.00%)
Change in valuation allowance	(4.00%)	(3.00%)	(6.00%)	10.00%
Stock based compensation	11.00%	5.00%	11.00%	(9.00%)
Uncertain tax positions	12.00%	7.00%	9.00%	15.00%
Disposition of BBI	0.00%	27.00%	0.00%	65.00%
Other	3.00%	6.00%	7.00%	(12.00%)
Effective tax rate	(9.00%)	54.00%	(6.00%)	72.00%

Guarantor Financial Informati89

Guarantor Financial Information - Additional Information (Detail) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015
Accounting Standards Update 2015-15 [Member]
Debt Instrument [Line Items]
Debt issuance cost	$ 49.6	$ 34.1
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	7.25%	7.25%	7.25%
Maturity year of debt instrument	2,018
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	6.50%	6.50%	6.50%
Maturity year of debt instrument	2,020
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	6.375%	6.375%	6.375%
Maturity year of debt instrument	2,023
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	8.625%		8.625%
Maturity year of debt instrument	2,018
Maturity date	Oct. 1, 2015

Guarantor Financial Informati90

Guarantor Financial Information - Revised Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 611,088	$ 623,371	$ 1,189,297	$ 1,236,263
Cost of net revenue	329,227	336,037	641,179	653,714
Income (loss) from continuing operations before benefit for income taxes	(33,896)	29,098	(49,115)	10,937
Provision for income taxes	3,117	15,689	2,909	7,836
Income (loss) from continuing operations	(34,891)	14,770	(44,868)	8,421
Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	339,100	329,809	670,884	656,101
Cost of net revenue	205,991	199,247	403,261	386,387
Income (loss) from continuing operations before benefit for income taxes	35,180	53,043	67,434	55,588
Provision for income taxes	(6,759)	10,830	6,509	11,581
Income (loss) from continuing operations		42,213		44,007
Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	349,659	362,644	660,279	712,912
Cost of net revenue	199,704	205,281	377,849	400,171
Income (loss) from continuing operations before benefit for income taxes	44,434	105,715	86,877	187,383
Provision for income taxes	$ (9,889)	21,203	$ 10,293	32,920
Income (loss) from continuing operations		84,936		158,455
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		629,156		1,237,309
Cost of net revenue		336,582		652,750
Income (loss) from continuing operations before benefit for income taxes		36,603		16,309
Provision for income taxes		17,701		8,915
Income (loss) from continuing operations		20,263		12,714
As Previously Reported [Member] | Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		330,820		659,282
Cost of net revenue		199,233		387,269
Income (loss) from continuing operations before benefit for income taxes		55,133		60,049
Provision for income taxes		11,277		13,097
Income (loss) from continuing operations		43,856		46,952
As Previously Reported [Member] | Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		367,418		710,777
Cost of net revenue		205,840		398,325
Income (loss) from continuing operations before benefit for income taxes		111,130		188,294
Provision for income taxes		22,768		32,483
Income (loss) from continuing operations		88,786		159,803
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		(5,785)		(1,046)
Cost of net revenue		(545)		964
Income (loss) from continuing operations before benefit for income taxes		(7,505)		(5,372)
Provision for income taxes		(2,012)		(1,079)
Income (loss) from continuing operations		(5,493)		(4,293)
Revision Adjustment [Member] | Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		(1,011)		(3,181)
Cost of net revenue		14		(882)
Income (loss) from continuing operations before benefit for income taxes		(2,090)		(4,461)
Provision for income taxes		(447)		(1,516)
Income (loss) from continuing operations		(1,643)		(2,945)
Revision Adjustment [Member] | Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		(4,774)		2,135
Cost of net revenue		(559)		1,846
Income (loss) from continuing operations before benefit for income taxes		(5,415)		(911)
Provision for income taxes		(1,565)		437
Income (loss) from continuing operations		$ (3,850)		$ (1,348)

Guarantor Financial Informati91

Guarantor Financial Information - Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Condensed Financial Statements, Captions [Line Items]
Net product sales	$ 483,746	$ 491,049	$ 943,517	$ 975,387
Services revenue	124,809	126,628	240,518	250,484
Net product sales and services revenue	608,555	617,677	1,184,035	1,225,871
License and royalty revenue	2,533	5,694	5,262	10,392
Net revenue	611,088	623,371	1,189,297	1,236,263
Cost of net product sales	250,398	257,893	487,859	497,994
Cost of services revenue	78,294	76,800	151,394	152,426
Cost of net product sales and services revenue	328,692	334,693	639,253	650,420
Cost of license and royalty revenue	535	1,344	1,926	3,294
Cost of net revenue	329,227	336,037	641,179	653,714
Gross profit (loss)	281,861	287,334	548,118	582,549
Operating expenses:
Research and development	28,446	27,198	55,508	55,214
Sales and marketing	102,516	108,024	202,329	217,103
General and administrative	128,354	61,173	243,310	153,864
Impairment and (gain) loss on dispositions, net	0	5,542	(3,810)	40,334
Operating income (loss)	22,545	85,397	50,781	116,034
Interest expense, including amortization of original issue discounts and deferred financing costs	(42,329)	(59,494)	(84,435)	(105,925)
Other income (expense), net	(14,112)	3,195	(15,461)	828
Income (loss) before provision (benefit) for income taxes	(33,896)	29,098	(49,115)	10,937
Provision (benefit) for income taxes	3,117	15,689	2,909	7,836
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(37,013)	13,409	(52,024)	3,101
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Equity earnings of unconsolidated entities, net of tax	2,122	1,361	7,156	5,320
Income (loss) from continuing operations	(34,891)	14,770	(44,868)	8,421
Income (loss) from discontinued operations, net of tax	0	0	0	216,777
Net income (loss)	(34,891)	14,770	(44,868)	225,198
Less: Net income attributable to non-controlling interests	143	359	246	447
Net income (loss) attributable to Alere Inc. and Subsidiaries	(35,034)	14,411	(45,114)	224,751
Preferred stock dividends	(5,308)	(5,308)	(10,617)	(10,558)
Net income (loss) available to common stockholders	(40,342)	9,103	(55,731)	214,193
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	0	0	0	0
Services revenue	0	0	0	0
Net product sales and services revenue	0	0	0	0
License and royalty revenue	0	0	0	0
Net revenue	0	0	0	0
Cost of net product sales	220	417	334	833
Cost of services revenue	104	80	104	130
Cost of net product sales and services revenue	324	497	438	963
Cost of license and royalty revenue	0	19	0	(21)
Cost of net revenue	324	516	438	942
Gross profit (loss)	(324)	(516)	(438)	(942)
Operating expenses:
Research and development	2,997	3,241	7,131	5,543
Sales and marketing	1,568	1,570	2,904	2,830
General and administrative	57,740	24,390	102,355	44,913
Impairment and (gain) loss on dispositions, net	0	44,378	0	80,901
Operating income (loss)	(62,629)	(74,095)	(112,828)	(135,129)
Interest expense, including amortization of original issue discounts and deferred financing costs	(41,857)	(59,086)	(82,944)	(105,184)
Other income (expense), net	(8,144)	3,596	(6,156)	7,243
Income (loss) before provision (benefit) for income taxes	(112,630)	(129,585)	(201,928)	(233,070)
Provision (benefit) for income taxes	19,765	(16,306)	(19,711)	(36,973)
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(132,395)	(113,279)	(221,639)	(196,097)
Equity in earnings of subsidiaries, net of tax	96,916	127,127	175,502	201,260
Equity earnings of unconsolidated entities, net of tax	588	922	1,269	1,346
Income (loss) from continuing operations				6,509
Income (loss) from discontinued operations, net of tax				218,689
Net income (loss)	(34,891)	14,770	(44,868)	225,198
Less: Net income attributable to non-controlling interests	0	0	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	(34,891)	14,770	(44,868)	225,198
Preferred stock dividends	(5,308)	(5,308)	(10,617)	(10,558)
Net income (loss) available to common stockholders	(40,199)	9,462	(55,485)	214,640
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	222,954	211,593	447,334	426,631
Services revenue	112,698	114,983	217,182	223,040
Net product sales and services revenue	335,652	326,576	664,516	649,671
License and royalty revenue	3,448	3,233	6,368	6,430
Net revenue	339,100	329,809	670,884	656,101
Cost of net product sales	126,795	120,953	251,553	233,248
Cost of services revenue	79,203	77,884	151,698	151,921
Cost of net product sales and services revenue	205,998	198,837	403,251	385,169
Cost of license and royalty revenue	(7)	410	10	1,218
Cost of net revenue	205,991	199,247	403,261	386,387
Gross profit (loss)	133,109	130,562	267,623	269,714
Operating expenses:
Research and development	16,194	13,993	30,653	28,912
Sales and marketing	53,155	52,101	107,620	105,328
General and administrative	30,460	51,288	63,646	89,058
Impairment and (gain) loss on dispositions, net	0	(39,412)	0	(8,804)
Operating income (loss)	33,300	52,592	65,704	55,220
Interest expense, including amortization of original issue discounts and deferred financing costs	(2,223)	(3,060)	(4,875)	(6,345)
Other income (expense), net	4,103	3,511	6,605	6,713
Income (loss) before provision (benefit) for income taxes	35,180	53,043	67,434	55,588
Provision (benefit) for income taxes	(6,759)	10,830	6,509	11,581
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	41,939	42,213	73,943	44,007
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Equity earnings of unconsolidated entities, net of tax	0	0	0	0
Income (loss) from continuing operations		42,213		44,007
Income (loss) from discontinued operations, net of tax				(1,912)
Net income (loss)	41,939	42,213	73,943	42,095
Less: Net income attributable to non-controlling interests	0	0	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	41,939	42,213	73,943	42,095
Preferred stock dividends	0	0	0	0
Net income (loss) available to common stockholders	41,939	42,213	73,943	42,095
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	335,540	345,289	632,377	675,395
Services revenue	12,111	11,645	23,336	27,444
Net product sales and services revenue	347,651	356,934	655,713	702,839
License and royalty revenue	2,008	5,710	4,566	10,073
Net revenue	349,659	362,644	660,279	712,912
Cost of net product sales	188,478	193,593	354,460	375,999
Cost of services revenue	7,760	7,524	15,800	15,964
Cost of net product sales and services revenue	196,238	201,117	370,260	391,963
Cost of license and royalty revenue	3,466	4,164	7,589	8,208
Cost of net revenue	199,704	205,281	377,849	400,171
Gross profit (loss)	149,955	157,363	282,430	312,741
Operating expenses:
Research and development	9,255	9,964	17,724	20,759
Sales and marketing	47,793	54,353	91,805	108,945
General and administrative	40,154	(14,505)	77,309	19,893
Impairment and (gain) loss on dispositions, net	0	576	(3,810)	(31,763)
Operating income (loss)	52,753	106,975	99,402	194,907
Interest expense, including amortization of original issue discounts and deferred financing costs	(2,775)	(4,702)	(5,842)	(8,745)
Other income (expense), net	(5,544)	3,442	(6,683)	1,221
Income (loss) before provision (benefit) for income taxes	44,434	105,715	86,877	187,383
Provision (benefit) for income taxes	(9,889)	21,203	10,293	32,920
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	54,323	84,512	97,170	154,463
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Equity earnings of unconsolidated entities, net of tax	1,557	424	6,138	3,992
Income (loss) from continuing operations		84,936		158,455
Income (loss) from discontinued operations, net of tax				0
Net income (loss)	55,880	84,936	103,308	158,455
Less: Net income attributable to non-controlling interests	143	359	246	447
Net income (loss) attributable to Alere Inc. and Subsidiaries	55,737	84,577	103,062	158,008
Preferred stock dividends	0	0	0	0
Net income (loss) available to common stockholders	55,737	84,577	103,062	158,008
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	(74,748)	(65,833)	(136,194)	(126,639)
Services revenue	0	0	0	0
Net product sales and services revenue	(74,748)	(65,833)	(136,194)	(126,639)
License and royalty revenue	(2,923)	(3,249)	(5,672)	(6,111)
Net revenue	(77,671)	(69,082)	(141,866)	(132,750)
Cost of net product sales	(65,095)	(57,070)	(118,488)	(112,086)
Cost of services revenue	(8,773)	(8,688)	(16,208)	(15,589)
Cost of net product sales and services revenue	(73,868)	(65,758)	(134,696)	(127,675)
Cost of license and royalty revenue	(2,924)	(3,249)	(5,673)	(6,111)
Cost of net revenue	(76,792)	(69,007)	(140,369)	(133,786)
Gross profit (loss)	(879)	(75)	(1,497)	1,036
Operating expenses:
Research and development	0	0	0	0
Sales and marketing	0	0	0	0
General and administrative	0	0	0	0
Impairment and (gain) loss on dispositions, net	0	0	0	0
Operating income (loss)	(879)	(75)	(1,497)	1,036
Interest expense, including amortization of original issue discounts and deferred financing costs	4,526	7,354	9,226	14,349
Other income (expense), net	(4,527)	(7,354)	(9,227)	(14,349)
Income (loss) before provision (benefit) for income taxes	(880)	(75)	(1,498)	1,036
Provision (benefit) for income taxes	0	(38)	0	308
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(880)	(37)	(1,498)	728
Equity in earnings of subsidiaries, net of tax	(96,916)	(127,127)	(175,502)	(201,260)
Equity earnings of unconsolidated entities, net of tax	(23)	15	(251)	(18)
Income (loss) from continuing operations				(200,550)
Income (loss) from discontinued operations, net of tax				0
Net income (loss)	(97,819)	(127,149)	(177,251)	(200,550)
Less: Net income attributable to non-controlling interests	0	0	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	(97,819)	(127,149)	(177,251)	(200,550)
Preferred stock dividends	0	0	0	0
Net income (loss) available to common stockholders	$ (97,819)	$ (127,149)	$ (177,251)	$ (200,550)

Guarantor Financial Informati92

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	$ (34,891)	$ 14,770	$ (44,868)	$ 225,198
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(44,135)	46,726	(21,942)	(33,616)
Minimum pension liability adjustment	531	(374)	686	(1,756)
Other comprehensive income (loss), before tax	(43,604)	46,352	(21,256)	(35,372)
Other comprehensive income (loss)	(43,604)	46,352	(21,256)	(35,372)
Comprehensive income (loss)	(78,495)	61,122	(66,124)	189,826
Less: Comprehensive income attributable to non-controlling interests	143	359	246	447
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	(78,638)	60,763	(66,370)	189,379
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	(34,891)	14,770	(44,868)	225,198
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	276	197	391	(460)
Minimum pension liability adjustment	0	0	0	0
Other comprehensive income (loss), before tax	276	197	391	(460)
Other comprehensive income (loss)	276	197	391	(460)
Comprehensive income (loss)	(34,615)	14,967	(44,477)	224,738
Less: Comprehensive income attributable to non-controlling interests	0	0	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	(34,615)	14,967	(44,477)	224,738
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	41,939	42,213	73,943	42,095
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(699)	689	(828)	117
Minimum pension liability adjustment	0	0	0	0
Other comprehensive income (loss), before tax	(699)	689	(828)	117
Other comprehensive income (loss)	(699)	689	(828)	117
Comprehensive income (loss)	41,240	42,902	73,115	42,212
Less: Comprehensive income attributable to non-controlling interests	0	0	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	41,240	42,902	73,115	42,212
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	55,880	84,936	103,308	158,455
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(43,720)	45,840	(21,513)	(33,273)
Minimum pension liability adjustment	531	(374)	686	(1,756)
Other comprehensive income (loss), before tax	(43,189)	45,466	(20,827)	(35,029)
Other comprehensive income (loss)	(43,189)	45,466	(20,827)	(35,029)
Comprehensive income (loss)	12,691	130,402	82,481	123,426
Less: Comprehensive income attributable to non-controlling interests	143	359	246	447
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	12,548	130,043	82,235	122,979
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	(97,819)	(127,149)	(177,251)	(200,550)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	8	0	8	0
Minimum pension liability adjustment	0	0	0	0
Other comprehensive income (loss), before tax	8	0	8	0
Other comprehensive income (loss)	8	0	8	0
Comprehensive income (loss)	(97,811)	(127,149)	(177,243)	(200,550)
Less: Comprehensive income attributable to non-controlling interests	0	0	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ (97,811)	$ (127,149)	$ (177,243)	$ (200,550)

Guarantor Financial Informati93

Guarantor Financial Information - Consolidating Balance Sheet (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Jan. 09, 2015
Current assets:
Cash and cash equivalents	$ 506,164	$ 502,200	$ 464,871	$ 378,461
Restricted cash	5,662	5,694
Marketable securities	74	164
Accounts receivable, net of allowances	427,222	445,833
Inventories, net	333,846	347,001
Deferred tax assets	0	0
Prepaid expenses and other current assets	162,339	152,233
Assets held for sale - current	0	4,165
Intercompany receivables	0	0
Total current assets	1,435,307	1,457,290
Property, plant and equipment, net	438,787	446,039
Goodwill	2,811,545	2,836,915
Other intangible assets with indefinite lives	28,279	28,110
Finite-lived intangible assets, net	909,208	997,281
Restricted cash	42,589	43,228
Other non-current assets	16,290	18,078
Investments in subsidiaries	0	0
Investments in unconsolidated entities	74,511	65,333
Deferred tax assets	18,638	13,993
Non-current income tax receivable	3,517	3,517
Assets held for sale - non-current	12,223	13,337
Intercompany notes receivables	0	0
Total assets	5,790,894	5,923,121
Current liabilities:
Short-term debt and current portion of long-term debt	43,681	199,992
Current portion of capital lease obligations	3,500	3,962
Accounts payable	194,235	195,752
Accrued expenses and other current liabilities	320,526	324,465
Liabilities related to assets held for sale - current	0	363
Intercompany payables	0	0
Total current liabilities	561,942	724,534
Long-term liabilities:
Long-term debt, net of current portion	2,920,789	2,831,166
Capital lease obligations, net of current portion	6,972	7,181
Deferred tax liabilities	140,864	147,618
Other long-term liabilities	148,165	154,193
Intercompany notes payables	0	0
Total long-term liabilities	3,216,790	3,140,158
Total stockholders' equity	2,007,654	2,054,165
Non-controlling interests	4,508	4,264
Total equity	2,012,162	2,058,429
Total liabilities and equity	5,790,894	5,923,121
Issuer [Member]
Current assets:
Cash and cash equivalents	49,465	139,153	42,407	2,149
Restricted cash	1,415	1,250
Marketable securities	0	0
Accounts receivable, net of allowances	0	0
Inventories, net	0	0
Deferred tax assets	(455)	(52,410)
Prepaid expenses and other current assets	12,194	7,575
Assets held for sale - current		0
Intercompany receivables	360,548	620,838
Total current assets	423,167	716,406
Property, plant and equipment, net	29,742	31,384
Goodwill	0	0
Other intangible assets with indefinite lives	0	0
Finite-lived intangible assets, net	2,745	2,951
Restricted cash	0	0
Other non-current assets	570	804
Investments in subsidiaries	3,455,642	3,294,857
Investments in unconsolidated entities	687	502
Deferred tax assets	(66,034)	(14,078)
Non-current income tax receivable	3,517	3,517
Assets held for sale - non-current	12,223	13,337
Intercompany notes receivables	1,887,589	1,905,188
Total assets	5,749,848	5,954,868
Current liabilities:
Short-term debt and current portion of long-term debt	40,073	197,084
Current portion of capital lease obligations	0	0
Accounts payable	23,789	15,981
Accrued expenses and other current liabilities	(514,898)	(554,350)
Liabilities related to assets held for sale - current		0
Intercompany payables	965,315	1,122,042
Total current liabilities	514,279	780,757
Long-term liabilities:
Long-term debt, net of current portion	2,874,825	2,784,913
Capital lease obligations, net of current portion	0	0
Deferred tax liabilities	(158,407)	(157,708)
Other long-term liabilities	14,741	14,962
Intercompany notes payables	496,756	477,779
Total long-term liabilities	3,227,915	3,119,946
Total stockholders' equity	2,007,654	2,054,165
Non-controlling interests	0	0
Total equity	2,007,654	2,054,165
Total liabilities and equity	5,749,848	5,954,868
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	6,881	21,150	75,005	69,154
Restricted cash	0	0
Marketable securities	74	164
Accounts receivable, net of allowances	190,438	192,591
Inventories, net	168,413	173,383
Deferred tax assets	6,513	31,285
Prepaid expenses and other current assets	33,489	27,095
Assets held for sale - current		0
Intercompany receivables	827,927	812,957
Total current assets	1,233,735	1,258,625
Property, plant and equipment, net	224,796	228,065
Goodwill	1,823,018	1,823,919
Other intangible assets with indefinite lives	7,538	7,638
Finite-lived intangible assets, net	566,973	627,269
Restricted cash	0	0
Other non-current assets	2,052	2,340
Investments in subsidiaries	158,195	158,195
Investments in unconsolidated entities	14,765	14,764
Deferred tax assets	24,785	(14)
Non-current income tax receivable	0	0
Assets held for sale - non-current	0	0
Intercompany notes receivables	708,708	672,032
Total assets	4,764,565	4,792,833
Current liabilities:
Short-term debt and current portion of long-term debt	0	0
Current portion of capital lease obligations	1,654	2,018
Accounts payable	77,283	76,890
Accrued expenses and other current liabilities	635,590	650,632
Liabilities related to assets held for sale - current		0
Intercompany payables	178,406	249,553
Total current liabilities	892,933	979,093
Long-term liabilities:
Long-term debt, net of current portion	0	0
Capital lease obligations, net of current portion	1,466	840
Deferred tax liabilities	250,292	250,495
Other long-term liabilities	56,618	59,309
Intercompany notes payables	1,162,748	1,181,168
Total long-term liabilities	1,471,124	1,491,812
Total stockholders' equity	2,400,508	2,321,928
Non-controlling interests	0	0
Total equity	2,400,508	2,321,928
Total liabilities and equity	4,764,565	4,792,833
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	449,818	341,897	347,459	307,158
Restricted cash	4,247	4,444
Marketable securities	0	0
Accounts receivable, net of allowances	236,784	253,242
Inventories, net	188,448	194,192
Deferred tax assets	(6,058)	23,244
Prepaid expenses and other current assets	110,122	110,961
Assets held for sale - current		4,165
Intercompany receivables	158,858	50,691
Total current assets	1,142,219	982,836
Property, plant and equipment, net	187,337	188,084
Goodwill	988,527	1,012,996
Other intangible assets with indefinite lives	20,800	20,531
Finite-lived intangible assets, net	342,690	370,261
Restricted cash	42,589	43,228
Other non-current assets	14,317	15,380
Investments in subsidiaries	57,650	57,650
Investments in unconsolidated entities	44,654	37,947
Deferred tax assets	62,006	28,085
Non-current income tax receivable	0	0
Assets held for sale - non-current	0	0
Intercompany notes receivables	2,901	6,900
Total assets	2,905,690	2,763,898
Current liabilities:
Short-term debt and current portion of long-term debt	3,608	2,908
Current portion of capital lease obligations	1,846	1,944
Accounts payable	93,163	102,881
Accrued expenses and other current liabilities	197,663	225,944
Liabilities related to assets held for sale - current		363
Intercompany payables	203,621	112,891
Total current liabilities	499,901	446,931
Long-term liabilities:
Long-term debt, net of current portion	45,964	46,253
Capital lease obligations, net of current portion	5,506	6,341
Deferred tax liabilities	48,897	54,749
Other long-term liabilities	77,455	80,369
Intercompany notes payables	939,694	925,173
Total long-term liabilities	1,117,516	1,112,885
Total stockholders' equity	1,283,765	1,199,818
Non-controlling interests	4,508	4,264
Total equity	1,288,273	1,204,082
Total liabilities and equity	2,905,690	2,763,898
Eliminations [Member]
Current assets:
Cash and cash equivalents	0	0	$ 0	$ 0
Restricted cash	0	0
Marketable securities	0	0
Accounts receivable, net of allowances	0	0
Inventories, net	(23,015)	(20,574)
Deferred tax assets	0	(2,119)
Prepaid expenses and other current assets	6,534	6,602
Assets held for sale - current		0
Intercompany receivables	(1,347,333)	(1,484,486)
Total current assets	(1,363,814)	(1,500,577)
Property, plant and equipment, net	(3,088)	(1,494)
Goodwill	0	0
Other intangible assets with indefinite lives	(59)	(59)
Finite-lived intangible assets, net	(3,200)	(3,200)
Restricted cash	0	0
Other non-current assets	(649)	(446)
Investments in subsidiaries	(3,671,487)	(3,510,702)
Investments in unconsolidated entities	14,405	12,120
Deferred tax assets	(2,119)	0
Non-current income tax receivable	0	0
Assets held for sale - non-current	0	0
Intercompany notes receivables	(2,599,198)	(2,584,120)
Total assets	(7,629,209)	(7,588,478)
Current liabilities:
Short-term debt and current portion of long-term debt	0	0
Current portion of capital lease obligations	0	0
Accounts payable	0	0
Accrued expenses and other current liabilities	2,171	2,239
Liabilities related to assets held for sale - current		0
Intercompany payables	(1,347,342)	(1,484,486)
Total current liabilities	(1,345,171)	(1,482,247)
Long-term liabilities:
Long-term debt, net of current portion	0	0
Capital lease obligations, net of current portion	0	0
Deferred tax liabilities	82	82
Other long-term liabilities	(649)	(447)
Intercompany notes payables	(2,599,198)	(2,584,120)
Total long-term liabilities	(2,599,765)	(2,584,485)
Total stockholders' equity	(3,684,273)	(3,521,746)
Non-controlling interests	0	0
Total equity	(3,684,273)	(3,521,746)
Total liabilities and equity	$ (7,629,209)	$ (7,588,478)

Guarantor Financial Informati94

Guarantor Financial Information - Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Cash Flows from Operating Activities:
Net income (loss)	$ (34,891)	$ 14,770	$ (44,868)	$ 225,198
Income (loss) from discontinued operations, net of tax	0	0	0	216,777
Income (loss) from continuing operations	(34,891)	14,770	(44,868)	8,421
Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			5,261	7,784
Depreciation and amortization	69,901	72,689	142,405	147,103
Non-cash stock-based compensation expense	11,004	7,130	20,607	12,279
Impairment of inventory			870	68
Impairment of long-lived assets			633	387
Loss on disposition of fixed assets			4,235	3,318
Equity earnings of unconsolidated entities, net of tax	(2,122)	(1,361)	(7,156)	(5,320)
Gain on sales of marketable securities			0	(8)
Deferred income taxes			(13,210)	(42,171)
(Gain) loss related to impairment and net (gain) loss on dispositions	0	5,542	(3,810)	40,334
Loss on extinguishment of debt			0	3,480
Other non-cash items			9,720	(2,332)
Non-cash change in fair value of contingent purchase price consideration			(1,780)	(52,867)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			20,023	(18,016)
Inventories, net			(5,820)	(45,219)
Prepaid expenses and other current assets			(24,881)	(27,077)
Accounts payable			(1)	(23,251)
Accrued expenses and other current liabilities			(1,676)	23,052
Other non-current liabilities			(6,106)	8,536
Cash paid for contingent consideration			(324)	(3,781)
Intercompany payable (receivable)			0	0
Net cash provided by (used in) continuing operations			94,122	34,720
Net cash provided by discontinued operations			0	318
Net cash provided by (used in) operating activities			94,122	35,038
Cash Flows from Investing Activities:
Increase in restricted cash			(449)	(424,025)
Purchases of property, plant and equipment			(32,318)	(47,284)
Proceeds from sale of property, plant and equipment			892	1,120
Cash received from (used in) disposition, net of cash divested			21,470	586,625
Cash paid for business acquisitions, net of cash acquired			(5,958)	0
Cash received from equity method investments			2,383	14,297
Cash received from sales of marketable securities			90	93
Cash paid for investments			(184)	0
(Increase) decrease in other assets			495	1,750
Net cash provided by (used in) continuing operations			(13,579)	132,576
Net cash used in discontinued operations			0	(209)
Net cash provided by (used in) investing activities			(13,579)	132,367
Cash Flows from Financing Activities:
Cash paid for financing costs			(19,564)	(15,731)
Cash paid for contingent purchase price consideration			(485)	(6,373)
Proceeds from issuance of common stock, net of issuance costs			11,124	56,332
Proceeds from issuance of long-term debt			381	2,121,851
Payments on short-term debt			(791)	(584)
Payments on long-term debt			(177,637)	(2,118,264)
Net payments under revolving credit facilities			126,213	(126,320)
Cash paid for dividends			(10,646)	(10,646)
Principal payments on capital lease obligations			(2,210)	(2,910)
Net cash used in continuing operations			(73,615)	(102,645)
Net cash used in discontinued operations			0	(76)
Net cash used in financing activities			(73,615)	(102,721)
Foreign exchange effect on cash and cash equivalents			(2,964)	(1,574)
Net increase (decrease) in cash and cash equivalents			3,964	63,110
Cash and cash equivalents, beginning of period - continuing operations			502,200	378,461
Cash and cash equivalents, beginning of period - discontinued operations			0	23,300
Cash and cash equivalents of continuing operations, end of period	506,164	464,871	506,164	464,871
Issuer [Member]
Cash Flows from Operating Activities:
Net income (loss)	(34,891)	14,770	(44,868)	225,198
Income (loss) from discontinued operations, net of tax				218,689
Income (loss) from continuing operations				6,509
Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	(96,916)	(127,127)	(175,502)	(201,260)
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			5,175	7,728
Depreciation and amortization			4,484	3,840
Non-cash stock-based compensation expense			10,541	6,458
Impairment of inventory			0	0
Impairment of long-lived assets			0	0
Loss on disposition of fixed assets			1	0
Equity earnings of unconsolidated entities, net of tax	(588)	(922)	(1,269)	(1,346)
Gain on sales of marketable securities				0
Deferred income taxes			0	(8,686)
(Gain) loss related to impairment and net (gain) loss on dispositions	0	44,378	0	80,901
Loss on extinguishment of debt				3,480
Other non-cash items			(66)	(159)
Non-cash change in fair value of contingent purchase price consideration			(800)	(30,895)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			0	0
Inventories, net			0	0
Prepaid expenses and other current assets			(4,283)	(3,052)
Accounts payable			7,807	(7,499)
Accrued expenses and other current liabilities			40,481	(8,944)
Other non-current liabilities			(1,054)	2,226
Cash paid for contingent consideration			(321)	(3,768)
Intercompany payable (receivable)			145,358	127,569
Net cash provided by (used in) continuing operations				(26,898)
Net cash provided by discontinued operations				0
Net cash provided by (used in) operating activities			(14,316)	(26,898)
Cash Flows from Investing Activities:
Increase in restricted cash			(165)	(422,169)
Purchases of property, plant and equipment			(2,680)	(5,147)
Proceeds from sale of property, plant and equipment			92	0
Cash received from (used in) disposition, net of cash divested			(1,337)	593,217
Cash paid for business acquisitions, net of cash acquired			0
Cash received from equity method investments			2,383	2,205
Cash received from sales of marketable securities			0	0
Cash paid for investments			(184)
(Increase) decrease in other assets			(50)	348
Net cash provided by (used in) continuing operations				168,454
Net cash used in discontinued operations				0
Net cash provided by (used in) investing activities			(1,941)	168,454
Cash Flows from Financing Activities:
Cash paid for financing costs			(19,564)	(15,731)
Cash paid for contingent purchase price consideration			0	(5,503)
Proceeds from issuance of common stock, net of issuance costs			11,124	56,332
Proceeds from issuance of long-term debt			0	2,119,125
Payments on short-term debt			0	0
Payments on long-term debt			(176,861)	(2,117,875)
Net payments under revolving credit facilities			125,000	(127,000)
Cash paid for dividends			(10,646)	(10,646)
Principal payments on capital lease obligations			0	0
Net cash used in continuing operations				(101,298)
Net cash used in discontinued operations				0
Net cash used in financing activities			(70,947)	(101,298)
Foreign exchange effect on cash and cash equivalents			(2,484)	0
Net increase (decrease) in cash and cash equivalents			(89,688)	40,258
Cash and cash equivalents, beginning of period - continuing operations			139,153	2,149
Cash and cash equivalents, beginning of period - discontinued operations				0
Cash and cash equivalents of continuing operations, end of period	49,465	42,407	49,465	42,407
Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income (loss)	41,939	42,213	73,943	42,095
Income (loss) from discontinued operations, net of tax				(1,912)
Income (loss) from continuing operations		42,213		44,007
Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			7	13
Depreciation and amortization			88,973	82,576
Non-cash stock-based compensation expense			5,462	2,633
Impairment of inventory			0	133
Impairment of long-lived assets			548	64
Loss on disposition of fixed assets			3,522	2,764
Equity earnings of unconsolidated entities, net of tax	0	0	0	0
Gain on sales of marketable securities				(8)
Deferred income taxes			(200)	(32,097)
(Gain) loss related to impairment and net (gain) loss on dispositions	0	(39,412)	0	(8,804)
Loss on extinguishment of debt				0
Other non-cash items			459	(1,497)
Non-cash change in fair value of contingent purchase price consideration			(823)	15,748
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			2,141	(2,599)
Inventories, net			(11,723)	(27,824)
Prepaid expenses and other current assets			(7,408)	(19,127)
Accounts payable			396	(11,331)
Accrued expenses and other current liabilities			(13,721)	61,472
Other non-current liabilities			(1,561)	6,171
Cash paid for contingent consideration			0	0
Intercompany payable (receivable)			(141,518)	(101,515)
Net cash provided by (used in) continuing operations				10,779
Net cash provided by discontinued operations				318
Net cash provided by (used in) operating activities			(1,503)	11,097
Cash Flows from Investing Activities:
Increase in restricted cash			0	0
Purchases of property, plant and equipment			(11,750)	(19,386)
Proceeds from sale of property, plant and equipment			45	738
Cash received from (used in) disposition, net of cash divested			0	(8,723)
Cash paid for business acquisitions, net of cash acquired			0
Cash received from equity method investments			0	0
Cash received from sales of marketable securities			90	93
Cash paid for investments			0
(Increase) decrease in other assets			13	409
Net cash provided by (used in) continuing operations				(26,869)
Net cash used in discontinued operations				(209)
Net cash provided by (used in) investing activities			(11,602)	(27,078)
Cash Flows from Financing Activities:
Cash paid for financing costs			0	0
Cash paid for contingent purchase price consideration			0	0
Proceeds from issuance of common stock, net of issuance costs			0	0
Proceeds from issuance of long-term debt			0	0
Payments on short-term debt			0	0
Payments on long-term debt			0	0
Net payments under revolving credit facilities			0	0
Cash paid for dividends			0	0
Principal payments on capital lease obligations			(1,324)	(1,263)
Net cash used in continuing operations				(1,263)
Net cash used in discontinued operations				(76)
Net cash used in financing activities			(1,324)	(1,339)
Foreign exchange effect on cash and cash equivalents			160	(129)
Net increase (decrease) in cash and cash equivalents			(14,269)	(17,449)
Cash and cash equivalents, beginning of period - continuing operations			21,150	69,154
Cash and cash equivalents, beginning of period - discontinued operations				23,300
Cash and cash equivalents of continuing operations, end of period	6,881	75,005	6,881	75,005
Non-Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income (loss)	55,880	84,936	103,308	158,455
Income (loss) from discontinued operations, net of tax				0
Income (loss) from continuing operations		84,936		158,455
Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			79	43
Depreciation and amortization			48,109	60,652
Non-cash stock-based compensation expense			4,604	3,188
Impairment of inventory			870	(65)
Impairment of long-lived assets			85	323
Loss on disposition of fixed assets			712	554
Equity earnings of unconsolidated entities, net of tax	(1,557)	(424)	(6,138)	(3,992)
Gain on sales of marketable securities				0
Deferred income taxes			(13,010)	(1,826)
(Gain) loss related to impairment and net (gain) loss on dispositions	0	576	(3,810)	(31,763)
Loss on extinguishment of debt				0
Other non-cash items			9,323	(676)
Non-cash change in fair value of contingent purchase price consideration			(157)	(37,720)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			17,882	(15,417)
Inventories, net			5,243	(15,984)
Prepaid expenses and other current assets			(13,258)	810
Accounts payable			(8,204)	(4,421)
Accrued expenses and other current liabilities			(28,367)	(33,374)
Other non-current liabilities			(3,491)	(1,476)
Cash paid for contingent consideration			(3)	(13)
Intercompany payable (receivable)			(3,836)	(26,054)
Net cash provided by (used in) continuing operations				51,244
Net cash provided by discontinued operations				0
Net cash provided by (used in) operating activities			109,941	51,244
Cash Flows from Investing Activities:
Increase in restricted cash			(284)	(1,856)
Purchases of property, plant and equipment			(18,972)	(23,907)
Proceeds from sale of property, plant and equipment			1,839	1,199
Cash received from (used in) disposition, net of cash divested			22,807	2,131
Cash paid for business acquisitions, net of cash acquired			(5,958)
Cash received from equity method investments			0	12,092
Cash received from sales of marketable securities			0	0
Cash paid for investments			0
(Increase) decrease in other assets			532	927
Net cash provided by (used in) continuing operations				(9,414)
Net cash used in discontinued operations				0
Net cash provided by (used in) investing activities			(36)	(9,414)
Cash Flows from Financing Activities:
Cash paid for financing costs			0	0
Cash paid for contingent purchase price consideration			(485)	(870)
Proceeds from issuance of common stock, net of issuance costs			0	0
Proceeds from issuance of long-term debt			381	2,726
Payments on short-term debt			(791)	(584)
Payments on long-term debt			(776)	(389)
Net payments under revolving credit facilities			1,213	680
Cash paid for dividends			0	0
Principal payments on capital lease obligations			(886)	(1,647)
Net cash used in continuing operations				(84)
Net cash used in discontinued operations				0
Net cash used in financing activities			(1,344)	(84)
Foreign exchange effect on cash and cash equivalents			(640)	(1,445)
Net increase (decrease) in cash and cash equivalents			107,921	40,301
Cash and cash equivalents, beginning of period - continuing operations			341,897	307,158
Cash and cash equivalents, beginning of period - discontinued operations				0
Cash and cash equivalents of continuing operations, end of period	449,818	347,459	449,818	347,459
Eliminations [Member]
Cash Flows from Operating Activities:
Net income (loss)	(97,819)	(127,149)	(177,251)	(200,550)
Income (loss) from discontinued operations, net of tax				0
Income (loss) from continuing operations				(200,550)
Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities:
Equity in earnings of subsidiaries, net of tax	96,916	127,127	175,502	201,260
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			0	0
Depreciation and amortization			839	35
Non-cash stock-based compensation expense			0	0
Impairment of inventory			0	0
Impairment of long-lived assets			0	0
Loss on disposition of fixed assets			0	0
Equity earnings of unconsolidated entities, net of tax	23	(15)	251	18
Gain on sales of marketable securities				0
Deferred income taxes			0	438
(Gain) loss related to impairment and net (gain) loss on dispositions	0	0	0	0
Loss on extinguishment of debt				0
Other non-cash items			4	0
Non-cash change in fair value of contingent purchase price consideration			0	0
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			0	0
Inventories, net			660	(1,411)
Prepaid expenses and other current assets			68	(5,708)
Accounts payable			0	0
Accrued expenses and other current liabilities			(69)	3,898
Other non-current liabilities			0	1,615
Cash paid for contingent consideration			0	0
Intercompany payable (receivable)			(4)	0
Net cash provided by (used in) continuing operations				(405)
Net cash provided by discontinued operations				0
Net cash provided by (used in) operating activities			0	(405)
Cash Flows from Investing Activities:
Increase in restricted cash			0	0
Purchases of property, plant and equipment			1,084	1,156
Proceeds from sale of property, plant and equipment			(1,084)	(817)
Cash received from (used in) disposition, net of cash divested			0	0
Cash paid for business acquisitions, net of cash acquired			0
Cash received from equity method investments			0	0
Cash received from sales of marketable securities			0	0
Cash paid for investments			0
(Increase) decrease in other assets			0	66
Net cash provided by (used in) continuing operations				405
Net cash used in discontinued operations				0
Net cash provided by (used in) investing activities			0	405
Cash Flows from Financing Activities:
Cash paid for financing costs			0	0
Cash paid for contingent purchase price consideration			0	0
Proceeds from issuance of common stock, net of issuance costs			0	0
Proceeds from issuance of long-term debt			0	0
Payments on short-term debt			0	0
Payments on long-term debt			0	0
Net payments under revolving credit facilities			0	0
Cash paid for dividends			0	0
Principal payments on capital lease obligations			0	0
Net cash used in continuing operations				0
Net cash used in discontinued operations				0
Net cash used in financing activities			0	0
Foreign exchange effect on cash and cash equivalents			0	0
Net increase (decrease) in cash and cash equivalents			0	0
Cash and cash equivalents, beginning of period - continuing operations			0	0
Cash and cash equivalents, beginning of period - discontinued operations				0
Cash and cash equivalents of continuing operations, end of period	$ 0	$ 0	$ 0	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - INRatio 2 PT/INR Monitoring System Voluntary Withdrawal [Member] - USD ($) $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Restructuring and impairment charges		$ 16		$ 38
Accelerated amortization of intangible assets		4.1
Accelerated depreciation of tangible assets	$ 0.8	$ 1.5
Scenario, Forecast [Member]
Subsequent Event [Line Items]
Accelerated amortization of intangible assets			$ 8.2
Accelerated depreciation of tangible assets			1.6
One time cash expenditures			$ 2